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Abstract 
The survival rate of previously incurable diseases in the modern era is staggering due 
to the rapid advancement of pharmaceutical chemistry and our understanding of the 
human body. However, one limitation which is still prevalent is the ability to correctly 
diagnose the disease in its early stages. The clear correlation between successful 
medical treatments and early disease diagnosis has led to numerous analytical methods 
being developed. Magnetic resonance imaging, MRI, has come to the fore in this field 
due to it being a versatile high-resolution non-invasive technique with no radiation 
exposure to the patient required. Considerable focus is now being applied to the 
development of contrast agents that can be administered to further aid diagnosis. This 
research has led to gadolinium-based contrast agents, GBCAs. However, the 
indiscriminate interactions of previous clinically used GBCAs and the emergence of 
gadolinium deposits in the tissues of patients after multiple scans has resulted in 
increased demand for MRI contrast agents with higher specificity and lower dosages. 
Mesoporous silica nanoparticles, MSNs, have been shown to excel in this field due to 
its high surface area, facile functionalisation, and low toxicity. The application of 
MSNs as an MRI contrast agent could therefore result in earlier diagnosis of patients 
and consequently less global deaths from treatable diseases (Chapter 1). So, the 
optimisation of the MSN structure to be utilised as a GBCA is performed by variation 
of the pore diameter and gadolinium ion chelate location to obtain the highest amount 
of contrast with the minimum dosage of gadolinium (Chapter 3). Following this 
investigation, the possibilities of stimuli interactive GBCAs are pursued by the 
formation of a polymer/MSN hybrid system which can change its properties 
depending on the temperature of the surrounding environment. This response is 
explored further by observing the tuneability of the interaction by varying the grafting 
density and length of the MSN bound polymer (Chapter 4). Finally, polymer/MSNs 
hybrid systems are investigated to allow for specific binding interactions to occur 
between the system and colorectal cancer cells. This begins with research into how to 
remove indiscriminate interactions between GBCAs and neighbouring cells. Then, 
having achieved this, a lectin able to differentiate between healthy and cancerous rectal 
cells was chemically attached to the MSN bound polymer and shown to highlight 
colorectal cancer cells by retention of their specific intermolecular interactions. The 
non-toxicity of the polymer/MSN system was confirmed in-vitro (Chapter 5).
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Chapter 1 
1. Introduction 
1.1 Summary 
Nanomaterials have seen a burst of research in recent years, thanks to their unique size 
dependent properties such as high surface area, high loading capacities and strength 
density.1 These have made nanomaterials ideal candidates to a wide range of 
applications of electronics,2 civil engineering,3 agriculture,4 cosmetic5 and catalysis.6 
An application where nanomaterials have really progressed is in medicine where there 
has been extensive research of nanomaterials in long life medical implants and drug 
delivery.7 Silica nanomaterials have come to the fore in the medical field due to its 
biocompatibility, ease of synthesis and functionalisation.8 Silica has a lattice structure 
based on a tetrahedron where silicon is in the centre surrounded by four oxygen 
atoms.9 An advantage of silica lattice structure is the high adaptability to its overall 
structure allowing multiple bespoke morphologies to be synthesised.10 
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1.2 Silica Nanoparticles, SiNPs 
Silica nanostructures were described by Stöber et al. in the seminal 1968 paper, 
which described a robust method of synthesising silica spheres in the nano-micron size 
regime.11 In this silica spheres were prepared by adding tetra alkyl silicates to basic 
solution of ammonia and an alcohol/aqueous  solvent system. The reaction proceeded 
through the hydrolysis of the tetra alkyl silicate and condensation of the subsequent 
silicic acids (Figure 1.1).  
 
Figure 1.1. A) The hydrolysis of tetra alkyl silicates (tetraethyl silicate, TEOS) and the 
condensation of the subsequent silicic acid molecules to form silica. B) Electron 
micrograph of a sample of silica spheres obtained by Stöber et al.11 
The reaction conditions were basic pH with only agitation required. The reaction 
completed with most variants within an hour, with some only taking 15 minutes. The 
progress of the reaction being easily observed by the solution becoming increasing 
opalescent. It was also proven how scalable the reaction was by performing the 
CrystallineAmorphous
A)
B)
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reaction with 2 litres of solution and obtaining the same silica spheres obtained with 
the 80 mL reaction. 
The adaptability of this procedure has been investigated by changing the 
solvent system and alkyl silicate.11-13 These were found to change the rate of reaction 
and the particle diameters of the silica spheres obtained, the particle diameter 
increasing from 0.05 µm to 2 µm. The robustness of this procedure has been 
investigated by even performing the reaction in space.14 Thus proving the ease of 
formation and control of silica nanoparticle structure that can be obtained. 
1.2.1 Mesoporous Silica 
Porosity in nanostructures is an incredibly desirable property due to the large increase 
surface area that porosity provides.15 This results in porous nanomaterials having 
greater surface interactions between the surrounding molecules and the nanomaterial. 
There are numerous sizes of pore diameter that can be utilised. Nanomaterials with 
pores < 100 nm are defined as nanopores, mesopores are between 2 nm and 50 nm and 
micropores are < 2 nm.16 As the approximate size calculated using mean bond lengths 
and bond angles of a water molecule, the standard biological solvent, is around 2.75 
Å micropores significantly restricts the flow of water into the nanoparticle. This 
restriction inhibits interaction between molecules and the core of the pores.  The 
opposite is the case with nanopores where there is no inhibition of molecules flowing 
through the nanoparticle. However, the size of the pores has inherently reduced the 
amount of surface area that molecules can interact with. Mesoporosity sits in a 
goldilocks zone where the pores are large enough that they allow facile flow of 
molecules through the nanoparticle whilst minimising the amount of surface area lost 
to allow this to occur. 
In 1992, Kresge et al. published a paper on a new family of ordered mesoporous silica 
molecular sieves.17, 18 The desirability of these structures comes from the increased 
surface area (≥ 1000 m2/g) obtained which allows for greater interaction between 
molecules and the structure enhancing properties like catalytic activity and adsorptive 
capacity. In this paper the synthesis of this new family, named M41S, is described 
with emphasis on one member, MCM-41. In the synthetic protocol quaternary 
ammonium surfactant salts were utilised to provide the porosity. The proposed theory 
is the liquid crystal templating mechanism, whereby the surfactant forms a liquid 
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crystal structure in the water solvent, which the inorganic silicate present can form 
around to produce the observed porous inorganic structure (Pathway 1 of Figure 1.2). 
This mechanism conforms with the aggregation of quaternary ammonium surfactant 
salts in water, as hexagonal arrangements are observed in both.19, 20 Another possible 
mechanistic pathway involves the silicate influencing the formation of the liquid-
crystal phase (Pathway 2 of Figure 1.2). The subsequent growth of the mesoporous 
silica structure may be due to nucleation by the initial structure21 or assembly of 
several substructures.22 The surfactant can be removed from the mesoporous silica 
structure by calcination. 
 
Figure 1.2. Possible mechanistic pathways for the formation of MCM-41: 1) liquid 
crystal phase initiated and 2) silicate anion initiated.17, 18 
Kresge et al. pursued this investigation further by utilising surfactants with 
varying carbon chain lengths.17, 18 It was observed that lowering the carbon chain 
length of the surfactant obtained smaller pore diameters (pore diameter of 18 Å for 8 
Cs compared to 37 Å for 16 Cs). Also, the addition of an organic solvent, in this case 
1,3,5-trimethylbenzene, was found to increase pore diameter if added at the start of 
the synthesis. This is due to the swelling of the hydrophobic interiors of the micelles 
increasing the micelle diameter (Figure 1.3).23 Both these findings strongly suggesting 
the validity of the liquid crystal template mechanism proposed and the versatility of 
the synthetic protocol described. 
Surfactant 
Micelle
Micellar
Rod
Hexagonal
Array 
Silicate Calcination
MCM-41
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Figure 1.3. Transmission electron micrographs of several MCM-41 materials having 
a pore size of a) 20, b) 40, c) 65 and d) 100 Å.17 
The acquisition of a porous structure using surfactants is defined as an 
endotemplate method or soft matter templating. In exotemplating methods or hard 
templating a porous solid is used as the template instead of the surfactant which is 
subsequently cured. This provides a negative image porous structure compared to the 
template.24 Exotemplating was used by Zhao et al. to extend the family of highly 
ordered mesoporous structures by synthesising Santa Barbara Amorphous (SBA) 
materials.25 In particular, SBA-15 which was synthesised using the triblock copolymer 
of poly (ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide). The advantage 
of exotemplating is that reproducibility between nanoparticles can be more easily 
obtained due to the rigid nature of the template allowing for more precise dimensions. 
However, the separation of the template from the nanoparticles is more likely to cause 
damage to the nanoparticle structure due to the harsher conditions required. 
Endotemplates require softer methods of template removal, but the template is formed 
in the reaction allowing for less control over the resulting nanoparticle structure.26  
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1.2.2 Mesoporous Silica Nanoparticle, MSN, Synthesis 
The simple process to obtain mesoporous silica described by Kresge et al. was 
pursued in many directions, especially in the field of catalysis.27-32  In 1997, Grün et 
al. published a paper that combined the  Stöber synthesis with the synthesis of MCM-
41 to make the first spherical MSNs.33 This combining of protocols was performed 
simply by adding a quaternary ammonium surfactant salt, in this case n-
hexadecyltrimethylammonium bromide, CTAB, or n-hexadecylpyridinium bromide 
(Figure 1.4), to an otherwise identical solution described previously by Stöber of 
TEOS and ammonia in ethanol.  
 
Figure 1.4. The quaternary ammonium surfactant salts utilised to investigate 
mesoporosity of MCM 41 particles with scanning electron microscopy ,SEM, images 
of A, B) MSNs obtained using CTAB and C, D) MSNs obtained using n-
hexadecylpyridinium bromide by Grün et al.33 
Then the surfactant was removed from the pores by calcination in the work up. This 
yielded spherical MCM-41 particles which were essentially the same as silica spheres 
synthesised previously by Stöber et al., but with the additional property of having 
pores of diameter 3.14 nm using CTAB as a template and 3.05 nm using n-
hexadecylpyridnium bromide. The only other property affected by the variation in 
A)
B)
C)
D)
A)
B)
C)
D)
A)
B)
C)
D)
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surfactant in this investigation was the n-hexadecylpyridinium bromide promoted 
greater long-range order and homogeneity of pores.  
Since the first published synthesis of MSNs there has been a tremendous 
amount of research in adaptations to this protocol to obtain MSNs with tailored 
properties to suit their application.34 For example changing the pH of the reaction 
affects particle formation time, structural order and particle size by changing rates of 
hydrolysis and condensation of silane. This is due to the hydrolysis and condensation 
of the Si-OR bond in silanes being catalysed by acidic or basic conditions (Figure 1.5). 
 
Figure 1.5. The mechanisms for acid and base catalysed hydrolysis/condensation of 
alkyl silanes. 
The basic catalysed hydrolysis/condensation reaction has a rate of reaction which is 
parallel to the charge density. The rate of hydrolysis/condensation plateaus at pH 7.5 
and then decreases due to the gradual instability of silica at high pH. However, the 
addition of a cationic surfactant allows for the rate of hydrolysis/condensation to 
continue increasing up to pH 10.5. This is because of the strong interaction between 
the silicate and the surfactant having a stabilisation effect up to a pH 12. This pH 
dependence has allowed for fast pH-changing methods of MSN synthesis to be 
developed.35 Fowler et al. started the synthesis of MSNs using an alkaline solution, 
followed by neutralisation to significantly decrease the reaction rate.36 This introduced 
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mesoscopic order and control of the nanoparticle diameter. Mesoporous silica 
nanorods as well as hexagonal MSNs are also able to be synthesised by varying the 
pH.37, 38  
The variation of the base used has been investigated, for example Möller et al. 
substituted ammonia for triethanolamine, TEA.39 The use of TEA resulted in 
colloidally stable MSNs with worm-like pores due to TEA acting as a complexing 
agent for the silicate. Variation in TEA concentration also facilitated the synthesis of 
MSNs between 50 – 100 nm with high yield because of TEA encapsulating the MSNs, 
limiting growth as well as aggregate formation. In addition, Möller et al. describe a 
different extraction method of the ammonium surfactant salt from calcination. This 
method simply uses an acidified ethanol solution and sonification. Application of this 
method resulted in successful removal of the surfactant template without the use of 
high temperatures. Other methods have been investigated also to remove the surfactant 
from the pores of the nanoparticles such as dialysis.40 
Before the use of TEA the principal method for obtaining MSNs in the 50 – 
100 nm size range involved very high dilutions. Rathosky et al.  obtained MSNs of 
100 nm using 1:5300 dilution of sodium metasilicate/ water.41 Ostafin et al. obtained 
MSNs of 70 nm using a molar ratio of TEOS/solvent of 1:4000 and 60 nm with molar 
ratio of 1:1500 respectively.42 30 nm MSNs were obtained using a molar ratio of 
1:260035 and 60- 140 nm MSNs using 1:1200 by Cai et al.38 Finally Mann et al. created 
a highly versatile MSN synthetic protocol using an approximate molar ratio of 1:900.36 
The main drawback of these previous very dilute protocols is the scalability, the low 
yields and/or the difficult isolation procedures to obtain the MSNs. Whereas Möller et 
al. using TEA was able to lower the molar ratio of TEOS/water to 1:120, minimising 
the amount of solvent required. Other stabilising reagents have been researched to 
obtain colloidally stable 50 - 100 nanometre MSNs such as polyvinyl pyrrolidone 
(average Mw = 10,000 g/mol), PVP43, L-lysine
44 and Pluronic F127, 
EO106PO60EO106
45, 46 (Figure 1.6). 
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Figure 1.6. Examples of stabilising reagents used in previous publications with TEM 
images of the resulting nanoparticles obtained underneath.39, 43, 44, 46 
pH also affects the charge density of the silica species. Silica has an isoelectric 
point of 2.0 ± 0.3;47 therefore, below this the charge density is positive and above 
negative. This influences the interaction between the silica and the quaternary amine 
surfactant salt.  At pH < 2 the intermolecular interactions are hydrogen bonds, this 
requires an anionic mediator (usually a halide), a mixture of hydrogen bonding and 
electrostatic interactions between pH 2 and pH 9 to purely electrostatic at pH > 9.48 
MSN synthesis is highly versatile and different surfactants, solvents and pH conditions 
can be used. Anionic surfactants can be utilised in basic media with the addition of a 
cationic mediator to minimise the interaction between the anionic surfactant and the 
negatively charged silica species. Non-ionic surfactants can also be utilised through 
hydrogen bond formation between the silica species and the surfactant either with the 
addition of a molecule capable of hydrogen bonding or through ion pairs (Figure 
1.7).49, 50    
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Figure 1.7. Interactions between the inorganic silicate network and the head group of 
the surfactant with consideration of the possible synthetic pathways in acidic, basic 
or neutral media. A) Cationic surfactant in basic media, B) cationic surfactant in 
acidic media, C) anionic surfactant in basic media, D) anionic surfactant in acidic 
media, E) neutral surfactant in neutral media and F) neutral surfactant in acidic 
media.31 
MSNs with dual pore diameters have been investigated by Niu et al.51 This 
was achieved by the utilisation of an amphiphilic block copolymer, polystyrene-b-
poly(acrylic) acid, PS-b-PAA, and CTAB as co-templates. In aqueous ammonia 
conditions the PS-b-PAA forms rod-like aggregates that coupled with the CTAB 
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micelles due to the electrostatic interaction between the PAA- and the CTA+ 
molecules.  
1.2.3 Surface Functionalisation of MSNs 
 In addition to the ease of MSNs synthesis, another advantage is facile and 
versatile methods of functionalisation. These methods fall into three pathways, 1) 
post-synthetic modification or grafting, 2) co-condensation and 3) periodic 
mesoporous organo-silicas, (PMOs), production.52, 53 Grafting involves the 
modification of the MSN after its synthesis with silica phases with organic functional 
groups. This method in general uses an organosilane in the form of (R’O)3SiR, 
chlorosilanes Cl3SiR or silazanes HN(SiR3)2. These react with the free silanol groups 
on the pore surfaces (Figure 1.8).  
 
 
Figure 1.8. Grafting (post-synthetic modification) for organic modification of MSNs 
with terminal organosilanes of the type (R’O)3SiR. R = organic functional group and 
R’= alkyl chain.54 
Using the grafting method, a wide variety of organic groups can be added to the MSNs 
such as amino or aminopropyl groups,55-61 diamino,62, 63 triamino,63 ethylenediamine,64 
malonamide,65 carboxy,57, 60 thiol,55, 59, 66 1-allyl,67 a-benzoyl-3-propylthiourea,68, 69 
dithiocarbamate,70 imidazole groups71-73 as well as saccharides.74 Another advantage 
R+      -Si(OR’)3
H+(aq) / OH
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of the grafting method is that the mesostructure of the MSN is usually retained. 
However, depending on the mol% of organic residue added to the MSN, there is a 
possibility of reduction in the porosity of the subsequent hybrid material, leading to 
pore closure at high mol%.54 Also, organosilanes react preferentially to the surface or 
inside channels near the channel openings of the nanoparticle, resulting in a 
heterogenous distribution of the organic functional groups and can be detrimental to 
the diffusion of further molecules, lowering occupation.75 
 Co-condensation is a one pot synthetic method where organosilane is reacted 
with the tetralkyl silicate forming the MSNs before completion of the reaction. This 
results in organic residues anchored covalently inside the pore walls (Figure 1.9). 
 
Figure 1.9. Co-condensation method (direct synthesis for the organic modification of 
MSNs with terminal organosilanes of the type (R’O)3SiR. R = organic functional 
group and R’ = alkyl chain.54 
The advantage of co-condensation is that pore blocking is less likely to occur than 
with grafting because the organic functionalities are incorporated directly into the 
R
TEOS 
+      -Si(OR’)3 H+(aq) / OH
-
(aq)
Extraction/
Calcination
= surfactant micellar rod 
R
 13 
 
silica matrix in the presence of the template. However, a degree of structural intergrity 
is lost with increasing concentration of the organosilane, resulting in high mol%s with 
complete structural disorder.76 Therefore, organic functionalisation generally does not 
exceed 40 mol%.54 Also, the amount of organic functionalisation incorporated into the 
MSNs is lower than for grafting compared to the amount of added.54 This is due to 
uncontrolled homo-condensation of the organosilanes occurring at the cost of cross-
linking co-condensation reactions with the silica precursors.  Finally, for more 
complex organic functionalisation, the extraction method for the removal of the 
surfactant template needs to be carefully considered as calcination may not be 
appropriate. The versatility of the functional groups able to be bound to MSNs using 
co-condensation is vast. Using the respective organosilanes, alkyl,77, 78 thiol,78-82 
amino,76, 79, 82-87 cyano/isocyano,76, 83, 88 vinyl/allyl,75, 76, 78, 79, 82, 89-91 
organophosphines,88, 92 alkoxy79 and aromatic groups77, 79, 82, 88, 93, 94 have all been 
successfully bound to MSNs. This method as well as post-synthetic modification 
makes the functional groups accessible not just limited to the organic functional 
groups present in organosilanes. Once these functional groups have been bound to 
MSNs the functional groups can be chemically altered as they would following 
standard chemical techniques. For example, Asefa et al. have successfully transformed 
silica bound vinyl groups in to alcohols via hydroboration, the corresponding diols by 
epoxidation and bromide addition via bromination.95 Silica thiols have been 
transformed to sulfonic acid,96-99 in particular Stucky et al. who performed the 
oxidation of the thiol in situ to the co-condensation reaction with addition of H2O2.
100 
Also 2-cyanoethyl-functionalised MSNs can be converted to their respective 
carboxylic acid by careful hydrolysis with H2SO4
101 and phosphoric acids 
functionalisation by ester hydrolysis of diethyl phosphonate.102 
 PMOs were first synthesised in 1999.103-105 PMOs are organic-inorganic hybrid 
materials which are synthesised by hydrolysis and condensation reactions of 
organosilica precursors of the type (R’O)3Si-R-Si(R’O)3. R groups that have been 
successfully converted into PMOs are alkyl chains where C = 1 and 2103-107 and 
aromatic groups106, 108-115 and R’ is an alkyl chain, in the presence of a surfactant. 
Unlike post-synthetic modification and co-condensation, the organic unit is 
incorporated via covalent bonds into the three-dimensional framework of the MSN. 
This leads to complete homogeneity of the MSN functionality (Figure 1.10).   
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Figure 1.10. General synthetic pathway for PMOs that are constructed from bis-
silylated organic bridging units. R = organic bridge, R’ = alkyl chain.54  
The advantages of PMOs is there large inner surface areas of up to 1800 m2 g-1, high 
thermal stability, periodically organised pore systems and very narrow pore radius 
distributions.54 The key disadvantage being that grafting has to be performed after 
PMO synthesis in order to perform further surface modification.  
1.2.4 Polymer Modification of MSN Surfaces 
The functionalisation of MSNs with polymers has become a popular method to change 
or add desirable physical properties.116 These properties can range from biological 
inertness by pegylation117, to allowing the MSN to react to external stimuli.118-120 
There are two methods to nanoparticle surface polymer functionalisation, ‘grafting to’ 
and ‘grafting from’. The ‘grafting to’ method requires an end-functionalised polymer 
reacting to or adsorbing onto the nanoparticle surface. Due to being able to fully 
characterise each component prior nanoparticle assembly this method allows for 
increased polymerisation reaction control resulting in more uniform polymer chain 
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lengths being obtained.121 In the ‘grafting from’ method the polymer chains are grown 
from a nanoparticle that has an initiator bound to the surface (Figure 1.11).122-125 
 
Figure 1.11. Schematic description of ‘Grafting to’ and ‘Grafting from’ approaches 
for the synthesis of polymer surface functionalisation of nanoparticles. 
The ‘grafting from’ method obtains a higher percentage of grafting density onto the 
surfaces of the nanoparticle.116, 121 However, control of polymer chain length is more 
challenging as observing the amount of initiator successfully bound to the nanoparticle 
is non-trivial and the amount of initiator in the polymerisation directly effects polymer 
chain length. There is no limitation in the mechanism of polymerisation which can be 
used for ‘grafting from’, with radical, anionic, cationic and living polymerisation 
having previously been utilised to immobilise polymers onto a range of different 
surfaces.126, 127  
 Hsin-Lien et al. successfully applied the ‘grafting to’ method of polymer 
functionalisation to obtain thermosensitive silica coated iron oxide nanoparticles.128 
This was achieved by polymerising N-isopropylacrylamide (NIPAM) with 
azobisisobutyronitrile, as the initiator. The resulting poly(N-isopropylacrylamide), 
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pNIPAM, was then incubated with silica-coated iron oxide nanoparticles, to allow the 
pNIPAM to adsorb to the silica surface. The thermosensitive nature was confirmed, 
and further investigation involved the analysis of different silica coating thickness on 
the iron oxide nanoparticles. The thermoresponsive nature of the pNIPAM 
functionalised nanoparticles varied with the thickest silica coating aggregating at the 
highest temperature observed 36 OC, and the lowest weight ratio obtaining the lowest 
at 34 OC. Zhu et al. also used the adsorption of polymer chains in a ‘grafting to’ 
methodology to obtain zwitterionic polymer-coated MSNs to promote stability in 
complex media and reduce protein fouling.129 The polymerisation was performed 
using L-3, 4-dihydroxyphenylalanine, DOPA, bromide as the initiator and 
carboxybetaine methacrylate, CBMA, monomer, to obtain the polymer DOPA-
pCBMA. This was then incubated with MSNs causing adsorption of the DOPA-
pCBMA via the surface adhesive catechol residue group. The DOPA-pCBMA MSNs 
were analysed for their fouling resistance capabilities and then, due to the free 
carboxyl groups in pCBMA, were Arginylglycylaspartic acid, RGD, protein 
functionalised and analysed for their uptake by cells. Whereas Yang et al. used a 
‘grafting from’ to obtain pNIPAM functionalised MSNs.118 These were obtained by 
post synthetic amine modification of fluorescent MSNs. These amine groups were 
then reacted with 2-bromoisobutyryrl bromide, BIBB to form amide bonds. The 
polymerisation of NIPAM occurred using the MSN bound BIBB as the initiator. The 
subsequent pNIPAM-MSNs exhibited an aggregation response at 35 OC. Further 
investigations analysed the uptake and cytotoxicity of these nanoparticles with MCF-
7 cancer cells. It was observed at 37 OC the nanoparticles were uptaken by the cancer 
cells and that the nanoparticles had a negligible effect on cell growth.  
1.2.5 SiNP Toxicity 
There have been numerous investigations into the toxicity and biocompatibility of 
MSNs. Yu et al. investigated silica toxicity on a cellular level with macrophages, lung 
carcinoma cells and human erythrocytes.130 Eight sets of silica nanoparticles, SiNPs, 
were synthesised, non-porous SiNPs (115 nm), MSNs (120 nm), mesoporous silica 
nanorods with aspect ratio 2, mesoporous silica nanorods with aspect ratio 4, 
mesoporous silica nanorods aspect ratio 8 and finally the aminated counterparts of 
each variant. The quantitative association of SiO2 to the cells under investigation was 
obtained using inductively couple plasma mass spectrometry (ICP-MS). Association 
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was found to increase in the order: MSNs (aspect ratio 1, 2, 4, 8) < aminated MSNs 
(aspect ratio 1, 2, 4, 8) < aminated non-porous SiNPs < non-porous SiNPs. The amount 
of association was directly linked to plasma membrane damage. This trend agreed with 
previous research which found the addition of porosity reducing toxicity.131-134 This 
was due to the high silanol groups on the external surface of non-porous SiNPs being 
accessible to the cell membrane, causing higher cellular impact. The addition of 
cationic functional groups like amine groups to MSNs increasing cellular uptake was 
also confirmed using cervical cancer cells.135 In addition, it was confirmed that below 
100 µg/mL there was no haemolytic toxicity observed for any of the MSNs or 
mesoporous silica nanorod variants. The effect of surface charge was pursued further, 
the results confirming an increased immune response and cytotoxicity with cationic 
surface charge compared to anionic and neutral, but were advantageous for trans 
vascular transport in tumours, neutral having the longest circulation times and 
interstitial transports in tumours.136, 137 
Nabeshi et al. have investigated the relationship between SiNP diameter and 
toxicity both in vivo and in vitro.138 SiNPs with particle diameters ranging from 70 to 
1000 nm were investigated to observe their skin and nuclear penetration. It was found 
that the SiNPs with a diameter of 70 nm penetrated the skin barrier and exerted various 
negative biological effects in both the regional and systemic level, such as DNA 
fragmentation. Rancan et al. also investigated MSNs skin penetration properties.139 
the size dependent manner was confirmed with amorphous silica nanoparticles ranging 
from 42 ± 3 nm to 291 ± 9 nm. SiNPs of diameter >75 nm were found to be blocked 
from penetrating by the skin. Making the SiNP surface positively charged was also 
found to increase cellular uptake.  
This cellular uptake below 100 nm is however a desirable property for drug 
delivery. Awaad et al. investigated the uptake of fluorescent organosilica particles of 
varying particle diameters by the small intestine.140 The Peyer’s Patches ,PPs, small 
masses of lymphatic tissue in the small intestine, were focussed on.141 The diameters 
investigated were 95 nm, 110 nm, 130 nm, 200 nm, 340 nm, 695 nm and 1050 nm. 
Quantitative analysis showed that within this range of diameters investigated the 
optimal was 95 nm, which had 124.0 % fluorescent areas of the PPs with respect to 
110 nm. With 130 nm, 200 nm, 340 nm, 695 nm and 1050 nm having 110 nm 
respective fluorescent areas of 89.1 %, 73.8 %, 20.2 %, 9.2 % an 0.5 % respectively. 
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Additionally, two novel pathways through the PPs were observed, transcellular, 
through the cells, and paracellular, between cells. Mou et al. investigated cellular 
uptake further with MSN and Hela cells.142 The trend between size dependence and 
cellular uptake was found to be 50 nm > 30 nm > 110 nm > 280 nm > 170 nm. The 
optimal particle diameter of ~50 nm observed was consistent with other previous 
research using different nanoparticles on the size dependence of cellular uptake.143, 144 
  Despite Yu et al. finding no toxicity difference between MSNs and 
mesoporous silica nanorods of various aspect ratios, their organ distribution after 
administration in vivo differ.130 Huang et al. investigated the distribution of 
intravenously administered fluorescent mesoporous silica nanorods with aspect ratios 
of 1.5 and 5 as wells as pegylated mesoporous silica nanorods into mice after 2 hrs.145 
>80 % of all types of silica nanorods were found in the liver, spleen and lung of various 
ratios depending on nanorod aspect ratio and pegylation. The 1.5-aspect ratio 
mesoporous silica nanorods were primarily observed in the liver whereas the 5-aspect 
ratio nanorods were found in the spleen. Pegylation of either the 1.5 or the 5-aspect 
ratio nanorods resulted in increased accumulation in the lungs. No significant toxicity 
was found in any of the MSNs investigated and the MSNs were mainly excreted in the 
urine and faeces. Xie et al. also investigated organ distribution of intravenous 
administered fluorescent and 125I labelled SiNPs with varying particle diameters 20 
nm and 80 nms.146 It was found that nanoparticles of these diameters were evenly 
located in the liver, but were concentrated in the white pulp of the spleen. Also, it was 
observed that both the 20 nm and 80 nm SiNPs were able to be excreted using the 
renal pathway.  
The surface functionalisation of the SiNPs affects circulation organ 
distribution. He et al. investigated SiNPs with particle diameters ~45nm and their 
surface either unfunctionalized, carboxylic acid functionalised or pegylated.147 The 
SiNPs were intravenously administered and it was found that the pegylated SiNPs had 
significantly longer circulation times and liver uptake. All SiNPs investigated were 
able to be cleared from circulation and excreted through the renal pathway. 
Intravenous administration is the most popular method of exposure for 
investigating SiNPs toxicity. Liu et al. investigated both the lethal dose and the effect 
of continuous administration for 14 days of 110 nm mesoporous hollow silica 
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nanoparticles in mice.148 The lethal dose was found to be > 1000 mg/kg of the mouse’s 
body mass and no death was observed for continuous intravenous injection of 
nanoparticles with doses ranging from 20, 40 and 80 mg/kg for 14 days. In addition, 
complete clearance of the nanoparticles from the body could be achieved and the entire 
clearance completed after four weeks. Fu et al. expanded this investigation into 
different exposure routes using the same 110 nm silica nanoparticles.149 This included 
intravenous, hypodermic, intramuscular injection and oral administration. 
Hypodermic and intramuscular injection obtained the lowest absorption rates as the 
nanoparticles were unable to cross different biological barriers effectively. It was also 
found that these methods caused inflammatory responses around the injection sites 
due to muscle and hypodermic tissue damage. Oral administration of nanoparticles 
was more successful however with the SiNPs being absorbed into the intestinal tract 
and observed in the liver. It was also further confirmed that silica nanoparticles were 
excreted in the urine and faeces. 
There have been multiple studies on the transplacental transport of 
nanomaterials in pregnant animals and the nanomaterial induced neurotoxicity in their 
offspring.150-155 These investigations have mainly focussed on titanium dioxide, 
polystyrene and quantum dots. Yamashita et al. investigated the resorption of 
intravenously administered 70 nm silica nanoparticles and foetal growth restriction.156 
The SiNPs were observed in the placenta, foetal liver and foetal brain. Also, the 
presence of the SiNPs caused pregnancy complications, smaller uteri and smaller 
foetuses than the controls. However, these detrimental effects were abolished with 
surface functionalisation of the SiNPs to carboxyl and amine groups. 
The toxicity research performed on silica has led the US Food and Drug 
Administration (FDA) to approve silica as a “generally recognised as safe” (GRAS) 
and has resulted in silica being widely used in cosmetic and food additives.10, 157 
1.2.6 Applications in Medicine 
Due to the robust, simple and scalable method of synthesis, ease of functionalisation 
and low toxicity, SiNPs have had large amount of research in the applied field of 
nanomedicine,158, 159 in particular as biosensors.160 Azioune et al. bound human serum 
albumin (HSA) to ester functionalised polypyrrole SiNPs and observed the activity of 
the bound HSA to anti-HSA after incubation.161 Kim et al.162 and Kang et al.163 
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independently synthesised fluorescent SiNPs with surface Ni2+ modification  for 
specific interaction with histidine-tagged proteins. This allowed for protein isolation 
and purification as well as site specific labelling, essential techniques in the field of 
proteomics. Shiomi et al. covalently bound haemoglobin to a SiNP and then grew the 
SiNPS around the haemoglobin with a second layer of silica. Which, after the removal 
of the haemoglobin templates were now able to obtain haemoglobin recognition.164 
SiNPs have been utilised for other forms of biological recognition. Wang et al. 
synthesised aptamer functionalised SiNPs that were able to detect lysozymes in the 
range 0-22.5 µM.165 Hilliard et al. immobilised oligonucleotides to fluorescent SiNPs 
by disulphide bridges.166 These were then incubated with deoxyribonucleic acid, 
DNA, to cause hybridisation which could be observed by fluorometry. SiNPs have 
also been utilised for pharmaceutical applications. Gore et al. used colloidal silica to 
stabilise aspirin tablets,167 whilst colloidal silica has also been used to strengthen 
magnesium stearate tablets.168 SiNPs have been investigated for the possible 
application as a glidant.169  
An application where MSN research dominates is in drug delivery.159 Vallet-
Regi et al. first applied MCM-41 silica to drug delivery.170 The charge and pore 
diameter were investigated to observe their effects on ibuprofen release. Using MCM-
41 silica nanoparticles high drug capacity was obtained with constant drug release. It 
was concluded that the charge of the material had more effect on drug release than 
pore diameter. The ability to change the surface charge of MSNs allows for a wide 
range of pharmaceutical drugs, with varying hydrophobicity and molecular weight, to 
be incorporated into MSNs such as doxorubicin,171 camptothecin,172 cisplatin173 and 
itaconazole.174 There has been an explosion of research of MSNs as drug delivery 
systems with a vast range of possible drugs and targets including bone/tendon tissue 
engineering,175-178 diabetes,179, 180 inflammation181 and cancer172 being investigated.  
Another interesting feature of MSNs as therapeutic delivery agents are their 
ability to transport membrane impermeable native proteins into the cytosol of cells, of 
vital importance to ensure that the drug can reach the target on which it is designed to 
act, rather than being digested or expelled from the typical cellular endocytic pathway 
of nanoparticles.182-184 Slowing et al. highlighted the MSNs efficacy as a carrier 
system through membranes by successfully storing cytochrome c, a membrane 
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impermeable protein that triggers apoptosis in cells,185 in the pores and transporting it 
through a cell membrane whilst retaining its activity (Figure 1.12).186 
 
Figure 1.12. Cytochrome c transportation into the cytoplasm using MSNs.186 
MSNs have been also applied to gene delivery, a process in which DNA is transported 
to the nucleus of the host cell allowing for genetic research or gene therapy.187 Here 
polycation polymers, for example polyamidoamine (PAMAM),188 polyethylenimine 
(PEI)189 and mannosylated polyethylenimine (MP),190 have been utilised for the non-
covalent attachment of DNA/RNA. The attachment of PEI additionally being found 
to increase cellular uptake due to the proton sponge effect whereby the cationic nature 
of PEI in physiological conditions causes H+ and Cl- ions to enter the endosome 
containing the PEI functionalised nanoparticle causing osmotic swelling and resulting 
in endosome rupture.191, 192 Polymer functionalisation is not a necessity however for 
DNA or RNA MSN uptake. Gu et al adsorbed DNA/RNA using MSNs without surface 
modification.193, 194 In this application MSN pore size is of paramount importance.195, 
196 Large pore sizes being able to transport plasmids in the supercoiled formed, 
providing protection from nucleases.196  
MSN
MSN
Cytochrome cCytoplasm
Cell Membrane
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 A particularly useful feature of MSNs is its non-discriminatory ability to 
uptake and host different molecule, allowing for co-drug delivery.171, 180, 197-199 This 
attribute has been utilised against multi-drug resistant cancer cells. He et al. used 
MSNs loaded with doxorubicin and Bcl-2 small interfering RNA, SiRNA, to reverse 
drug resistance in cancer cells.171 Brinker et al. were able to have a kill effect on cancer 
cells 106 greater than comparable liposomes by delivering a cocktail of doxorubicin, 
5-fluorouracil and cis-platin using surface lipid bilayer functionalised MSNs.197  
 Despite the overwhelming amount of research into MSNs as drug delivery 
systems, especially in the field of tumour targeting, there are only two major examples 
of clinically used nanoparticles, Abraxane® and Doxil®. The reason for this is previous 
nanoparticle research reliance on the enhanced permeability and retention, EPR, 
effect.200 The EPR effect states that due to the hyperpermeable nature of tumour 
vasculature, the permeability of large particles, such as proteins, macromolecules, 
liposomes, micelles and other soluble particles, is enhanced. These large particles can 
avoid renal clearance, which when combined with an impaired lymphatic drainage 
system limiting the removal of tumour particles, causes enhanced retention of the 
nanoparticles at tumour sites (Figure 1.13). 
 
Figure 1.13. A schematic representation of the conceptual passive targeting (EPR 
effect) of nanomedicine.201 
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The EPR effect however has a severely muted effect in humans carcinoma tissue  
compared to in mice.202 this is due to murine models being drastically different to 
human cancer tissue in rate of development, the size relative to the host, metabolic 
rates and host lifespan. Specifically, human tumours have different 
microenvironments compared to murine tumours simply because rodent tumours grow 
faster. A subcutaneous tumour grows roughly 1 cm (~0.5 g) in 2-4 weeks. In humans 
this would represent a growth of 20 cm (1-2 kg).203 Due to this rapid murine tumour 
growth, blood vessels in mouse tumour do not develop properly, resulting in a leaky 
nature. This is not necessarily the case in humans, resulting in a heterogenous 
distribution of pore sizes and therefore heterogenous extravasation and delivery.204 
Also the large tumour to host’s body ratio significantly alters the pharmacokinetics of 
the drug carriers. Murine tumours are usually observed to be 10 % of the mouse’s body 
weight. This in a 70 kg human would be a 7 kg tumour, which would be roughly the 
volume of a basketball.205 This has forced researchers to use more relevant in vivo 
tumour models, such as patient derived tumour explant, PDX, models, which more 
faithfully reflect the morphology, complexity and heterogeneity of clinical tumours.206   
The failure of the EPR effect in clinical trials has led to greater research into 
stimuli responsive drug delivery systems, SRDDS, in a bid to ensure that therapeutics 
are released at the appropriate place for maximum impact. Lin et al. bound cadmium 
sulphide (CdS) into the pores of MSNs using disulphide bridges.207 The disulphide 
bridges can be cleaved by disulphide bond reducing molecules to release the 
encapsulated drug molecules from within the pores allowing for controlled drug 
release (Figure 1.14). 
 
Figure 1.14. A schematic representation of the CdS nanoparticle capped MSN-based 
drug delivery system.207 
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This has been developed further by the group to incorporate gold208 and magnetic 
nanoparticle capping, allowing the gating mechanism to react to different external 
stimuli.209 SRDDs have been developed to respond to a wide range of stimuli such as 
UV,208, 210-214 pH,215-219 ultrasound,179 redox,220-222 magnetic field,223 electric field,224 
enzymes225-229, temperature118 and even multi-responsive DDSs.230-232 However very 
few of these have progressed into in vivo studies.233 This is due to the challenge of 
remotely manipulating them in vivo using the correct stimuli. 
Another avenue of research explored is the bioconjugation of targeting ligands to the 
surface of MSNs that specifically bind to cancer cells.234 The range of targeting ligands 
previously bound to MSNs for cancer cell targeting consists of folate to target folate 
receptors,235-237 transferring to target transferrin receptors,238 aptamer to target PTK7 
(human protein kinase-7) overexpressed in colon carcinomas239 and antibodies that 
target Her-2 receptors overexpressed in breast or lung cancer.240 Li et al. has bound 
silica nanoparticles to mesenchymal stem cells, MSCs, which has a tumour-tropic 
property towards malignant cells.241 Up to 1500 Doxorubicin loaded nanoparticles 
were anchored to MSCs by specific antibody-antigen recognition. These silica 
burdened cells delivered doxorubicin with a wider distribution and longer retention 
time than both free doxorubicin and silica encapsulated doxorubicin, resulting in 
greater apoptosis.  
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1.3 Magnetic Resonance Imaging, MRI 
1.3.1 MRI History 
The history of MRI begins with the fundamental studies performed by Rabi et 
al. measuring the magnetic moment of a molecular beam of LiCl, LiF, NaF and Li2 to 
obtain the magnetic moments of  3Li
6, 3Li
7 and 9F
19.242 This was developed further to 
be able to acquire the magnetic moment of H2.
243 This is an essential step in the 
development of clinical MRI as this technique only measures the magnetic moment of 
1H predominantly in the form of H2O. For this work he was awarded a Nobel prize in 
1944. Bloch et al.244 and Purcell et al.245 extended this work to solids and liquids which 
resulted in them jointly receiving the Nobel prize in 1952. Damadian et al. performed 
the first research into using MR relation times as a medical diagnostic tool to decipher 
between healthy and cancer cells in 1971.246 Lauterbur et al. published an image using 
MR in 1973 of two capillaries of H2O, submersed in a glass tube of D2O by rotating 
the specimen.247Mansfield et al. simultaneously producing an image utlising magnetic 
gradients.248 This culminated in the imaging of a human finger in 1977249 and an image 
of the human body in 1978 using variable magnetic gradients called the line-scan 
technique.250 For this work Paul Lauterbur and Sir Peter Mansfield were awarded the 
Nobel prize in 2003. 
1.3.2 MRI Basic Principles 
 Atomic nuclei have a spin quantum number, I. If I ≥ ½ then the nuclei have an 
intrinsic magnetic moment and spin angular momentum. When not in a magnetic field 
the magnetic moments of the nuclei are randomly orientated leading to no net magnetic 
field. However, if a magnetic field is applied, B0, then the nuclei start precessing at 
the Larmor frequency, ω0, which is proportional to B0 and the gyromagnetic moment 
of the nucleus, γ (Equation 1.1). 
𝜔0 =  𝛾𝐵0 (𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.1) 
The nuclei either precess around B0 in the low energy state or against B0 in the high 
energy state exclusively (Figure 1.15). 
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Figure 1.15. A schematic representation of 12 nuclei with I ≥ ½ in A) no magnetic 
field and B) addition of magnetic field, B0.  
As more nuclei are present precessing in the direction of B0 than against, there is a net 
longitudinal magnetic moment in the direction of B0 (Figure 1.16). 
 
 
 
Figure 1.16. A schematic showing 6 nuclei with I ≥ ½ precessing around B0 with a 
common origin in either the low energy state, in the direction of B0 or the high energy 
state, and its simplification representing the net longitudinal direction of the magnetic 
moment of the nuclei. 
When a radiofrequency pulse is applied to the system at the Larmor frequency of the 
nuclei (42.58 MHz for 1H at 1 Tesla) perpendicular to B0, known as B1, energy is 
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provided to the nuclei in the low energy state such that nuclei are promoted to the high 
energy state, neutralising the longitudinal magnetic moment. The precession of the 
nuclei is also synchronised by B1, causing a net transverse magnetic moment 
perpendicular to B0, which can be observed by electromagnetic induction (Figure 
1.17). 
 
Figure 1.17. The promotion of nuclei from the low energy state to the high energy 
state and the synchronisation of precession by the addition of a radiofrequency pulse 
at Larmor frequency perpendicular to B0, B1. Thus, rotating the net magnetisation of 
the nuclei from a net longitudinal direction to a net transverse direction. 
Upon removal of B1, the nuclei return to their original state aligned with B0 in a process 
known as relaxation. This occurs in two different mechanisms. Firstly, the precession 
of the nuclei desynchronises, leading to loss of the transverse magnetisation, with the 
relaxation referred to as T2 relaxation or spin-spin relaxation and the time it takes to 
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relax as T2. The return of the magnetic moment from the xy plane to the z axis, leads 
to a regaining of the longitudinal magnetisation, with the relaxation referred to as T1 
relaxation or spin-lattice relaxation, with a relaxation time of T1 (Figure 1.18).  
 
Figure 1.18. A schematic representing of the addition of B1 to 6 nuclei in B0 and the 
subsequent relaxation steps, T2 and T1 relaxation observed after removal of B1. 
T2 and T1 relaxation of a nucleus is affected by the local magnetic fields of 
neighbouring nuclei via dipole/dipole interactions. Therefore, analysing T2 and T1 
relaxation allows for the observation of deviations in the nuclei’s local environment, 
for instance between different healthy tissues and cancerous tissue. T2 relaxation is 
observed by applying B1, removing B1, pausing such that there is maximum variation 
between nuclei with slow relaxation and fast relaxation, which is known as Echo Time 
or TE, and then recording the transverse magnetisation. Nuclei with fast T2 relaxation 
would have desynchronised more than the nuclei with slower T2 relaxation resulting 
in nuclei with fast relaxation having less transverse magnetisation observed (Figure 
1.19). On application of a grey-scale, this would result in slow T2 relaxation nuclei 
appearing lighter whereas fast T2 relaxation nuclei appearing darker. 
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Figure 1.19. A) The loss of transverse magnetisation against time for nuclei with fast 
and slow T2 relaxation and B) the general theory behind observing the differences in 
T2 relaxation between nuclei with fast and slow relaxation experimentally. 
Analysing T1 is more complicated due to only transverse magnetisation being able to 
be analysed effectively, due to all variation in longitudinal magnetisation being 
overwhelmed by B0. First B1 is applied, then time is allowed for T2 and T1 relaxation 
to occur, the time gap between B1 pulses being known as the Repetition Time or TR. 
TR should enable nuclei with fast T1 relaxation to have completely relaxed whereas 
nuclei with slow T1 relaxation to be still in the process.  Then a second B1 pulse is 
administered. The purpose of the secondary pulse is to promote the nuclei in the fully 
relaxed state. For a nucleus with fast T1 the nuclei promoted should be proportionately 
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the same as for the initial B1 pulse as the nuclei have returned to their relaxed state. 
However, for nuclei with slow T1 relaxation, the nuclei have not returned to their 
completely relaxed state. So, this second B1 will result in more nuclei being promoted 
to the high energy state from the low energy state despite the low energy state not 
having been completely repopulated from the first B1, leading to more nuclei being in 
the high energy state than the low. This imbalance causes the direction of the net 
magnetisation of the nuclei to have an antiparallel characteristic with B0. Reducing 
transverse magnetisation and therefore causing a detectable difference between nuclei 
with fast and slow T1 relaxation (Figure 1.20). 
 
Figure 1.20. A) The recovery of longitudinal magnetisation against time for nuclei 
with fast and slow T1 relaxation and B) the general theory behind observing the 
differences in T1 relaxation between nuclei with fast and slow relaxation 
experimentally. 
As multiple analyses are performed for one image, T1 and T2 weighted images are 
described by their pulse sequence. T2 weighted images have a long TR to allow for 
complete relaxation between B1 pulses and a long TE to allow for the deviation 
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between T2 relaxation to be maximised. Whereas T1 weighted images have a short TR 
time to minimise complete relaxation to only the nuclei with fast T1 relaxation and a 
short TE to minimise T2 relaxation between the pulse and data acquisition. 
1.3.3 Contrast Agent Theory 
The sensitivity of MRI is based on the population difference between the number of 
nuclei in the low energy state compared to the high energy state when B0 is applied. 
The population difference is based on a Boltzmann distribution (Equation 1.2), where 
PLow/PHigh is the population difference between the low (PLow) and the high (PHigh) 
energy states, ΔE is the energy difference between the high and the low energy state 
(Joules), kb is the Boltzmann constant (1.38 ×10
-23 J/K) and T is temperature in Kelvin. 
𝑃𝐿𝑜𝑤
𝑃𝐻𝑖𝑔ℎ
=  𝑒
∆𝐸
𝑘𝑏𝑇 (𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.2) 
ΔE for 1H at 20 Tesla = 5.6 x10-25 J, so at 298 K PLow/PHigh = 1.0001. This means for 
every 10,001 1H atoms precessing aligned to B0, 10,000 are aligned against. This 
makes MRI have a very low signal to noise ratio. 
This can be improved by the addition of an MRI contrast agent. As previously stated 
the T1 and T2 relaxation of a nucleus is affected by local magnetic fields via 
dipole/dipole interactions. The dipole/dipole interaction between a nucleus is 
proportional to the γ of the nucleus squared and the external γ squared as stated in the 
Solomon-Bloembergen-Morgan (SBM) Theory for two hydrogen nuclei (Equation 1.3 
and 1.4).251 In these equations for T1 and T2 τc is the correlation time or the time a 
nuclei takes to rotate 1 radian (~57 O), ω is angular velocity, ℏ is h/2π (1.055 x10-34 
J.s), r is distance between spins and γ is the gyromagnetic constant. 
1
𝑇1
=  
6
20
×
ℏ2𝛾4
𝑟6
[
𝜏𝑐
1 +  𝜔2𝜏𝑐2
+  
4𝜏𝑐
1 +  4𝜔2𝜏𝑐2
 ]  (𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.3) 
1
𝑇2
=  
3
20
×
ℏ2𝛾4
𝑟6
[3𝜏𝑐 + 
5𝜏𝑐
1 +  𝜔2𝜏𝑐2
+  
2𝜏𝑐
1 +  4𝜔2𝜏𝑐2
 ]  (𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.4) 
As a lone electron has a gyromagnetic moment 660 times greater than that of a 
hydrogen proton, the dipole/dipole interaction between an electron and a proton is 
435,600 greater than between two protons.252 Therefore to obtain the greatest effect as 
a contrast agent the element or ion with a high number of unpaired electrons would 
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have the greatest effect on neighbouring 1H nuclei and by consequence relaxation. 
Gadolinium, Gd, has an electron configuration [Xe] 4f7 5d1 6s2, which when in its 
ionised (3+) form, Gd3+, is [Xe] 4f7, with each electron unpaired in the f suborbitals. 
This is the largest number of unpaired electrons in any stable element or ion, making 
Gd3+ an excellent candidate for application as an MRI contrast agent. Gd3+ is 
administered to patients in a chelated form to minimise Gd3+ deposition in tissues by 
providing a physical barrier between Gd3+ and cells. However the Gd3+ requires a site 
for water coordination in which to interact with the water in the inner sphere of the 
complex as dipole interaction deteriorates with distance , r, between dipoles by r6 
(Figure 1.21).253 
 
 
Figure 1.21. Schematic representation of inner, second and outer sphere water 
interactions with a Gd3+ contrast agent where τm = water residence time. 
The overall T1 observed by the addition of a contrast being the sum of the T1 relaxation 
provided by the inner sphere (water molecules directly coordinated to the Gd3+ centre), 
TIS, second sphere (water molecules hydrating the complex), TSS, and outer sphere 
(those diﬀusing near the chelate), TOS, (Equation 1.5). However TIS is thought to be 
the largest contributor.254 
Gd3+
Inner sphere
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1
𝑇1
=  
1
𝑇𝐼𝑆
+  
1
𝑇𝑆𝑆
+  
1
𝑇𝑂𝑆
 (𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.5) 
 In 1988 the first Gd3+ based contrast agent, GBCA, known as Gadopentetate 
dimeglumine®, was approved by the U.S Drug and Food Administration, FDA. 
Gadopentetate dimeglumine® used diethylenetriaminepentaacetic acid, DTPA, a 
linear ionic ligand to chelate the Gd3+, Gd3+-DTPA. The latest approved GBCA, 
Dotarem®, uses the macrocyclic ionic ligand 1,4,7,10-Tetraazacyclododecane-
1,4,7,10-tetraacetic acid, DOTA, as the ligand, Gd3+-DOTA (Figure 1.22). 
 
Figure 1.22. The molecular structure of Gd3+-DTPA and Gd3+-DOTA with a single 
coordinated water molecule. 
All MRI contrast agents lower both T1 and T2 relaxation. However, Gd
3+ lowers T1 
significantly more than Gd3+ lowers T2. This is due to T1 primarily being stimulated 
by fluctuating magnetic fields near the Larmor frequency sourced by nearby protons 
and electrons whereas T2 is primarily stimulated by local static magnetic fields such 
as ferromagnetism, represented by the 3τc in Equation 1.6.244 Therefore, Gd3+-DOTA 
is described as a positive contrast agent as it makes the area of its location brighter in 
a T1 weighted image. An MRI contrast agent which lowers T2 more than T1 is called 
a negative contrast agents as it makes the area of its location darker in a T2 weighted 
image.255 Negative contrast agents are based predominantly on iron oxide 
nanoparticles.256 
 
 
Gd-DTPA Gd-DOTA
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1.3.4 Gd3+ Based Contrast Agent, GBCA, Toxicity 
GBCAs are now administered in 35 % of all MRI examinations.257 The possibility of 
having a true allergic reaction is exceptionally rare and most commonly concern mild 
anaphylactoid reactions.258 Immediate adverse reactions, defined as unintended side 
effects occurring within 1 hour of GBCA exposure, are also exceptionally rare.259 
Despite >200 million GBCA administrations, there have been only 614 reports of 
severe adverse reactions (for example hypertensive urgency or refractory vasovagal 
reactions). Of these at least a subset of these physiological reactions may be attributed 
to the Weber and Lalli effects, in which a new pharmaceutical agent to the market or 
to an individual patient results in increased perception and reporting of potential 
adverse effects.260, 261 These results did not vary significantly depending on GBCA 
administered.259, 262-264  
 Kanda et al. reported the increased accumulation of Gd3+ in the brain after 
multiple GBCA administrations.265 The observation of Gd3+ deposits in the brain was 
subsequently confirmed by cadaver studies.266 This finding was GBCA specific 
however with no T1 hypersensitivity found in  rat brain using repeated doses of the 
GBCAs that are based on macrocyclic ligands, such as Dotarem®.267 This variation 
between Gd3+ deposits and GBCAs is due to the linear ligands  allowing 
transmetalation, where endogenous cations such as Cu2+, Zn2+ and Ca2+ displace 
Gd3+.268 Linear ligands are flexible open chains which do not offer strong kinetic 
stability. In contrast macrocyclic ligands are rigid preorganised rings which have been 
specifically designed to be of optimal size to cage Gd3+. This results in the Gd3+ 
complexation within a macrocyclic ligand to be 105 more kinetically stable than linear 
ligand complexation.269, 270  Macrocyclic complexes being more stable than linear 
complexes results in macrocyclic ligand based GBCAs, Like Dotarem®, performing 
less transmetalation as Gd3+ is bound more strongly to the ligand.271 Despite the 
occurrence of these deposits in the brain there have been no histopathological effects 
observed and the identity of the speciation within which Gd is retained in tissues is 
still an ongoing challenge.272, 273  Gd3+ deposits have also been found in the bone274, 
skin275 and liver.276 However Gd3+ was able to be partially  removed from the liver 
tissue by subsequent administration of a chelating agent, deferoxamine®.276 
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 In 2006 the connection between GBCA administration in patient with 
advanced renal disease and the development of nephrogenic systemic fibrosis, NSF, 
was observed.277, 278 NSF is usually a fatal disease that occurs due to the excessive 
production of fibrous connective tissue in the skin, joints, eyes, and internal organs 
because of a reparative response to injury or damage. NSF symptoms most commonly 
appear within 6 months of GBCA exposure, with the clear majority of patients with 
NSF developing the symptoms within 2 years of GBCA exposure.279, 280 However, 
some cases have appeared after 10 years of GBCA exposure.281-283 NSF is exceedingly 
rare with only 1,000 recorded after >200 million GBCA administrations.257 No cases 
have been described in patients without significant renal disease.257 Chronic liver 
disease does not predispose patients to NSF like previously thought.284, 285 Patients 
with chronic kidney disease have decreased incidence of NSF with subsequent dialysis 
after GBCA administration.286 Also, the vast majority of NSF cases occurred after 
receiving a GBCA dose far greater than the currently advised dosages.279, 284 This 
lowering of administered GBCAs and the development towards macrocyclic ligands 
has resulted in few if any cases of NSF resulted from GBCA administration after 
2010.257 There have also been cases of GBCA-induced recurrent pancreatitis and renal 
failure from acute tubular nercosis.287 
 Regarding prenatal and neonatal GBCA administration, there has been no 
statistically increased risk of stillbirth/death, NSF-like outcomes, or congenital 
anomalies after GBCA administration in the first trimester. However, there is an 
increased adjusted relative risk in rheumatological/ inflammatory  conditions and 
stillbirth/neonatal death after administration in the second and third trimester.288 Less 
than 1% of the GBCA dose appears in the patient’s breast milk and of that less than 1 
% reaches the infant bloodstream.289 
1.3.5 GBCAs based on MSNs 
 The limitation of current clinically used GBCAs is that they are based on small 
molecules that lack the sensitivity to provide satisfactory image enhancement in the 
early stages of disease. A method of increasing positive contrast is to further enhance 
T1 relaxation. For GBCAs, T1 relaxation can be enhanced by increasing the number of 
directly coordinated water molecules around Gd3+. However, this leads to less sites 
filled by the ligand, leading to weaker kinetic stability between the Gd3+ and the ligand 
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resulting in greater likelihood of transmetalation and potential Gd3+ deposition in 
tissues. Another method described by Solomon et al. involves the variation of the 
tumbling rate, τR, of the Gd3+ chelate around the Larmor frequency of 1H.290 Solomon 
et al. observed an increase in T1 relaxation when the tumbling rate became closer to 
the Larmor frequency. This observation can be applied to GBCAs by binding the Gd3+ 
complex to a macromolecule, protein or nanoparticle (Figure 1.23).291 
 
Figure 1.23. A schematic illustrating how binding a Gd3+-chelate to a macromolecule 
decreases the tumbling rate, τR, therefore increasing T1 relaxation. A) The τR of the 
lone Gd3+-Chelate, B) The τR Gd3+-chelate chemically bound to a macromolecule. 
Lin et al. in 2004 incorporated Gd3+ into MSNs.292 4 different weight 
percentages, wt%, of Gd3+ with respect to MSN were investigated, 1.6 wt%, 2.3 wt%, 
3.1 wt% and 6.8 wt%. A proportional relationship was observed with wt% of Gd3+ and 
T1 relaxation time at 400 MHz changing T1 in the order 1.6 wt% < 2.3 wt% < 3.1 wt% 
< 6.8 wt%. However, all Gd3+ incorporated MSNs shortened T1 relaxation more than 
Gd3+-DTPA. Taylor-Pashow et al. and Hsiao et al. both independently investigated 
Gd3+- chelate bound to MSNs.293, 294 Taylor-Pashow et al. performed a post synthetic 
modification method on 75 nm MCM-41 nanoparticles with pore diameter ~2.4 nm, 
using Gd bound (trimethoxysilylpropyl)die-ethylenediaminetetraacetate, Gd3+-Si-
DTTA. These MSNs were analysed in-vitro using 3.0 T and 9.4 T MR scanners. Very 
short T1 relaxation rates were observed compared to non-porous silica nanoparticles 
synthesised by the same group.295 This is due to the mesopores of the MSNs providing 
easier access into the magnetic centre, which significantly reduces T1 and T2 
relaxation.296 However, it should be noted that the solid silica nanoparticles used as a 
Fast τR
Slow τR
= Gd3+-Chelate = Macromolecule
A) B)
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comparison in this investigation used DTPA as the chelating ligand for Gd3+, which 
has one coordination site for Gd3+/water interactions to occur compared to DTTA’s 
two. In-vivo studies were performed using the 9.4 T scanner and it was found that the 
same amount of T1 relaxation could be observed administering into mice significantly 
lower dosages than clinically administered using the MSN bound Gd3+-DTTA (2.1 
µmol/kg compared to 0.1-0.3 mmol/kg). Hsiao et al. synthesised 120 nm MSNs with 
mean pore diameter 2.31 nm, that were dual functionalised with fluorescein and Gd3+-
DTPA. These MSNs were successfully applied to the tracking of stem cells in-vivo 
using a 1.5 T clinical MRI scanner. The application of MSNs to the function as a 
GBCA was investigated further by Carniato et al. by substituting the weak chelating 
agents of DTTA and DTPA utilised previously with DOTA.297 Carniato et al. pursued 
the importance of the MSN bound chelate species by modifying the 1,4,7,10‐
tetraazacyclododecane structure and the MSN surface functional groups (Figure 
1.24).297, 298 
 
Figure 1.24. The molecular structure and the computational molecular optimisation 
in 3D space (above) of the DOTA variants investigated by Carniato et al.298 
Craniato et al. concluded from this work that DOTA derivative 1 and the surface 
acetylation of the MSNs provided the largest T1 relaxation. 
The observed enhancement of binding Gd3+-DOTA to MSNs was optimised by Davis 
et al. by manipulating the location of Gd3+-DOTA location.299 In this research 66.3 ± 
6.6 nm MCM-41 MSNs with pore diameter 3.2 ± 1.3 nm were synthesised and Gd3+-
DOTA functionalised using post-synthetic modification and two variants of co-
condensation depending on DOTA-silane addition time. A significant increase of T1 
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relaxation was observed for the co-condensation functionalised MSNs with a long 
delay between the start of MSN synthesis and Gd3+-DOTA addition at 7 T. Also, the 
percentage loading of Gd3+-DOTA on the MSN was investigated with the lowest 
loading analysed (1.37 wt% of Gd3+ with respect to MSN) providing the shortest T1 
relaxation. This agreed with the trend described previously by Lin et al. with Gd3+ 
incorporated MSNs.292  Interestingly 1.37 wt% provided the shortest T1 relaxation 
times compared to the other wt%s even after biomodification with PEG5000. This 
shows that the steric hindrance of water to the Gd3+ complexes from the surface 
modification of MSNs with long polymer chains and proteins doesn’t inhibit the use 
of MSNs as an MRI contrast agent. Karaman et al. pursued the optimisation of MSN’s 
physical properties investigation further.300 Gd3+  was non-covalently incorporated 
into ~500 nm MSNs or hollow MSNs using two different ionic compounds (GdCl3 
and Gd(acetylacetone)3) either post graft or in situ. The effect of whether surfactant 
removal by solvent extraction or calcination was also observed. The conclusion of this 
investigation being that hollow MSNs with post-synthetic Gd(acetylacetone)3 
incorporation with calcination removal of the surfactant provided the optimised MSN 
based GBCA. 
The principal advantage of using MSNs as the macromolecule in which to bind the 
Gd3+-chelate to is their high porosity and high surface area allowing for multiple 
functionality. This allows the GBCA MSNs to have multi modal imaging 
capabilities.301The most popular combination of imaging techniques are MRI and 
optical due to the application of optical imaging being beneficial in surgery and MRI 
for post operation investigations.294, 302-305 The possibility of multiple functionality has 
also been utilised to vary the T1 relaxation enhancement by the response to an external 
stimulus. Huang et al. synthesised Gd3+-DOTA bound biotinylated MSNs (66.3±6.6 
nm diameter) that pores (3.2±1.3 nm diameter) were capped with streptavidin (~5 nm), 
blocking water/Gd3+ interactions and therefore increasing water T1 relaxation times. 
The streptavidin was able to be removed by biotinylated bovine serum albumin, BSA, 
to recover water/Gd3+ interactions and therefore regain shorter water T1 relaxation 
times.306 In addition cell targeting GBCA MSNs have been explored with Taylor et al. 
synthesising Gd3+ doped MSNs that surface functionalised with RGD peptides to 
target colorectal cancer cells.307 It should be noted that considerable non-specific 
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binding between MSNs with no RGD peptide functionalisation and colorectal cancer 
cells was observed.  
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1.4 Aims and Objectives of the PhD 
We initially aimed to probe the impact of pore size on the relaxation behaviour of 
Gd3+-chelate loaded MSNs. It is well known that the diffusional behaviour of water 
changes when confined in different sized spaces. The versatility of MSNs enables ease 
of variation of the pore diameter and coupled with variation of the location of Gd3+-
chelate contrast agents, will facilitate the production of new families of contrast agents 
with relaxation properties which are tuneable according to the nanostructure itself. We 
further aimed to produce stimuli responsive MRI contrast agents based on MSNs 
through the production of hybrid organic-inorganic nanomaterials that would vary 
their physical properties with temperature variation. The ability of MSNs to be used 
for this function is facilitated by their facile functionalisation and high thermal 
stability. Finally, we investigated targeting cells using MSNs that have minimal 
binding affinity to colorectal cancer cells, CRCs, provided again by organic surface 
modification. MSNs utilisation being advantageous to this application again due to the 
ease of MSNs functionalisation and their inherent inertness. Then to induce specific 
binding to the MSNs using lectins to allow for observation of the target cells. MSN 
being able to be dual functionalised being a necessity in this application. 
The specific objectives are: 
• Production of MSNs with varying pore size and similar particle diameters. 
• Immobilisation of Gd3+-chelates onto MSNs with varying pore diameters and 
analysis of their relaxation behaviour. 
• Investigation of polymer functionalisation of MSNs by covalent binding of a 
thermoresponsive polymer 
• Analysis of the polymer’s response to temperature with change in polymer 
density on MSN surface. 
• Immobilisation of Gd3+-chelates onto thermoresponsive polymer surface 
functionalised MSNs and analysis of their relaxation behaviour. 
• Polymer surface functionalisation of MSNs with a biocompatible low cell 
affinity polymer. 
• Varying low cell affinity polymer surface density on MSNs and observe the 
effect on non- specific binding with cells. 
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• Optimisation of polymer surface functionalisation with low cell binding 
affinity polymer to remove reactant impurities. 
• Binding of a lectin to the low affinity polymer MSN surface and investigation 
into specific affinity to colorectal cancer cells, CRC.  
• Investigate toxicity of lectin bound to MSNs with surface modification of low 
cell binding affinity to CRCs. 
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Chapter 2 
2. Experimental Methods 
 
2.1 Materials and General procedures 
2.1.1 Starting Materials 
Triethanol amine (TEA), triethyl amine, tetraethyl orthosilicate (TEOS), (3-
aminopropyl) triethoxysilane (APTES), anhydrous N, N-dimethylformamide (DMF), 
hexadecyltrimethylammonium bromide (CTAB), myristyltrimethylammonium 
bromide, (MYRI), dodecyltrimethylammonium bromide (DODE), α-bromoisubutyryl 
bromide (BIBB), copper bromide, N-isopropylacrylamide (NIPAM). 4,4’-azobis (4-
cyanovaleric acid) (ACVA), N-methyl-N-vinyl acetamide (NVA), methacrylic acid 
(MAA), N-hydroxysuccinimide (NHS), Arachis hypogaea (peanut agglutinin) and 
anhydrous GdCl3 were all purchased from Sigma Aldrich (Haverhill, UK). Absolute 
ethanol and aqueous hydrochloric acid (37 v/v%) were supplied by VWR chemicals 
(Lutterworth, UK). 2,2',2''-(10-(2-((2,5-dioxopyrrolidin-1-yl) oxy)-2-oxoethyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid (DOTA-NHS ester) was 
supplied by CheMatech (Dijon, France). 1,1,4,7,7-pentamethyldiethyltriamine 
(PMDETA) was brought from Acros Organics (Geel, Belgium). NHS fluorescein 
(NHS-FITC) supplied by Thermo Scientific (Loughborough, UK). N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide hydrochloric acid (EDC-HCl) supplied 
by Apollo Scientific (Stockport, UK). All chemicals were used as provided. Ultrapure 
water was obtained from a Millipore Milli-Q gradient machine fitted with a 0.22 µm 
filter operated at 18.2MΩ (at 298 K).  
For the cell assays the Human Caucasian colorectal adenocarcinoma cells (SW480 
(ECACC 87092801)) were obtained from European Collection of Authenticated Cell 
Cultures (Nottingham, UK). 75 cm2 Nunc cell culture flasks, 200 µL of cell culture 
medium in 96-well plates, 0.25% trypsin 1 mM EDTA balanced salt solution, 
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Advanced Dulbecco's Modified Eagle (A-DMEM) Medium were supplied by 
Thermofisher (Rugby, UK). USA-origin foetal bovine serum (FBS), Dulbecco’s 
phosphate buffered saline (PBS) and resazurin sodium salt were supplied by Sigma 
Aldrich (Haverhill, UK).  Penicillin, streptomycin, amphotericin B (PSA) were 
supplied by HyClone (Utah, USA). All chemicals were used as provided. 
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2.2 Experimental Procedures 
2.2.1 Experimental Details for Chapter 3: Investigating the Impact of 
Nanoparticle Design on MRI Contrast Behaviour 
2.2.1.1 Preparation of Mesoporous Silica Nanoparticles with Pore Diameter 
Variation 
MSNs were prepared with varying pore diameters, as described below, following 
previously published techniques.1-3 
hexadecyltrimethylammonium bromide, CTAB, (0.64 g, 1.78 x10-3 mol) was added to 
a solution of MilliQ water (16.02 mL, 0.89 mol) and ethanol (1.84 mL, 0.03 mol). 
Triethanol amine (TEA; 1.03 g, 6.9 x10-3 mol) was added and the solution was stirred 
at 80 OC. Tetraethyl orthosilicate (TEOS; 1.454 mL, 6.51 x10-3 mol) was added 
dropwise and the reaction was stirred for 2 hrs at 80 oC. After this time, the mixture 
was centrifuged (13200 rpm, 20 mins) and the supernatant removed. The nanoparticles 
were dispersed into an acidified ethanol solution (6 mL, 37% HCl in 40 mL ethanol) 
using sonication, then centrifuged and the supernatant removed. This was repeated a 
minimum of three times to remove the surfactant. The nanoparticles were then washed 
three times with ethanol using the same procedure as for the acid washes and retained 
in an ethanol suspension for characterisation.  
An identical procedure with the same relative amounts of chemicals was used initially 
for MSNs prepared using Myristyltrimethylammonium bromide, MYRI, and 
Dodecyltrimethylammonium bromide, DODE. The temperatures of the reactions were 
then repeated with the reaction temperature lowered to 40 OC and 15 OC for MYRI 
and DODE respectively.  
2.2.1.2 Preparation of Mesoporous Silica Nanoparticles with Amine Location 
Variation 
MSNs were prepared with amine functional groups present in different loading 
locations, as described below, following previously published techniques.4, 5  
The MSNs with amine location variation were prepared using the same protocol as the 
mesoporous silica nanoparticles with pore variation using CTAB and MYRI 
surfactants. Except Internally amine functionalised, Internal, MSNs were prepared by 
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10 mins after dropwise addition of TEOS (1.454 mL, 6.51 x10-3 mol) at 80 OC (CTAB) 
or 40 OC (MYRI), APTES/TEOS solution (4.7 µL of a mixture of 1 x10-4 mol APTES 
and 1 x10-4 mol TEOS) was added and the reaction stirred at 80 OC (CTAB) or 40 OC 
(MYRI) for a further 1 h and 50 mins. For edge amine functionalised, Edge, MSNs 
the APTES/TEOS solution (4.7 µL of a mixture of 100 x10-4 mol APTES and 100 
x10-4 mol TEOS) was added 1 hr after dropwise addition of TEOS (1.454 mL, 6.51 
x10-3 mol) at 80 OC (CTAB) or 40 OC (MYRI) and the reaction left at 80 OC (CTAB) 
or 40 OC (MYRI) for a further 1 hr. Finally, externally amine functionalised, External, 
MSNs were left at 80 OC (CTAB) or 40 OC (MYRI) for 2 hrs after dropwise addition 
of TEOS (1.454 mL, 6.51 x10-3 mol). Then the mixture was centrifuged (13200 rpm, 
20 mins), the supernatant removed, and the particles resuspended in a 2:1 volume ratio 
of ethanol to water solution (10 mL). APTES (2.35 µL, 1.03 x10-5 mol) was added and 
this solution allowed to stir overnight at room temperature (~16 hrs). The nanoparticles 
were dispersed into an acidified ethanol solution (6 mL, 37% HCl in 40 mL ethanol) 
using sonication, then centrifuged. This was repeated a minimum of three times to 
remove the surfactant. The nanoparticles were then washed three times with ethanol 
and retained in an ethanol suspension for characterisation. 
2.2.1.3 Gd3+-DOTA Functionalisation 
Aminated MSNs (75 mg) were suspended in anhydrous N, N-dimethylformamide 
(DMF; 6 mL, 7.8 x10-2 mol). DOTA-NHS-ester (2.1 mg, 2.76 x10-6 mol) and 
triethylamine (150 μL, 1.98 x10-3 mol) were added and the suspension was stirred at 
room temperature overnight (~16 hrs). The nanoparticles were washed with ethanol 3 
times using centrifugation (13200 rpm, 20 mins) and re-suspended in ethanol (10 mL, 
1.6 x10-1 mol). Anhydrous GdCl3 (2.1 mg, 7.97 x10
-6 mol) was added and the 
suspension was stirred for 24 hrs at room temperature. Purification was carried out via 
dialysis (3.5 kDa Snakeskin dialysis tubing) against MilliQ water for a minimum of 
24 hrs, changing the Milli-Q water regularly. Nanoparticles were collected in aqueous 
suspension for characterisation. 
Samples were tested for non-specific Gd3+ physisorption to nanoparticle surfaces by 
stirring aminated nanoparticles with GdCl3 (in the same ratio as used for Gd
3+-DOTA 
loading above) overnight at room temperature. Samples were washed using dialysis. 
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2.2.2 Experimental Details for Chapter 4: Thermo-responsive MSNs 
as Diagnostic MRI Contrast Agents 
2.2.2.1 Internally Gd3+-DOTA Functionalised MSN synthesis 
CTAB (0.64 g, 1.78 x10-3 mol) was added to a solution of MilliQ water (16.02 mL, 
0.89 mol) and ethanol (1.84 mL, 0.03 mol). TEA (1.03 g, 6.9 x10-3 mol) was added 
and the solution was stirred at 80 OC to mix. TEOS (1.45 mL, 6.5 x10-3 mol) was added 
dropwise and the reaction stirred for 10 mins at 80 OC. An APTES/TEOS solution (4.7 
µL of a mixture containing a 1:1 molar ratio of APTES:TEOS) was added dropwise 
and the reaction stirred at 80 OC for a further 1 hr and 50 mins. After this time, the 
mixture was centrifuged (11,000 rpm for 10 mins) and the supernatant removed. The 
nanoparticles were centrifuged and dispersed into an acidified ethanol solution (6 mL 
of 37% HCl in 40 mL ethanol) using sonication, centrifugation and removal of the 
supernatant to remove the surfactant. This step was repeated a minimum of 3 times. 
The nanoparticles were subsequently washed three times with ethanol. Nanoparticles 
were centrifuged and resuspended in anhydrous DMF (6 mL, 7.8 x10-2 mol). DOTA-
NHS-ester (2.1 mg, 2.76 x10-6 mol) and triethylamine (150 μL, 1.98 x10-3 mol) were 
added and the suspension was stirred at room temperature overnight (~16 hrs). The 
nanoparticles were washed with ethanol 3 times using centrifugation (11,000 rpm for 
10 mins) and re-suspended in ethanol (10 mL). Anhydrous GdCl3 (2.1 mg, 7.97 x10
-6 
mol) was added and the suspension was stirred for 24 h at room temperature. Washing 
was carried out by dialysing (3.5 kDa Snakeskin dialysis tubing) against MilliQ water 
for a minimum of 24 hrs, changing the Milli-Q water regularly.  
2.2.2.2 ‘Grafting From’ Method of pNIPAM Addition to MSNs 
Using a modified literature procedure,6 the Gd3+-DOTA MSNs were suspended in a 
mixture of ethanol (20 mL, 3.3 x10-1 mol) and water (10 mL, 5.6 x10-1 mol). Varying 
amounts of APTES (measured in mol% with respect to moles of TEOS used in the 
MSN synthesis step; 3.2 µL, 1.4 x10-5 mol for 0.2 mol% loading; 16 µL, 6.8 x10-5 mol 
for 1 mol% loading; 40 µL, 1.7 x10-4 mol for 2.5 mol% loading) were added and stirred 
at room temperature for ~16 hrs. These externally aminated Gd3+-DOTA MSNs were 
washed three times with ethanol and resuspended in dichloromethane (DCM; 7 mL, 
1.1 x10-1 mol). BIBB (1 mL, 8.1 x10-3 mol) and triethylamine (20 µL, 1.43 x10-4 mol) 
was added with. The solution was stirred at 0 OC for 2 hrs, then allowed to warm to 
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room temperature and stirred at room temperature for 14 hrs. The MSNs were then 
washed with MIlliQ water three times using centrifugation (11,000 rpm for 10 mins). 
Finally, NIPAM was attached to the particles by re-suspending the prepared (BIBB 
surface modified) MSNs in a mixture of methanol (4 mL, 9.9 x10-2 mol) and water (6 
mL, 3.3 x10-1 mol), using ultrasonication. This suspension was degassed by bubbling 
with N2 for 30 minutes. Separately, copper bromide (6 mg, 4.18 x10
-5 mol), PMDETA 
(50 µL, 2.44 x10-4 mol), and NIPAM (0.75 g, 6.63 x10-3 mol) was added to a mixture 
of methanol (4 mL, 9.9 x10-2 mol) and water (6 mL, 3.3 x10-1 mol). This solution was 
degassed by bubbling with N2 for 30 mins. These two suspensions were combined and 
stirred under N2 for 16 hrs and subsequently centrifuged at 13,200 rpm for 10 minutes, 
followed by re-suspension in acidified MilliQ water (20 mL MilliQ water and 2 mL 
of a 0.1 M HCl solution) and dialysed (3.5 kDa Snakeskin dialysis tubing) against 
MilliQ water for a minimum of 24 hrs, changing the MilliQ water regularly. Resulting 
polymer-grafted Gd3+-DOTA MSNs were collected in aqueous suspension for 
characterisation. 
2.2.2.3 Preparation of pNIPAM 
To determine the approximate length of the polymer chains grafted from the 
nanoparticle surfaces, pNIPAM was synthesised using the same conditions as used 
above, but in the absence of nanoparticles. In separate reaction vessels, amounts of 
BIBB equivalent to that grafted onto nanoparticles surfaces (1.69 µL, 1.4x10-5 mol, 
equivalent to 0.2 mol% grafting density; 8.45 µL, 6.8 x10-5 mol, equivalent to 1 mol% 
grafting density; and 21.1 µL, 1.7 x10-4 mol, equivalent to 2.5 mol% grafting density) 
were added to a mixture of methanol (4 mL, 9.9 x10-2 mol) and water (6 mL, 3.3 x10-
1 mol) and degassed by bubbling with N2 for 30 mins. Separately, copper bromide (6 
mg, 4.18 x10-5 mol), PMDETA (50 µL, 2.44x10-4 mol), and NIPAM (0.75 g, 6.63x10-
3 mol) were added to a mixture of methanol (4 mL, 9.9 x10-2 mol) and water (6 mL, 
3.3 x10-1 mol). This solution was degassed by bubbling with N2 for 30 mins. These 
two suspensions were combined and stirred under N2 for 16 hrs and subsequently dried 
using rotary evaporation and suspended in methanol (1 mL, 2.5 x10-2 mol) and added 
to diethyl ether (40 mL, 3.8 x10-1 mol) to precipitate the polymer. The suspension was 
centrifuged at 11,000 rpm for 10 minutes, the solvent removed, and the precipitate re-
suspended again in methanol (1 mL, 2.5 x10-2 mol) and precipitation in diethyl ether 
was repeated. The polymers were finally stored as dried powders.  
 65 
 
2.2.3 Experimental Details for Chapter 5: The Application of MSNs 
as a Fluorescent Marker for Colorectal Cancer Cells 
2.2.3.1 Preparation of Internally Fluorescein Functionalised MSNs  
CTAB (0.64 g, 1.78 x10-3 mol) was added to a solution of MilliQ water (16.02 mL, 
0.89 mol) and ethanol (1.84 mL, 0.03 mol). TEA (1.03 g, 6.9 x10-3 mol) was added 
and the solution was stirred at 80 OC to mix. TEOS (1.45 mL, 6.5 x10-3 mol) was added 
dropwise and the reaction was stirred for 10 mins at 80 OC. An APTES/TEOS solution 
(4.7 µL of a mixture containing a 1:1 molar ratio of APTES:TEOS) was added 
dropwise and the reaction stirred at 80 OC for a further 1 hr and 50 mins. After this 
time, the mixture was centrifuged (11,000 rpm for 10 mins) and the supernatant 
removed. The nanoparticles were centrifuged and dispersed into an acidified ethanol 
solution (6 mL of 37% HCl in 40 mL ethanol) using sonication, centrifugation and 
removal of the supernatant to remove the surfactant. This step was repeated a 
minimum of 3 times. The nanoparticles were subsequently washed three times with 
ethanol. Nanoparticles were centrifuged and resuspended in anhydrous 
tetrahydrofuran (THF; 10 mL, 1.2 x10-1 mol). FITC-NHS-ester (2.1 mg, 2.76 x10-6 
mol) and triethylamine (75 μL, 9.45 x10-4 mol) were added and the suspension was 
stirred at room temperature overnight (~16 hrs). The nanoparticles were washed with 
ethanol 3 times using centrifugation (11,000 rpm for 10 mins) and re-suspended in 
ethanol (20 mL, 3.3 x10-1 mol).  
2.2.3.2 ‘Grafting From’ Method of NVA/MAA Copolymer Addition to MSNs 
using Free Radical Polymerisation 
the FITC-modified MSNs were suspended in a mixture of ethanol (20 mL, 3.3 x10-1 
mol) and water (10 mL, 5.6 x10-1 mol). Varying amounts of APTES (measured in 
mol% with respect to moles of TEOS used in the MSN synthesis step; 3.2 µL, 1.4 x10-
5 mol for 0.2 mol% loading; 16 µL, 6.8 x10-5 mol for 1 mol% loading). Then using a 
modified literature procedure,7, 8 These externally aminated FITC MSNs were washed 
three times with ethanol and resuspended in DMF (10 mL, 1.3 x10-1 mol). Separately, 
4,4′-Azobis(4-cyanovaleric acid), (ACVA; 0.05 g, 1.78 x10-4 Mol),  N-Ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC-HCl; 0.1 g, 5.22 x10-4 mol), 
N-hydroxysuccinimide (NHS; 0.1 g, 8.68 x10-4 mol) were dissolve into DMF (10 mL, 
1.3 x10-1 mol) and left stirring for 30 mins. Then this ACVA solution was added to 
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the MSN solution and left for overnight (~16 hrs). This solution was then washed three 
times using ethanol and dispersed in ethanol (25 mL, 3.3 x10-1 mol). Dodecanethiol 
(514 µL, 2.15 x10-3 Mol) was added and the solution degassed under N2 atmosphere 
for 30 mins. N-vinylacetamide (NVA; 5 mL, 0.048 mol) and methacrylic acid (MAA; 
5 mL, 0.059 mol) were degassed for 30 mins under N2 atmosphere and subsequently 
added to the MSNs solution. This combined solution was freeze thawed three times 
and heated to 60 OC and left for 16 hrs in the absence of light. Finally, the solution 
was dried using rotary evaporation and suspended in methanol (1 mL, 2.5 x10-2 mol) 
and added to ethyl acetate (40 mL, 4.1 x10-1 mol) to precipitate the polymer. The 
suspension was centrifuged at 11,000 rpm for 10 minutes, the solvent removed, and 
the precipitate re-suspended again in methanol (1 mL, 2.5 x10-2 mol) and precipitation 
in ethyl acetate was repeated. The precipitated polymer surface functionalised MSNs 
were then stored in ethanol (~20 mL, 3.3 x10-1 mol). 
2.2.3.3 NVA/MAA Copolymer Synthesis using Free Radical Polymerisation 
To determine the approximate length of the polymer chains grafted from the 
nanoparticle surfaces, NVA/MAA copolymer was synthesised using the same 
conditions as used above, but in the absence of nanoparticles. In separate reaction 
vessels, amounts of ACVA equivalent to that grafted onto nanoparticles surfaces (4 
mg, 1.4x10-5 mol, equivalent to 0.2 mol% grafting density; 19 mg, 6.8 x10-5 mol, 
equivalent to 1 mol% grafting density) was dissolved in ethanol (25 mL, 4.1 x10-1 
mol). to this solution dodecanethiol (514 µL, 2.15 x10-3 mol) was added and degassed 
under N2 atmosphere for 30 mins. NVA (5 mL, 4.8 x10
-2 mol) and MAA (5 mL, 5.9 
x10-2 mol) were degassed for 30 mins under N2 atmosphere and added to the ACVA 
solution. This combined solution was freeze thawed three times. Then the solution was 
heated up to 60 OC and left for 16 hrs. Finally, the solution was dried using rotary 
evaporation and suspended in methanol (1 mL, 2.5 x10-2 mol) and added to ethyl 
acetate (40 mL, 4.1 x10-1 mol) to precipitate the polymer. The suspension was 
centrifuged at 11,000 rpm for 10 minutes, the solvent removed, and the precipitate re-
suspended again in methanol (1 mL, 2.5 x10-2 mol) and precipitation in ethyl acetate 
was repeated. The polymers were stored as dried powders. 
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2.2.3.4 ‘Grafting From’ Method of NVA/MAA Copolymer Addition to MSNs 
using Atom Transfer Radical Polymerisation 
Using a modified literature procedure,6 the FITC-modified MSNs were suspended in 
a mixture of ethanol (20 mL, 3.3 x10-1 mol) and water (10 mL, 5.6 x10-1 mol).  APTES 
(measured in mol% with respect to moles of TEOS used in the MSN synthesis step; 
3.2 µL, 1.4 x10-5 mol for 0.2 mol% loading) were added and stirred at room 
temperature for 16 hrs. These externally aminated FITC modified MSNs were washed 
three times with ethanol and resuspended in dichloromethane (7 mL, 1.1 x10-1 mol). 
BIBB (1 mL, 8.1 x10-3 mol) and triethylamine (20 µL, 1.43 x10-4 mol) was added. The 
solution was stirred at 0 oC for 2 hrs, then allowed to warm to room temperature and 
stirred at room temperature for 16 hrs. The MSNs were then washed with MIlliQ water 
three times using centrifugation (11,000 rpm for 10 mins). Finally, NVA/MAA 
copolymer was attached to the particles by re-suspending the prepared (BIBB surface 
modified) MSNs in a mixture of methanol (4 mL, 9.9 x10-2 mol) and water (6 mL, 3.3 
x10-1 mol), using ultrasonication. This suspension was degassed by bubbling with N2 
for 30 minutes. Separately, copper bromide (6 mg, 4.18 x10-5 mol), PMDETA (50 µL, 
2.44 x10-4 mol), NVA (1 mL g, 9.6 x10-3 mol) and MAA (1 mL, 1.2 x10-2 Mol) was 
added to a mixture of methanol (4 mL, 9.9 x10-2 mol) and water (6 mL, 3.3 x10-1 mol). 
This solution was degassed by bubbling with N2 for 30 mins. These two suspensions 
were combined and stirred under N2 for 16 hrs and subsequently centrifuged at 11,000 
rpm for 10 minutes, followed by re-suspension in acidified MilliQ water (20 mL 
MilliQ water and 2 mL of a 0.1 M HCl solution) and dialysed (3.5 kDa Snakeskin 
dialysis tubing) against MilliQ water for a minimum of 24 hrs, changing the MilliQ 
water regularly. Resulting polymer-grafted FITC-MSNs were collected in aqueous 
suspension for characterisation. 
2.2.3.5 PNA Functionalisation of NVA/MAA Surface Functionalised Fluorescein 
MSNs 
NVA/MAA copolymer surface functionalised fluorescein MSNs obtained using 
ATRP (50 mg) were suspended in water (10 mL, 5.6 x10-1 mol).  NHS (5 mg, 4.34 
x10-5 Mol) and EDC-HCl (5 mg, 2.61 x10-5 mol) were added to the solution and the 
solution left stirring for 30 mins. Then peanut agglutinin (PNA, 5 mg) was added and 
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left overnight (~16 hrs). The MSNs were then washed with water 3 times and left in 
an aqueous solution.  
2.2.3.6 NVA/MAA Copolymer Synthesis using Atom Transfer Radical 
Polymerisation 
To determine the approximate length of the polymer chains grafted from the 
nanoparticle surfaces, NVA/MAA copolymer was synthesised using the same 
conditions as used above, but in the absence of nanoparticles. The amount of BIBB 
equivalent to that grafted onto nanoparticles surfaces (1.69 µL, 1.4x10-5 mol, 
equivalent to 0.2 mol% grafting density) was added to a mixture of methanol (4 mL, 
9.9 x10-1 mol) and water (6 mL, 3.3 x10-1 mol) and degassed by bubbling with N2 for 
30 mins. Separately, copper bromide (6 mg, 4.18 x10-5 mol), PMDETA (50 µL, 
2.44x10-4 mol), NVA (1 mL g, 9.6 x10-3 mol) and MAA (1 mL, 1.2 x10-2 Mol) were 
added to a mixture of methanol (4 mL, 9.9 x10-1 mol) and water (6 mL, 3.3 x10-1 mol). 
This solution was degassed by bubbling with N2 for 30 mins. These two suspensions 
were combined and stirred under N2 for 16 hrs and subsequently dried using rotary 
evaporation and suspended in methanol (1 mL, 2.5 x10-2 mol) and added to ethyl 
acetate (40 mL, 4.1 x10-1 mol) to precipitate the polymer. The suspension was 
centrifuged at 11,000 RPM for 10 minutes, the solvent removed, and the precipitate 
re-suspended again in methanol (1 mL, 2.5 x10-2 mol) and precipitation in ethyl acetate 
was repeated. The polymer was finally stored as dried powders.  
2.2.3.7 Colon Cancer Cell Interaction Assay Performed by Trisha Bailey 
Cell culture.  Human Caucasian colorectal adenocarcinoma cells (SW480 (ECACC 
87092801)) were grown in 75 cm2 Nunc cell culture flasks. Standard cell culture 
medium was composed of Advanced Dulbecco's Modified Eagle (A-DMEM) Medium 
supplemented with 10 % USA-origin fetal bovine serum (FBS), 100 units/mL 
penicillin, 100 µg/mL streptomycin, and 250 ng/mL amphotericin B (PSA). SW480 
cells were maintained in a humidified atmosphere of 5 % CO2 and 95 % air at 37 
OC 
and the culture medium was renewed every 3–4 days. The cells were subcultured every 
7 days or before reaching 90 % confluency. To subculture, cells were dissociated using 
0.25 % trypsin plus 1 mM EDTA in balanced salt solution and reseeded at 1.87 x105 
cells per 75 cm2 cell culture flasks.  
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Particle solutions. Particles were suspended in ethanol and then spun down at 2g for 
10 minutes.  Ethanol was removed, and particles were re-suspended in A-DMEM in 
the indicated concentrations.       
SW480 binding assay.  SW480 cells were seeded at 6.0 x104 cells per well in 200 µL 
of cell culture medium in 96-well plates. Cells were incubated for 2 hrs in a humidified 
atmosphere of 5 % CO2 and 95 % air at 37 
OC. Following the incubation period, cell 
medium was removed and replaced with the indicated concentration of particles in cell 
media.  Cells were then incubated for 24 hrs.    Cells were then washed twice with 
Dulbecco’s phosphate buffered saline (PBS) and fluorescent readings were taken at 
excitation 485 nm and emission at 528 nm. 
2.2.3.8 Cell Toxicity Screening Performed by Trisha Bailey 
Cell toxicity screening. SW480 cells were seeded at 6 x104 cells per well in 200 μL of 
complete cell culture medium in 96-well plates. Plates had an approximate growth 
area of 0.32 cm2 and plates were used with the accompanying lid.  Cells were allowed 
to attach to the entire free surface of the bottom of the well and formed a confluent 
layer not greater in height than one cell. Before experimental treatments, cells were 
allowed to attach for 2 hrs to the plates in a humidified atmosphere of 5 % CO2 and 
95 % air at 37 OC. The medium was exchanged against medium that was or was not 
supplemented with particles as indicated in the figures. Control cells received no 
additional solutes and experimental cells were incubated with concentrations of the 
individual particles ranging from 0.00122 to 2.5 mg mL-1 for 24 hrs in a humidified 
atmosphere of 5% CO2 and 95% air at 37 
OC. Following the incubation period, 
resazurin sodium salt was dissolved in phosphate buffered saline and added to wells 
in an amount of 1/10th initial well volume. Absorbance readings were taken at 570/600 
nm every 30 minutes until control cells reached ~70 % reduction.   
Statistical analyses.  Data was analyzed with a one-way analysis of variance 
(ANOVA) on ranks followed by comparison of experimental groups with the 
appropriate control group (Holm–Sidak method) followed by Tukey’s post hoc test. 
Excel 2013 (Microsoft, Redmond, WA) and R (R Foundation for Statistical 
Computing, Vienna, Austria) were used for the analyses. 
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2.3 Characterisation Techniques 
2.3.1 Infrared Spectroscopy 
FTIR spectra (4000-400 cm-1) were acquired using a Bruker Alpha FT-IR 
spectrometer fitted with a ZnSe crystal on solid powder samples. 
2.3.2 Thermogravimetric Analysis 
Thermogravimetric analysis (TGA) was carried out using a Mettler-Toledo DSC1-400 
using alumina pans heated from 30-600 OC after 30 minutes equilibration at 30 OC, 
heating at 10 OC/ min under an atmosphere of N2. 
2.3.3 Dynamic Light Scattering and Zeta Potential 
Hydrodynamic diameters and zeta potentials were determined by dynamic light 
scattering (DLS) using a Malvern Zetasizer Nano instrument. A 4 mW He-Ne 633 nm 
laser module was used, and scattered light was measured at 173o (back scattering). 
The attenuator and position were selected automatically by the instrument and the 
particle sizes reported as the average of five measurements. PDI indicated the 
polydispersity index of the suspensions. MSNs were suspended at 1 mg/mL 
concentrations in Ultrapure MilliQ water for measurement.   
2.3.4 Small Angle X-ray Scattering (SAXS) 
Small angle X-ray scattering (SAXS) was carried out using a PANalytical X’pert Pro 
MPD using a Cu Kα anode. Samples were analysed using 2-hour scans on solid powder 
samples on EasySAXS software. 
2.3.5 Porosimetry 
Porosimetry data was acquired using a Micromeritics ASAP 2020 surface area and 
porosity analyser using N2 as the analytical gas. Pore size distributions were calculated 
from adsorption using the Barrett-Joyner-Halenda (BJH) method.9 
2.3.6 Transmission Electron Microscopy 
Transmission electron microscope (TEM) images were obtained on a JEOL 2000FX 
TEM, 200 kV, LaB6 instrument operated with a beam current of ~115 mA. Images 
were captured using a Gatan Orius 11-megapixel camera. Samples were prepared by 
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deposition and drying of nanoparticle samples (10 µL water suspension) onto formvar-
coated 300 mesh copper TEM grids (Agar Scientific). Diameters were measured using 
Image J version 3.2; average values were calculated by counting a minimum of one 
hundred particles. 
2.3.7 Gel Permeation Chromatography Performed by Christopher 
Stubbs 
Size exclusion chromatography was performed on an Agilent 390-LC MDS 
instrument equipped with differential refractive index (DRI), viscometry (VS), dual 
angle light scatter (LS) and UV detectors. The system was equipped with 2 x PLgel 
Mixed D columns (300 x 7.5 mm) and a PLgel 5 µm guard column. The eluent is DMF 
with 5 mmol NH4 BF4 additive. Samples were run at 1 ml/min at 50 
OC. Poly (methyl 
methacrylate) standards (Agilent EasyVials) were used for calibration between 
955,000–550 gmol-1. Analyte samples were filtered through a nylon membrane with 
0.22 μm pore size before injection. Respectively, experimental molar mass (Mn, SEC) 
and dispersity (Đ) values of synthesized polymers were determined by conventional 
calibration and universal calibration using Agilent GPC/SEC software. 
2.3.8 Turbidimetry Analysis 
Turbidimetry analysis was carried out through the acquisition of UV-vis spectra 
using a UV-Vis Agilent Technologies Cary 60 UV/Vis at λ = 700 nm every 1 
OC, with temperature controlled by Quantum North West TC1 Temperature 
controller starting at 25 OC and ending at 50 OC with an equilibration time of 3 
mins and the temperature increasing by 1 degree/min. Samples were prepared 
by diluting using MilliQ water to 2.5 mg/mL.  
2.3.9 UV/vis Spectroscopy and Fluorometry with Cell Cultures 
The cells were incubated in 96 well plates and analysed using the Synergy HTX Multi-
Mode Reader (BioTek, Swindon, UK) at 570/600 nm absorbance for the toxicity test 
and fluorescent readings were taken at excitation 485 nm and emission at 528 nm for 
the cell binding assay. 
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2.3.10 Ion Coupled Plasma Mass Spectroscopy 
An Agilent 7500cx Inductively Coupled Plasma Mass Spectrometer (ICP-MS) was 
used to determine Gd3+ concentrations of aqueous suspensions of particles treated by 
hot nitric acid digestion and diluted in ultrapure MilliQ water. 
2.3.11 T1 relaxation Spectroscopy 
2.3.11.1 13.1 MHz Xigo 
Relaxation measurements (T1) were carried out at room temperature using a XIGO 
Acorn instrument with a resonant frequency of 13.1 MHz. Samples were prepared by 
dispersing a known mass of nanoparticles or Gd3+-DOTA into Ultrapure water. A 
minimum of 4 different concentrations were prepared and protic relaxation time 
measured for each sample. r1 relaxivity values were calculated from curves plotted of 
R1 (1/T1, s
-1) vs. [Gd] concentration (mM, as measured by ICP-MS) and analysis of 
the slope of the line of best fit for each sample. Multiple batches of samples were 
analysed to confirm reproducibility and to provide standard deviations (a minimum of 
3 separately prepared samples were measured at least 3 times).  The water 1H 
longitudinal relaxation rates of these aqueous samples were measured at 293 K using 
the standard inversion-recovery method with settings: Rx Gain 10 dB, pre-amp tuning 
310, 90o pulse duration 6.2 µs, 180o pulse duration 13.9 µs. 
2.3.11.2 9.4 T MRI Scanner Performed by Ziedo Solomon 
High field relaxation measurements were carried out on a Bruker 400 MHz (9.4 T) 
NMR Spectrometer fitted with a Bruker micro-imaging MicWB40 probe, funded 
through Birmingham Science City Translational Medicine Project. The water 1H 
longitudinal relaxation times of the aqueous samples (as prepared above) were 
measured at 293 K using the standard inversion-recovery method with settings: echo 
time 10 ms (1 average, 1 repetition); T1 experiments taken of 7 slices with 2 mm 
thickness; image size 64x64 with 12x12 mm field of view; resolution 0.188x0.188 
mm. Standard deviation results from the analysis of pixels within a (circular) region 
of interest on at least one slice containing a minimum of 6366 pixels.  
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2.3.11.3 3 T MRI Scanner Performed by Dr Sarah Wayte 
MR images were acquired on a Siemens 3 T clinical imaging machine. T1 
weighted fast spin echo images were acquired using the following parameters: 
- TR/TEeff = 600/8.9ms, field of view=200x160mm, matrix size = 256x224, slice 
width = 2.5mm, slice gap = 0mm, 4 signal averages and acquisition time = 2min 
27s. Samples were prepared by diluting using MilliQ water to 2.5 mg/mL. 
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Chapter 3 
3. Investigating the Impact of 
Nanoparticle Design on MRI Contrast 
Agent Behaviour 
 
3.1 Chapter Summary 
Magnetic resonance imaging, MRI, is a popular clinical analytical method due 
to its non-invasive nature and ability to provide a high-resolution deep tissue 
penetrating images. The administration of contrast agents to enhance the efficacy of 
MRI is common practice and an area in which nanomaterials have shown great 
promise. Despite their clear potential as high contrast agents, the influence of the 
nanostructure itself on contrast enhancement has been largely overlooked. Herein, 
mesoporous silica nanoparticles, MSNs, with different pore sizes were prepared by 
employing different surfactants during preparation. During synthesis, the surfactants 
control the size of templating micellar structures around which the silica network of 
the particles form, through their different hydrocarbon tail group lengths.  The 
surfactants utilised were dodecyltrimethylammonium bromide, DODE, 
myristyltrimethylammonium bromide, MYRI, and hexadecyltrimethylammonium 
bromide, CTAB. The MSNs were prepared using similar protocols and analysed by 
transmission electron microscopy, TEM. Synthetic protocol optimisation was carried 
out by varying the reaction temperature to produce particles of comparable particle 
diameter. This is a vital consideration in ensuring that only pore size impacts MRI 
behaviour as particle diameter affects relaxation through τR.  Optimisation was only 
achieved reproducibly with CTAB and MYRI MSNs. Therefore, CTAB and MYRI 
MSNs were further characterised and the pore diameter was proven to be smaller for 
MYRI MSNs than for CTAB MSNs by small angle X-ray scattering, SAXS, and 
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porosimetry. Subsequent immobilisation of Gd3+-chelates on these different pore sized 
MSNs was investigated to determine the effect of different pore sized nanoparticles 
MRI relaxation behaviour. MSNs were Gd3+ bound in 1,4,7,10-
Tetraazacyclododecane-1,4,7,10-tetraacetic acid complex, Gd3+-DOTA, 
functionalised in three differing locations, inside the pores, Internal, both in the pore 
and on the surface, Edge, or on the surface of the MSNs, External, through control of 
the synthesis. These variations were then analysed at 13.1 MHz to obtain their 
relaxivity trends. It was observed that for the CTAB MSNs, which obtained the larger 
pores, Gd3+-DOTA location had no significant effect on relaxivity due to no significant 
water and Gd3+ interaction variation. However, for the MYRI MSNs the relaxivity was 
suppressed when the Gd3+-DOTA was deeply internalised within the pore structures, 
then partially regained when the Gd3+-DOTA was bound at the mouths of the pores, 
and fully recovered when the Gd3+-DOTA was bound to the external surfaces of the 
MSNs. This is due to the smaller pores of the MYRI MSNs restricting the availability 
of the Gd3+-DOTA therefore hindering water/Gd3+ interactions. Particles were 
characterised in detail using TEM, small angle x-ray scattering, SAXS, gas sorption 
porosimetry, Fourier transform infrared spectroscopy, FTIR, dynamic light scattering, 
DLS, and zeta potential, thermogravimetric analysis, TGA, and relaxometry at 13.1 
MHz.  
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3.2 Introduction 
In 2008, Kecht et al. proposed a method of selective location functionalisation 
of MSNs.1 This was achieved by performing a co-condensation reaction to form the 
MSNs with the addition of the amine functionalised silanol, (3-
Aminopropyl)triethoxysilane, APTES, varied by alteration in APTES administration 
time to the MSNs synthesis to alter subsequent location  on the MSNs. The variation 
of functional group location was confirmed by zeta potential in acidic solution. It was 
found that the addition of an APTES/TEOS solution during the MSN synthesis after 5 
mins produced MSNs with a lower zeta potential than addition after 10 mins and the 
MSNs obtained from the 10 mins addition having a lower zeta potential than after 30 
minutes. This variation is due to the amine functional groups in APTES all being 
protonated, therefore giving the MSNs a positive charge at low pH. The MSNs 
obtained after APTES/TEOS addition after 30 minutes have more protonated amine 
groups on the surface of the MSNs and therefore contribute to the zeta potential. The 
MSNs with APTES/TEOS addition after 5 and 10 mins have more protonated amine 
groups inside the pores which do not contribute as much to the zeta potential of the 
MSNs, resulting in less positive zeta potential. APTES/TEOS addition after 30 mins 
did not increase the zeta potential significantly as the MSNs are already fully formed 
and surface functionalised at this point. The location was also confirmed using 
scanning transmission electron microscopy, STEM, where iridium was bound to the 
aminopropyl groups and used as a contrast agent to observe APTES location. This 
control of functional group location was developed further by V. Cauda et al. by 
synthesising bi-functional MSNs with controlled functional group location.2 The 
location of the functional groups confirmed by a fluorescence quenching experiment. 
J. Davis et al. utilised this method of functionalisation location control to 
investigate nanoconfinement effects of Gd3+-DOTA chelates bound to various 
locations and MRI contrast efficacy.3 Using a 2 hrs reaction protocol with the CTAB 
surfactant being utilised as the soft template, a 1:1 molar solution of APTES and TEOS 
was added to the MSN synthesis reaction either 10 minutes into the reaction, Internal, 
1 hr into the reaction, Edge, and APTES post grafted onto the surface of the MSNs, 
External. These aminated MSNs at various locations were then Gd3+-DOTA 
functionalised and analysed in a 7 T MRI scanner. A considerable increase in MRI 
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activity was observed for the Edge MSNs (33.57 ± 1.29 mM-1 s-1) compared to the 
Internal (17.14 ± 0.49 mM-1 s-1) and External (10.77 ± 0.22 mM-1 s-1). This observed 
phenomenon was attributed to the porous network affecting the diffusion and the 
rotation mobility of pore confined water compared to bulk water. S. Aime et al. 
observed a similar enhancement encapsulating Gd3+-DOTA into aptoferritin.4 
Aptoferritin is a spherical protein shell consisting of 24 subunits and a central cavity. 
The spherical shell can be disassembled and reassembled by pH variation. This 
methodology of assembly was utilised to encapsulate Gd3+-DOTA into the central 
cavity resulting in a massive relaxivity enhancement of >20x that of free Gd3+-DOTA 
at 20 MHz (80 ± 5 mM-1 s-1 to 4.2 mM-1 s-1 respectively). J. S Ananta et al. observed 
T1 relaxation enhancement by confining Gd
3+ ions into the nonporous structure of 
silicon nanoparticles.5 Again exceptional enhancements in relaxivities were observed, 
the encapsulation of gadofullerenes into porous silicon nanoparticles resulted in a 
relaxivity of 200 mM-1 s-1 at 20 MHz, a 50x increase compared to clinically available 
GBCAs. P. H. Fries et al. investigated this encapsulation enhancement theoretically.6 
The suggested factor which contributes to this observed relaxivity enhancement after 
encapsulation is the increased local viscosity of the aqueous solution around the Gd3+-
chelate increasing the amount of water molecules surrounding the Gd3+-chelate, 
therefore increasing the amount of water which can interact with Gd3+, hence 
increasing relaxivity.  
 There have been numerous investigations into how nanoconfinement effects 
water molecules and how variation in the pore diameter effects water mobility. S. 
Takahara et al. analysed MSNs suspended in water by neutron scattering to observe 
the translational diffusion of water in pores of diameter 21.4 Å and 28.4 Å.7 A 
significant deceleration in diffusion was observed with the decreased pore size. I. 
Brovchenko et al. studied water phase transitions in nanopores theoretically and 
observed an increase in phase transition temperature with increased pore diameter.8 A. 
A Milischuk et al. investigated theoretically the structure and dynamics of water in 
silica nanopores.9 Analysing pore diameter of 20 Å and 40 Å the mobility of the water 
molecules was found to modestly increase with increased pore diameter. E. Belorizky 
et al. investigated how confining water into the nanopores of Imogolite, a hydrous 
aluminosilicate found in soil, of outside pore diameter of 2.3 - 2.7 nm and internal 
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diameters of ~ 1 nm.10 the diffusion of the water was found to be ~ 4x slower in the 
pores than in the bulk water, which resulted in a significantly enhanced relaxation rate. 
 Since mesoporous silica nanostructures are widely used in several applications 
from catalysis to sorption, their structural parameters have been varied in a bid to tune 
their behaviour in these applications. Their overall size can be modified through small 
changes to the synthetic protocol, such as increasing temperature, amount of catalyst 
and source silicates; their pore sizes can also be varied through careful choice of 
reagents.11, 12 One method was by changing the carbon chain length of the cationic 
surfactant for example varying  the chain length from CnH2n +1(CH3)N
+ from n = 8 to 
n = 16 changed the pore diameter from 18 Å to 36 Å. Whilst the pore diameter was 
shown to increase on addition of mesitylene of various quantities to pore diameters 
between 85 Å and 120 Å. Therefore the ease of controlling functional group location,1 
the facile method of changing the pore diameter11 and the simple methodology of 
covalently binding Gd3+-DOTA to MSNs via surface amination of the MSNs and 
2,2′,2”-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTA-NHS-ester) 13 makes them a 
perfect scaffold in which to investigate the effect of varying water accessibility to 
Gd3+-chelate. 
3.2.1 Aims 
The aim of this chapter was to investigate the impact on MRI contrast 
enhancement behaviour (in terms of protic relaxation) of varying the pore diameter of 
MSNs while controlling particle diameter. 
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3.3 Preparation and Characterisation of MSNs with 
Controlled Variation of Pore Diameter and Gd3+-DOTA 
Functionalisation Location 
MSNs samples were synthesised using a basic hydrolysis and condensation 
reaction in the presence of surfactants to produce mesoporous nanostructures (Figure 
3.1).14 
 
 
Figure 3.1. General schematic representation of the synthesis of mesoporous silica 
nanoparticles. 
In this reaction the surfactant provides a surface in which the tetraethyl 
orthosilicate, TEOS, can react via hydrolysis/condensation, causing the porosity of the 
MSNs. Three different surfactants with varying hydrophobic carbon chain lengths 
were used, DODE (n = 11), MYRI (n = 13) and CTAB (n = 15), to analyse what effect 
this would have on the properties of the MSNs produced using otherwise identical 
protocols.  
3.3.1 Transmission Electron Microscope Analysis 
To observe the particle diameter of the MSNs obtained using the three separate 
surfactants, CTAB, MYRI and DODE, at 80 OC, the samples were investigated by 
transmission electron microscopy, TEM (Figure 3.2). 
+ +
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Surfactant Triethanol amine,
TEA
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Figure 3.2. TEM images of MSNs synthesised using three different surfactants, A) 
CTAB, B) MYRI and C) DODE, at 80 OC. Average particle diameter was calculated 
by the mean and standard deviation of at least 100 particles viewed using ImageJ. 
The particle diameters of the MSNs synthesised using the three surfactants 
varied considerably from 43.8 ± 7.0 nm for CTAB to 100.9 ± 12.9 nm for MYRI and 
finally 460.0 ± 34.0 nm for DODE. This size deviation is due to the variation in 
surfactant micelle diameter affecting the kinetics of mesoporous silica formation by 
changing the pore template structure which the hydrolysis/condensation of tertraethyl 
silicates reactions occur.15, 16 This variation in particle diameter needed to be 
controlled as the MSNs made using each surfactant were to be investigated to observe 
whether changing the pore diameter affected relaxation enhancement. It is already well 
known that changing the particle diameter of the nano-construct that the Gd3+ chelate 
is bound to lower tumbling and therefore enhance relaxation.17 Therefore, the particle 
diameter was required to be the same to control a known variable and confirm that any 
variation in relaxivity was solely because of changes in the Gd3+-DOTA and water 
interaction due to pore diameter variation. 
Optimisation of the protocols was required to remove this particle diameter 
variable. It was found that the variation to the protocol that affected particle diameter 
significantly was the variation in temperature in which the MSNs were synthesised in. 
The CTAB diameter of 43.8 ± 7.0 nm was used as the target diameter to allow direct 
comparison to the previous literature (Figure 3.3).3 
50 nm 100 nm 0.5 µm
Particle diameter 
= 43.8  7.0 nm
Particle diameter 
= 100.9  12.9 nm
Particle diameter 
= 460.0  34.0 nm
A) B) C)
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Figure 3.3. The TEM images and the particle diameter of MSNs synthesised using the 
surfactants A) MYRI and B) DODE at 40 OC and 15 OC respectively. The particle 
diameter calculated by measuring 100 MSNs. 
After optimisation for the MYRI surfactant MSNs, 40 OC was observed to be 
the required reaction temperature to obtain equivalent particle diameters to those 
obtained using CTAB as 40 OC provided MSNs of particle diameters of 41.1 ± 4.7 nm 
by TEM. 15 OC was found to be the lowest temperature in which the yield of the MSN 
synthesis was not significantly affected by the temperature for the DODE temperature 
optimisation. However, the particle diameter obtained at 15 OC was found to be 
significantly different at 62.9 ± 10.6 nm from the particle diameters obtained using 
CTAB (43.8 ± 7.0 nm) and MYRI (41.1 ± 4.7 nm) for the pore diameter investigation 
to be progressed using the DODE surfactant protocol for MSN synthesis. 
Using the selective location functionalisation observed by Kecht et al., the 
optimised CTAB and MYRI protocols were amine functionalised through the addition 
of (3-aminopropyl)triethoxysilane, APTES, at three precisely tuned times in different 
MSN synthesises.1 This reaction, termed a co-condensation, since APTES condenses 
alongside the TEOS in the reaction, was performed where APTES was added after 
three separate time intervals within the MSN synthesis. The time intervals for APTES 
addition were 10 minutes into the 2 hrs MSN synthesis of the MSN formation, 
functionalising the MSNs within the pores, Internal, 1 hr into the 2 hrs synthesis, 
functionalising the MSNs both in the pores and on the surface, Edge, and post grafted 
after the MSN synthesis had completed but the surfactant had not been removed from 
the pores, resulting in functionalisation on the surface of the MSNs, External (Figure 
3.4). The amount of mole of APTES added to the reaction was calculated as 0.15 mol% 
Particle diameter = 62.9  10.6 nmParticle diameter = 41.1  4.7 nm
A) B)
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of the overall moles of tetraethyl orthosilicate, TEOS, added. This low concentration 
of APTES was used to increase the control of amine location allowing for greater 
clarity in the differentiation between these three methods of functionalisation and to 
minimise steric hindrance between Gd3+-chelates.3 
 
Figure 3.4. A schematic of an MSN with the cross section of a pore highlighted to 
show the difference between the three Gd3+-DOTA functionalisation locations used in 
investigating the effect of changing the pore diameter on relaxivity and therefore MRI 
contrast applicability. 
The amine functionalised MSNs using the Internal, Edge and External 
methodologies in combination with both CTAB and MYRI optimised protocols were 
analysed by TEM to confirm their particle diameters were not adversely affected by 
the addition of the amine functional group (Figure 3.5). 
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Figure 3.5.TEM images of A) Plain MSNs, B) CTAB Internal MSNs, C) CTAB Edge 
MSNs, D) CTAB External MSNs, E) MYRI Internal MSNs, F) MYRI dge MSNs and G) 
MYRI External MSN. H) Bar chart of the particle diameter analysis by TEM of the 6 
MSNs families synthesised with CTAB Plain and MYRI Plain as a comparison between 
aminated and non-aminated MSNs. 
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The particle diameter calculated for each methodology is within error of each 
other. Also, these particle diameters are within error of the non-amine functionalised 
MSNs (CTAB = 43.8 ± 7.0 nm and MYRI = 41.1 ± 4.7 nm) showing that amine 
functionalisation by the addition of APTES at various stages in the synthesis of MSNs 
does not affect MSN formation. 
3.3.2 Infrared Spectroscopy 
Fourier transform infrared, FTIR, spectroscopy was used to confirm the 
successful formation of silica particles as well as removal of the surfactant from the 
pores of the MSNs (Figure 3.6). 
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Figure 3.6. The FTIR spectra of A) CTAB Internal MSNs, CTAB Edge MSNs and 
CTAB External MSNs compared to CTAB surfactant and B) MYRI Internal MSNs, 
MYRI Edge MSNs and MYRI External MSNs compared to MYRI surfactant. 
For both the CTAB and MYRI surfactants the IR spectra are very similar due 
to the only difference between their chemical structure being an extra ethyl group 
within the aliphatic hydrocarbon tail. They have stretches around 2840 cm-1 and 2920 
cm-1 which represent C-H stretching and ~1460 cm-1 which represents C-H bending.18 
These are not observed in any of the MSNs synthesised proving that the removal of 
surfactant has been successful from the pores of the MSNs by repeated acid washes. 
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The stretches observed for all amine-modified MSNs are similar, with stretches 
between 1015-1190 cm-1 representing Si-O-Si stretching and bending vibrations,19-21 
stretches around 800 cm-1, indicative of Si-O-Si stretches,22 and those centred at ~550 
and ~450 cm-1 representing tri and tetracyclosiloxane rings of siloxanes.23 There are 
no stretches observed in the FTIR spectra of any of the amine functionalised MSNs 
between 3100 - 3500 cm-1 representing amine stretching or between 1550 and 1640 
cm-1 representing amine bending.18 this is due to the very low amine functionalisation 
(0.15 mol%) being below the sensitivity of the machine. The broad band observed for 
all samples at 3400–3500 cm-1 can be assigned to water and hydroxyl groups on the 
surfaces of the nanoparticles. 
3.3.3 Thermogravimetric Analysis 
To further confirm the successful removal of surfactant from the pores, 
thermogravimetric analysis, TGA, was performed (Figure 3.7). 
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Figure 3.7. The TGA analysis between 30 - 600 OC of A) CTAB Internal MSNs, CTAB 
Edge MSNs and CTAB External MSNs compared to CTAB surfactant and B) MYRI 
Internal MSNs, MYRI Edge MSNs and MYRI External MSNs compared to MYRI 
surfactant. 
For both MYRI and CTAB surfactants there is a distinguishable loss of mass 
between 215 OC and 350 OC which corresponds to the removal of the surfactant. There 
is no significant mass loss in this temperature range in any of the MSNs prepared 
further confirming the removal of surfactant from the pores of the MSNs. There is a 
distinctive mass loss of varying degrees between 80 OC and 120 OC for the MSNs 
which represents the loss of water and surface hydroxyl groups. The loss of the amino 
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groups from APTES surface modification cannot be observed, due to the very low 
grafting densities employed (0.15 mol%) being below the sensitivity threshold of the 
machine. The almost complete loss of mass for the surfactant and the relative low mass 
loss of the MSNs is due to variation in stability between these two structures between 
30 OC and 600 OC.  
3.3.4 Dynamic Light Scattering and Zeta Potential Analysis 
Dynamic light scattering, DLS and zeta potential measurements were 
performed in aqueous suspension on all the MSNs to provide information on 
hydrodynamic diameter and surface charge (Table 3.1).   
Table 3.1. The mean hydrodynamic diameter obtained by DLS and zeta potential for 
all MSNs with amine functionalisation locations, Internal, Edge and External, using 
the CTAB and MYRI surfactants. Values are an average of 5 measurements of each 
sample, across 3 batches of prepared MSNs. 
Sample Mean 
hydrodynamic 
diameter /nm 
Mean 
polydispersity 
index, PDI / AU 
Zeta potential 
/mV 
CTAB Internal 221.7 ± 53.8  0.26 ± 0.05 -19.7 ± 4.8 
CTAB Edge 253.9 ± 19.6 0.19 ± 0.03 -25.0 ± 7.0 
CTAB External 224.2 ± 3.6 0.17 ± 0.08 -18.6 ± 1.7 
MYRI Internal 169.5 ± 20.9 0.18 ± 0.02 -27.4 ± 0.7 
MYRI Edge 209.4 ± 31.5 0.20 ± 0.06 -18.4 ± 6.2 
MYRI External 257.6 ± 53.5 0.23 ± 0.08 -22.0 ± 3.0 
 
The mean diameter of MSNs by DLS are larger than their diameters measured 
by TEM for all samples (CTAB MSNs = 43.8 ± 7.0 nm and MYRI MSNs = 41.1 ± 4.7 
nm). This is due to differences between the measurement techniques. In TEM, images 
are taken of nanoparticles after they have dried onto a surface; DLS, on the other hand, 
is carried out on samples in suspension. This technique therefore considers Brownian 
motion effects, as well as any hydrogen bonding and Van Der Waals interactions 
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between the particles and surrounding solvent molecules which may contribute to the 
overall particle size. Due to these effects, DLS measures the hydrodynamic radius of 
the particles in liquid and hence show a larger value for the nanoparticles’ diameter. 
24-26  
The hydrodynamic diameters are similar for all particles demonstrating that 
surface modification with amine groups does not affect the overall size of the MSNs 
at all (169.5±20.9 to 257.6±53.5 nm for MYRI MSNs and 221.7±53.8 to 253.9±19.6 
nm for CTAB MSNs). Their colloidal stability is confirmed by the polydispersity 
index, PDI, which shows all particles to be colloidally stable (PDI values<1). The zeta 
potentials (-19.7 ± 4.8 mV, -25.0 ± 7.0 mV -18.6 ± 1.7 for CTAB MSNs and -27.4 ± 
0.7 mV, -18.4 ± 6.2 mV and -22.0 ± 3.0 mV for MYRI MSNs), are within range of 
one another showing that the MSNs obtained are similar in surface chemistry and 
further confirms colloidal stability in aqueous solution. The MSNs are negative due to 
the Si-OH functional groups being predominantly deprotonated, due the isoelectric 
point of Si-OH being 2,27 overwhelming any positive charge obtained by the 
protonated amine functional groups of the APTES (which exists at very low grafting 
densities). The information obtained by DLS and zeta potential shows that the 
synthetic protocols optimised to obtain MSNs of the same size using CTAB and MYRI 
surfactants and amine functionalisation at various locations has had no significant 
effect on the overall colloidal stability of the MSNs synthesised.   
3.3.5 Small Angle X-ray Scattering Analysis 
Small angle X-ray scattering, SAXS, was performed using EasySaxs software 
on dried samples of all variations of amine location using MYRI and CTAB surfactant 
to obtain information about the effect the changing of the surfactant and location of 
amine functionalisation had on the pore diameter (Figure 3.8 an Table 3.2).28, 29 The 
lower q values being modelled for particle diameter and the higher q values for pore 
diameter due to the pores being smaller than the particles and larger objects having 
faster oscillation time.29 
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Figure 3.8. An example of the data acquired by SAXs for CTAB Internal MSNs with 
the area representing A) the particle diameter and B) the pore diameter of the MSNs 
being analysed using the EasySAXS modelling software.28 q = [4πsin(θ)] / λ where θ 
is the scattering angle and λ being the x-ray wavelength being used to analyse the 
sample.  
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Table 3.2. The particle diameter and pore diameter analysed by SAXS for each of the 
MSNs obtained using all the variations of amine functionalisation location and CTAB 
and MYRI surfactants. Values are the average of the three batches of MSNs 
synthesised separately.   
Sample Particle diameter/ nm Pore diameter/ nm 
CTAB Internal 47.7 ± 7.7 3.55 ± 1.15 
CTAB Edge 46.7 ± 8.1 3.45 ± 1.21 
CTAB External 47.2 ± 10.3 3.47 ± 1.16 
MYRI Internal 49.4 ± 9.7 2.40 ± 1.03 
MYRI Edge 50.8 ± 10.8 2.55 ± 1.05 
MYRI External 53.3 ± 11.3 2.83 ± 0.94 
 
The SAXS analysis of particle diameter for all the 6 different MSNs are within 
standard deviation of the particle diameter results obtained by TEM (CTAB MSNs = 
43.8 ± 7.0 nm and MYRI MSNs = 41.1 ± 4.7 nm). This demonstrates SAXS analysis 
of particle parameters is reasonable and comparable to TEM. The mean pore diameter 
obtained for the CTAB MSNs of 3.49 ± 1.29 nm is the same as was found previous 
literature which used CTAB surfactant to provide porosity in silica molecular sieves 
(3.0 nm).11, 12 The mean pore diameter of the MSNs obtained using MYRI is 2.60 ± 
1.12 nm showing that there is a lowering in pore diameter using MYRI surfactant 
compared to CTAB, as expected due to the smaller hydrocarbon chain length, as 
discussed in the introduction. However, due to the large standard deviation obtained 
by the analysis, it is not possible to confirm that there is a significant change in pore 
diameter variation. 
3.3.6 Gas Sorption Porosimetry Analysis 
To these three variants of amine functionalisation for both MYRI and CTAB 
MSNs, Gd3+-DOTA was bound to the MSNs by firstly amide formation with the N-
hydroxysuccinimide, NHS, activated DOTA ester. The gadolinium ion, Gd3+, was 
bound within the DOTA chelates attached to the MSNs by addition of DOTA MSNs 
 93 
 
to a GdCl3 solution and excess Gd
3+ removed by dialysis. To confirm that there is a 
statistically significant difference between the pore diameter obtained using CTAB 
and MYRI, and that Gd3+-DOTA functionalisation had no effect on the smaller pore 
diameter MSNs obtained, gas sorption porosimetry was utilised using the Barrett-
Joyner-Halenda (BJH) method (Figure 3.9).30 
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Figure 3.9. Plots of the pore diameters obtained by porosimetry, A) All the pore 
diameters obtained for the aminated MSNs CTAB variations, Internal, Edge and 
External (2.82 nm). B) The pore diameters obtained before and after Gd3+-DOTA 
functionalisation of the MYRI Internal MSNs (1.90 nm), C) The pore diameters 
obtained before and after Gd3+-DOTA functionalisation of the MYRI Edge MSNs (1.87 
nm), D) The pore diameters obtained before and after Gd3+-DOTA functionalisation 
of the MYRI External MSNs (1.89 nm). 
The pore diameters obtained for CTAB Internal, Edge and External (A) prove 
again that there is no variation in pore diameter on changing the position of the amine 
functionalisation. The pore diameter mean value is different compared to the pore 
diameter obtained by SAXS (2.82 ± 0.02 nm and 3.49 ± 1.29 nm for porosimeter and 
SAXS respectively). The reason for this restriction in pore diameter found by 
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porosimetry is due to the non-linear worm like structure of the pores restricting N2 
access and therefore lowering the calculated pore diameter.14  
Comparing the pore diameter obtained for CTAB of 2.82 ± 0.02 nm and MYRI 
(B, C, D) mean of 1.89 ± 0.02 nm there is a clear variation in pore diameter between 
the MSN synthesised using the MYRI compared to CTAB. An issue with the MYRI 
analysis was that the pore diameter was right at the lower limitation of the instrument. 
Usually there is a bell curve set of data which allows interpretation of the pore size of 
the materials, which is absent for MSNs prepared using MYRI surfactant. Therefore, 
the SAXS pore sizes will be referred to hereafter. 
Porosimetry was also used to confirm that the Gd3+-DOTA (~1.1 nm diameter 
chelate) binding to the MSNs had no effect on the small pore diameter (1.89 ± 0.02 
nm) of the MYRI MSNs (B, C, and D). No variation was observed between pore 
diameter of the MSNs before and after Gd3+-DOTA functionalisation showing that the 
addition of the Gd3+-DOTA binding has no significant effect on the pore diameter. 
Further analytical experiments probing the nanostructure of the Gd3+-DOTA MSNs 
were not performed due to this confirmation of no variation in pore diameter and the 
low yields of Gd3+-DOTA MSNs acquired. 
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3.4 Investigation of MSN Pore Diameter and Gd3+-DOTA 
Location on Relaxivity 
3.4.1 Relaxometry Analysis at 13.1 MHz 
After having completely characterised the MSNs obtained using MYRI and 
CTAB surfactants and Gd3+-DOTA functionalising them, the effect of pore diameter 
on relaxivity was explored. This is probed by calculating the relaxivity, r1, (mM
-1 s-1) 
of the contrast agent. This was acquired by obtaining the longitudinal relaxation, T1, 
(s) of the water suspension containing the contrast agent under investigation at a 
minimum of four differing concentrations. The T1 times acquired for each dilution are 
converted to R1, observed and relaxivity using Equation 3.1 and Equation 3.2. 
R1 =  
1
T1
⁄  (Equation 3.1) 
Relaxivity =  r1 =  
R1,observed-R1,solvent
[Gd]
  (Equation 3.2) 
The R1, observed is normalised by subtracting the R1 of ultrapure water, R1, solvent 
(T1 = 2.59 s or R1 = 0.39 s
-1). This is plotted against the Gd3+ concentration (mM) of 
each dilution of contrast agent obtained by inductively coupled plasma mass 
spectrometry, ICP-MS. The relaxivity of the contrast agent is calculated from the slope 
of the linear plot (see appendix).  
Both the MYRI and CTAB MSNs without Gd3+-DOTA functionalisation were 
analysed at 13.1 MHz to observe if there was an inherent decrease in T1 on addition 
of the MSNs. The T1 of the CTAB and MYRI MSNs was found to be 2.32 ± 0.05 s 
and 2.37 ± 0.07 s respectively. This agrees with previously published research that 
observed a lowering in the T1 of water on addition of silica nanoparticles due to water 
surface association onto the nanoparticles lowering tumbling rates.31 Then the six 
variations of Gd3+-DOTA functionalisation location on MSNs synthesised using 
CTAB and MYRI surfactants were analysed (Figure 3.10). 
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Figure 3.10. A) A schematic of the variation in location, Internal, Edge and External, 
of the Gd3+-DOTA functionalisation on the MSNs and B) bar chart of the relaxivity at 
13.1 MHz of the 6 families of MSNs synthesised using the two surfactants, MYRI and 
CTAB, and the three functionalisation locations, Internal, Edge and External 
compared to molecular Gd3+-DOTA. The mean and standard deviation obtained by 
analysing three batches of MSNs. 
All MSNs analysed gave significantly enhanced relaxivity compared to the 
molecular Gd3+-DOTA (5.38 ± 0.20 mM-1 s-1). This highlights the dramatic MRI 
contrast agent enhancement obtained by attaching a Gd3+ chelate to a nanostructure. 
This well-known behaviour is provided by the covalent linking of the chelate to the 
MSNs increasing τR and this increasing relaxation, which is expected and documented, 
both experimentally and theoretically.3, 32-35 For the MSNs synthesised using the 
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CTAB surfactant, there was no change in relaxivity with changing the location of the 
Gd3+-DOTA from Internal (31.39 ± 4.17 mM-1 s-1), Edge (29.55 ± 2.61 mM-1 s-1) and 
External (30.81 ± 0.75 mM-1 s-1). Therefore, for MSN synthesised using CTAB as the 
surfactant, the interaction with Gd3+ located inside the pores with water molecules, 
Internal functionalisation, is the same as the Gd3+ interacting with the bulk water on 
the outer surface of the MSNs, External functionalisation, or at the mouths of the 
pores, Edge functionalisation. The explanation is that the pore diameter of 3.49 ± 0.05 
nm facilitates excellent water exchange and mobility within the pore network, with no 
apparent spatial restrictions.36 This results varies from previously published data 
where 0.15 mol% Gd3+-DOTA functionalised MSNs synthesised using CTAB as a 
soft template.3 In this research Edge localisation resulted in relaxation enhancement 
compared to Internal and External functionalisation (‘Short delay’ [≡Internal] = 17.14 
± 0.49 mM-1 s-1, ‘Long delay’ (≡Edge) = 33.57   1.29 mM-1 s-1 and ‘Post graft’ 
[≡External] = 10.77 ± 0.22 mM-1 s-1). It should be noted that in the previous study the 
relaxivity was analysed at 300 MHz, where the impact of τR and τM are different37, 38 
whereas here, at lower magnetic fields, dipole-dipole interactions dominate.39, 40 
However, MSNs prepared using MYRI as the surfactant, there is a reduction of the 
relaxivity to 19.29 ± 1.38 mM-1 s-1 when the MSNs are Internal functionalised (CTAB 
Gd3+-DOTA Internal MSNs = 31.39 ± 4.17 mM-1 s-1). This is partially recovered to 
the relaxivity obtained from the CTAB MSNs analogue when the Gd3+ is located on 
the Edge of the pores (MYRI Gd3+-DOTA Edge MSNs = 25.99 ± 1.06 mM-1 s-1 and 
CTAB Gd3+-DOTA Edge MSNs = 29.55 ± 2.61 mM-1 s-1) and fully regained when the 
Gd3+ is located on the External of the MSNs (MYRI Gd3+-DOTA External MSNs = 
31.33 ± 2.70 mM-1 s-1 and CTAB Gd3+-DOTA External MSNs = 30.81 ± 0.75 mM-1 
s-1). This is due to the smaller pore diameter obtained by using MYRI (2.60 ± 1.12 
nm) compared to CTAB (3.49 ± 1.29 nm) restricting the diffusion and mobility of 
water molecules to Gd3+ when the Gd3+-DOTA is located inside the pores, Internal. 
This restriction lowers the interaction between Gd3+ and the water molecules, retarding 
relaxation. This restriction is partially alleviated when the Gd3+-DOTA is Edge 
localised on the MSNs. Finally, the relaxivity is like the relaxivities obtained with the 
CTAB MSNs when the Gd3+ is fully able to interact with the bulk water when attached 
to the External surfaces of the MSNs. In addition, this research has shown that the 
optimum relaxation of MSNs synthesised in this way is ~30 mM-1 s-1 which is 
approximately 6 times the relaxivity obtained by molecular Gd3+-DOTA (5.38 ± 0.20 
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mM-1 s-1) . The enhanced relaxivity obtained allows for the possibility of significantly 
reduced dosages with equal or better levels of signal. Therefore, drastically lowering 
the amount of Gd3+ administered to a patient minimising the side effects such as 
nephrogenic fibrosis and Gd3+ build up in the brain.41, 42 
The quantity of Gd3+ per mg of MSN was investigated by ICP-MS to confirm 
that there was no large variation in the amount of Gd3+ immobilised onto the MSNs. 
In addition, the amount of adsorbed Gd3+ per mg of MSNs was also investigated by 
synthesising MSNs and leaving the sample overnight in GdCl3 without the NHS-
DOTA functionalisation step, Gd3+ Adsorption Control, (Table 3.3).  
Table 3.3. The mass of Gd3+ per mg of MSNs for each repeat of the six families 
synthesised plus the Gd3+ Adsorption Control. The values stated are the average of 
the three batches of MSN functionalised with varying surfactant and Gd3+-DOTA 
functionalisation location. 
Sample Mass of Gd per mg of MSN (ng mg-1) 
CTAB Internal  109.9 ± 61.1  
CTAB Edge 74.4 ± 37.2 
CTAB External 124.9 ± 35.5 
MYRI Internal 85.8 ± 30.7 
MYRI Edge 84.1 ± 56.1 
MYRI External 96.1 ± 8.6 
Gd3+ Adsorption Control 0.52 ± 0.1 
 
As can be seen in Table 3.3 all the Gd3+-DOTA functionalised MSNs are 
within error of one another and the very low amount of adsorption observed means 
that the relaxivity of the designed MSNs was due to the chelated lanthanide species 
and that negligible adsorption took place throughout. 
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3.5 Conclusions 
MSNs were synthesised using three surfactants of varying aliphatic chain 
lengths, CTAB, MYRI and DODE in order to obtain MSNs with varying pore 
diameters. These surfactants are well known to lead to different pore sizes due to the 
varying micelles into which the self-assemble and around which the silica 
nanostructure forms to obtain MSNs. The MSNs obtained had a large variation in 
particle diameter (CTAB MSNs = 43.8 ± 7.0 nm, MYRI MSNs = 100.9 ± 12.9 nm and 
DODE MSNs = 460.0 ± 34.0 nm) because of variation in the kinetic rates of formation 
due to different micelle layer packing. The MSNs had to be the same size to minimise 
tumbling variation between MSN batches allowing for the variation in pore diameter 
and its effect on relaxivity to be examined exclusively. This was successfully achieved 
by changing the temperature in which MSN synthesis was performed from 80 OC with 
CTAB (43.8 ± 7.0 nm) to 40 OC for MYRI (41.1 ± 4.7 nm). DODE was unable to be 
optimised by varying the temperature as at 15 OC, the observed limit to which the yield 
was not drastically affected, the MSNs obtained had a particle diameter of 62.9 ± 10.6 
nm, which was not within error of the MSNs obtained by CTAB or MYRI.  
These optimised synthetic protocols were subsequently used to synthesise 
families of MYRI and CTAB MSNs with surface amine functionalities in different 
locations by carefully controlling the addition of an aminosilane precursor to yield 
Internally, Edge or Externally amine-functionalised MSNs, following modified 
literature procedures. Various characterisation techniques (FTIR and TGA) confirmed 
that the surfactant had been completely removed from the pores. TEM analysis 
confirmed no change to the particle diameter or porosity on amine functionalisation. 
The hydrodynamic size and the zeta potential were analysed for each of the MSNs 
synthesised to confirm that there was no loss in stability of the MSNs suspended in 
water and that the surface charge was not affected by changing the location of the 
amine groups. 
The pore diameters of the MSNs obtained using CTAB and MYRI were 
analysed by SAXS (CTAB = 3.49 ± 0.05 nm, MYRI = 2.60 ± 0.22 nm) and 
porosimetry (CTAB = 2.82 ± 0.02 nm, MYRI = 1.89 ± 0.02 nm). The variation in pore 
diameter obtained by the aliphatic carbon tail of MYRI (14 Cs) being shorter than 
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CTAB (16 Cs), resulting in smaller diameter micelles which provide the porosity of 
MSNs as a soft template.   
Finally, the effect of changing the pore diameter and the location on relaxivity 
was monitored at 13.1 MHz. It was found that the Gd3+-DOTA modified CTAB MSNs 
all obtained strong protic relaxation enhancement regardless of the Gd3+-DOTA 
location on the MSNs (Internal = 31.39 ± 4.17 mM-1 s-1, Edge = 29.55 ± 2.61 mM-1 s-
1 and External 30.81 ± 0.75 mM-1 s-1). This is due to the excellent water access to the 
paramagnetic chelate facilitated by the unrestricted diffusion through the pores of the 
MSNs. However, when the MSNs were synthesised in the presence of MYRI 
surfactant, the smaller pore diameter obtained caused a lower relaxivity enhancement 
when Gd3+-DOTA was located inside the pores (Internal = 19.29 ± 1.38 mM-1 s-1). 
This is due to the smaller pores obtained using MYRI as a soft template lowering 
diffusion rates of water in the pores therefore lowering water interaction with Gd3+. 
This restriction is partially alleviated when the Gd3+-DOTA is localised on the Edge 
(25.99 ± 1.06 mM-1 s-1) and finally the strong protic relaxation rates are observed when 
Gd3+-DOTA is located on the surface (External = 31.33 ± 2.70 mM-1 s-1).  
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3.6 Future Work 
The first avenue would be to see whether the same trends for relaxation are 
found for these MSNs at varying magnetic fields. This is important as T1 relaxation is 
dependent on magnetic field strength.32, 33 This has already been started for the MYRI 
Internal, MYRI Edge and MYRI External MSNs which were analysed at 9.4 Tesla 
(Figure 3.13). 
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Figure 3.11. The relaxivity at 9.4 Tesla of the 3 families of MSNs synthesised using 
the MYRI surfactant in the three locations, Internal, Edge and External. 
It is interesting to observe the significant lowering in relaxivity obtained (13.1 MHz 
relaxivities were MYRI Internal = 19.29 ± 1.38 mM-1 s-1, MYRI Edge = 25.99 ± 1.06 
mM-1 s-1 and MYRI External = 31.33 ± 2.70 mM-1 s-1 compared to 9.4 Tesla = 14.81 
mM-1 s-1, 17.26 mM-1 s-1 and 18.56 mM-1 s-1 respectively). This represents a previously 
observed phenomena whereby at higher fields the enhancement by increased tumbling 
rate is partially suppressed.37 It seems the general trend observed at 13.1 MHz is 
observed 9.4 Tesla where the small pore diameter obtained using MYRI (2.60 ± 0.22 
nm) seems to lower the interaction between the water molecules and Gd3+ causing a 
decrease in the relaxivity. Further work is required to confirm reproducibility. Also, 
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investigation into the CTAB MSNs to observe whether their trend of no deviation 
between Gd location and relaxivity should be investigated, with repeats, at 9.4 T. 
Another direction this could go into is optimisation of a synthetic protocol that 
reproducibly obtains MSNs which have pore diameters of > 3.49 ± 1.29 nm. This 
would provide more information into the effect of pore diameter on relaxivity. initial 
studies were performed by the addition of mesitylene to the CTAB protocol to cause 
pore swelling, replicating Kresge et al. findings using molecular sieves.11 However, 
issues with reproductivity hampered further work. 
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Chapter 4 
4. Thermo-responsive MSNs as 
Diagnostic MRI Contrast Agents 
 
4.1 Chapter Summary 
The optimisation of MRI contrast agents is in high demand due to the constant 
need for better acquired images to allow for the correct diagnosis to be obtained. 
Nanomaterials are ideal in this field due to their high surface areas and potential for 
surface modification allowing for dual-functionality possibilities of both contrast and 
stimuli responsive properties. Therefore, an MSN based MRI contrast agent with a 
switchable MRI contrast in response to an external stimulus would be a highly 
desirable and accessible objective. 
Herein MRI-active Gd3+-DOTA-modified MSNs (previously tuned in Chapter 
3 to present strong protic relaxation enhancement behaviour) surface functionalised 
with the thermoresponsive polymer poly(N-isopropylacrylamide), pNIPAM, were 
prepared using a ‘grafting from’ methodology using atom transfer radical 
polymerisation, ATRP. It was found that the synthetic protocol obtained successfully 
bound pNIPAM to the MSNs’ surface with minimum physisorption of unbound 
pNIPAM and unreacted monomer. The surface coverage and pNIPAM chain length 
was varied to produce a small family of polymer-grafted MRI active nanoparticles, in 
a bid to tune the temperature of any observed stimuli-response and hence switchable 
contrast behaviour. The transition temperature (indicative of a ‘stimuli-response’) was 
tuneable according to the grafting density and chain length of the polymer chains on 
the nanoparticle surfaces, from 36.4 OC to 42.3 OC. As the nanocomposite transitioned 
through this temperature, precipitation of the particles was observed.  The MSNs 
produced were analysed for their applicability to the function of being MRI contrast 
agents by relaxometry and phantom T1 weighted images from a clinical MRI scanner. 
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There was found to be no suppression of the Gd3+-DOTA MSNs previously confirmed 
enhanced contrast ability. Finally, it was investigated whether the precipitation effect 
provided by the pNIPAMs interaction with temperature had any qualitative effect on 
an MRI image. This was found to be the case with there being a stark variation between 
the precipitated MSNs and the surrounding water, thus proving the relevance of these 
MSNs as a method of observing temperature variation within a patient. This is 
promising result as it facilitates the possibility of tumour tissue identification by the 
MRI contrast agent aggregating around the hotter tumour tissue compared to the 
surrounding healthy tissue. 
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4.2 Introduction 
Making a MRI contrast agent system that is able to respond to changes in the 
environment is highly desirable due to the control in location of the system that entails 
in the patient.1 This control provides 2 major benefits, firstly the ability to localise 
contrast only in the tissues of interest, reducing background noise thus making correct 
diagnosis more likely. Secondly the control of location allows for the minimisation of 
GBCA administered to the patient, limiting the possibility of side effects for example 
Gd3+ deposition in tissues.2-5 
Localised hyperthermia ablation is an established method of treating malignant 
tissues.6 In this treatment the malignant tissue is heated to between 41 OC and 45 OC 
to initiate cancer cell death. The method of localised heating varies from the use of 
lasers,7 microwaves,8 radiofrequency9 and ultrasound.10 However being able to 
observe the shape and size of the ablation is difficult due to heterogenous temperature 
distribution because of differences in tissue composition, tissue anatomy and 
vascularisation.11, 12 This results in between 30 % and 60 % malignant cells at the 
treated site proceeding to have tumour progression after ablation therapy.9, 13, 14 
Therefore the application of a contrast agent that was able to provide an 
intraprocedural  monitoring system would aid in the reduction of local tumour 
progression rates after ablation and in turn benefit long-term patient survival. The 
multiplanar imaging capabilities and excellent soft tissue contrast makes MRI an ideal 
analytical method to monitor ablation.15-20 The vast majority of research into thermo-
responsive MRI contrast agents are based on GBCAs encapsulated in liposomes with 
a suitable phase transition temperature such that the GBCA is released in the desired 
location with the additional advantage of simultaneously being a drug delivery 
system.21-30  
Iron oxide and silica nanoparticles have also been utilised as thermoresponsive 
MRI contrast agents.31-33 As iron oxide and silica nanoparticles are not inherently 
thermoresponsive, this is provided by polymer functionalisation. The polymer 
commonly used to provide thermoresponsive properties is poly(N-
isopropylacrylamide), pNIPAM.34 pNIPAM has a lower critical solution temperature, 
LCST, of 32 OC whereby below the LCST pNIPAM is miscible in water whilst above 
the polymer separates from the water phase. This occurs due to aggregation of 
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pNIPAM on formation of intermolecular hydrogen bonds between polymer chains and 
the weakening of the ordering effect of the water amide hydrogen bonds, a 
thermodynamically controlled process (Figure 4.1).35 This transition temperature can 
be observed by observation of the cloud point of the system, since aggregation leads 
to a distinctive change in turbidity and opaqueness of the aqueous system.36 
 
 
Figure 4.1. A schematic of the change in intermolecular interactions above and below 
the LCST of the thermoresponsive polymer, pNIPAM.  Temperature < LCST consists 
predominantly of intermolecular interaction with water, whilst when T > LCST most 
intermolecular interactions are with neighbouring polymers causing aggregation of 
the polymer. 
There has been a vast amount of research into pNIPAM’s application to medicinal 
chemistry.37 The desirability of pNIPAM stems from firstly its LCST of 32 OC 
meaning that it is soluble at room temperature and phase separates at body temperature 
(37 OC). This variation in property allowing pNIPAM to be utilised for drug 
delivery.38-40 In addition the LCST is able to be tuned by binding pNIPAM on 
nanoparticle surfaces at different densities and chain lengths.36 This enables pNIPAM 
to be used as a potential biomedical carrier in its linear polymer, hydrogel or 
copolymer form.41-45 pNIPAM has also been found to have a low toxicity both in 
vitro46-49 and in vivo.50, 51 Finally the versatility of pNIPAM synthesis allows for many 
various polymerisation methods to be performed.52-55 
v
ΔT > LCST
=Poly(N-isopropylacrylamide)
(pNIPAM)
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 Atom transfer radical polymerisation, ATRP, is an applicable method of 
pNIPAM synthesis.56 ATRP usually employs a transition metal halide with a transition 
metal having two stable oxidation state with a difference of one, for example Cu+ and 
Cu2+. The rate of polymerisation and polymer chain length is controlled by the 
transition metal being chelated by a multidentate ligand such as N, N, N’, N’’, N’’-
pentamethyldiethylenetriamine, PMDETA, to form the catalyst.57 The initiator is 
usually an alkyl halide and the monomer is an alkene species that has substituents 
which are able to stabilise the propagating radical.58 The objective of the transition 
metal halide chelate is to activate and deactivate the polymer chain by generating 
radicals via an one electron transfer process. This activation and deactivation of the 
polymer forms an equilibrium which is shifted predominantly to the deactivated 
polymer chains. Most of the polymer being in a deactivated state slows down the rate 
of propagation and minimises the amount of reactive radical species in the 
polymerisation, therefore minimising the amount of undesirable side reactions and 
polymer chain termination. This control allows for more uniform polymer chain 
lengths to be acquired (Figure 4.2).59  
 
Figure 4.2 The transition metal catalysed (i.e. copper bromide and PMDETA) ATRP 
of NIPAM to obtain pNIPAM.  
Y. Yang et al. utilised pNIPAM synthesised using ATRP to graft thermoresponsive 
polymers onto MSNs of particle diameter 200 nm.33 The ATRP initiator, α-
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bromoisobutyryl bromide, BIBB, was bound to the surface of the MSNs and pNIPAM 
polymerised on the surface using a ‘Grafting From’ technique. This method was 
utilised due to the high grafting density of polymer brushes on the surface of the MSNs 
that can be obtained.60-63  
4.2.1 Aims 
The aim of this work was to prepare a thermoresponsive MRI contrast agent based 
upon an MSN core and a polymer shell capable of demonstrating a change in MRI 
relaxation behaviour with changing temperature. A further aim was to tune the 
temperature at which this ‘response’ could be observed to provide tuneable-response 
composite systems through varying the grafting density of the thermoresponsive 
polymer on the composite surfaces. 
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4.3 Preparation and Characterisation of pNIPAM Surface 
Functionalised MSNs using a ‘Grafting From’ Method  
CTAB internally Gd3+-chelate functionalised MSNs, as prepared in chapter 3, 
were selected for this work, due to their high relaxivity values due to excellent water 
accessibility and internalised Gd-species which would not be detrimentally affected 
by subsequent polymer grafting. Briefly, 3.5 nm pore diameter MSNs using 
cetyltrimethylammonium bromide, CTAB, surfactant with amine groups located on 
internal surfaces by co-condensation of (3-aminopropyl)triethoxysilane had 2,2′,2”-
(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid (DOTA-NHS-ester) amide bound to the amine groups. Then 
these DOTA functionalised MSNs were suspended Gd3+ salt solution and 
subsequently dialysed to produce the MRI active nanoparticle systems (Figure 3.5, 
Section 3.4.1, Chapter 3). CTAB surfactant was used to maximise the relaxivity 
response of the nanoparticles, those with high relaxivity values, as found in section 
3.5.1, Chapter 3. Internal functionalisation of the MR-active Gd3+-DOTA probe was 
selected to minimise any possible interactions between the polymer and the Gd3+-
DOTA. As the polymer was required to be on the surface of the MSNs to increase the 
polymer’s interaction with the surrounding water, the Gd3+-DOTA was placed in the 
pores where they would be protected from the polymer. In order to graft the polymer 
onto the polymer surfaces, the ‘parent’ Gd3+-DOTA MSNs were firstly surface 
functionalised with amine groups using APTES utilising a post grafting technique. 
Amine surface coverage was varied between three different theoretical percentage 
coverages, 0.2 mol%, 1 mol% and 2.5 mol% relative to TEOS. These low loading 
densities were investigated in a bid to maintain good colloidal stability as well as water 
access to the internalised Gd3+ species. To these amine groups α-bromoisobutyryl 
bromide, BIBB, was chemically bound to the MSNs via an amide bond. The final 
synthetic step, ATRP of NIPAM, was performed using the MSN bound BIBB as the 
initiator, copper bromide as the metal catalyst and N, N, N’, N’’, N’’-
pentamethyldiethylenetriamine, PMDETA, as the ligand (Figure 4.3). 
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Figure 4.3. A Schematic of the functionalisation method to obtain thermoresponsive 
MRI contrast agents. A) Gd3+-DOTA functionalisation inside the pores of the MSNs, 
Gd3+-DOTA MSNs, B) external surface amine functionalisation of Gd3+-DOTA MSNs, 
C) α-Bromoisobutyryl bromide, BIBB, initiator surface functionalisation and D) N-
isopropylacrylamide, NIPAM, polymerisation onto the Gd3+-DOTA MSNs surface, 
where n represents the number of monomer repeat units. 
A control to determine the success of the polymerisation and therefore lack of surface 
physisorption of monomer onto nanoparticles surfaces, Adsorption Control, was 
performed to observe how much, if any, BIBB and therefore pNIPAM was adsorbed 
to the surface of the MSNs. For the adsorption control the final pNIPAM synthetic 
step was exactly as previously described for 0.2 mol%, 1 mol% and 2.5 mol%. 
However, the surface amination step (Figure 4.3, B) and Gd3+-DOTA 
functionalisation step (Figure 4.3, A) was removed. To ensure removal of the copper 
catalyst, all samples were washed using dialysis after brief stirring in an aqueous acid 
solution. 
4.3.1 Zeta Potential 
The synthetic steps shown in Figure 4.3 were followed by Zeta potential (Table 4.1). 
Zeta potential was found to be a more effective method of monitoring these changes 
than other analytical techniques, such as TGA or FTIR, in which the surface grafting 
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14 hrs
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density used on MSN surfaces would be too low to detect by these techniques. 
Hydrodynamic diameter was not used as confirmation of synthetic steps due to most 
synthetic steps involved between the parent MSNs and the final composite inducing 
colloidal instability. 
Table 4.1. The Zeta potential obtained after key steps in the synthesis of 
thermoresponsive MSNs. The samples shown being the Adsorption Control, 0.2 mol%, 
1 mol% and 2.5 mol%. 
Synthetic step Sample 
Adsorption 
Control / mV 
0.2 mol%* / 
mV 
1 mol%* / 
mV 
2.5 mol%* / 
mV 
Parent MSNs -27.9 ± 1.2  -28.9 ± 5.7  -27.5 ± 2.8 -27.5 ± 2.4 
Gd3+-DOTA 
modified 
MSNs 
X** -17.50 ± 0.4 -24.4 ± 0.6 -17.6 ± 0.3 
Externally 
aminated 
MSNs 
X* 2.5 ± 0.6 11.0 ± 1.6 22.8 ± 1.3 
Final 
composite 
after pNIPAM 
modifictaion 
-11.3 ± 0.2 0.6 ± 0.1 13.9 ± 0.5 21.6 ± 0.5 
*mole percent (mol%) with respect to tetraethyl orthosilicate, TEOS for external 
amine modification. 
**Step omiited to allow accurate investigation into adsorption of pNIPAM onto the 
surface of the MSNs. 
The Zeta potential of parent MSNs were all within error of each other confirming that 
there was no significant variation between batches of MSNs and the reproducibility of 
the method. The zeta potential is negative due to the abundance of Si-OH on the 
surface of the MSNs. The Gd3+-DOTA functionalisation of the MSNs also had no 
significant effect on colloidal stability as all MSNs had a strong negative zeta 
potential. Small changes in zeta potential after Gd3+-DOTA functionalisation indicate 
this modification step was successful, as some silanol groups are used to graft this 
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chelate onto MSN surfaces. Overall, the charge remains negative, as would be 
expected due to the negative silanol groups dominating. The surface amination had the 
most dramatic effect on Zeta potential for 0.2 mol%, 1 mol% and 2.5 mol%, all 
samples changing from negative Zeta potentials to positive surface charge. This is due 
to the amine groups added to the surface of the MSNs being basic and therefore being 
protonated in water. The degree of positivity clearly coincides with the percentage 
surface amination with 0.2 mol% = 2.49 ± 0.62 mV, 1 mol% = 11.00 ± 1.60 mV and 
2.5 % = 22.80 ± 1.30. This shows that the increase in amine groups has changed the 
surface of the MSNs as expected. 
The grafting of the pNIPAM had little effect on the zeta potential due to the charge 
neutrality of NIPAM. For the Adsorption control, on the other hand, there is a 
significant change in surface charge, which is likely due to some surface physisorption 
of NIPAM monomers on MSN surfaces causing the charge of the surface silanol 
groups to be less available for measurement by this technique. The physisorption of 
NIPAM leading to possible colloidal instability. 
4.3.2 Transmission Electron Microscopy 
Transmission electron microscopy, TEM, was performed on all final NIPAM 
nanoparticle composites and the parent MSNs to confirm that the surface modification 
and NIPAM loading did not impact particle structure (Figure 4.4). 
 
Figure 4.4. The TEM images obtained for the 0.2 mol%, 1 mol%, 2.5 mol% pNIPAM 
surface functionalised Gd3+-DOTA MSNs, Adsorption Control Gd3+-DOTA MSNs and 
the Parent MSNs. The particle diameters were calculated by the mean and standard 
deviation of 100 MSN diameters. 
All samples had similar core particle sizes (43.1 ± 5.8 to 47.4 ± 4.5 nm) and their pore 
structure remained intact. Importantly the mean diameter does not vary from the parent 
MSNs, indicating that the multiple surface modification steps did not impact the 
0.2 mol% 1 mol% 2.5 mol%
43.1  5.8 nm
Adsorption Control
44.2  4.9 nm 44.2   6.3 nm 46.5   5.8 nm
Sample
TEM 
Image
Diameter
50 nm50 nm 50 nm 50 nm
Parent
50 nm
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particles’ morphologies and sizes. The pNIPAM surface functionalisation can’t be 
observed in these images because of the low-density nature of the polymer (with no 
sample staining performed) and grafting densities were relatively low.  
4.3.3 Infrared Spectroscopy 
FTIR was used to confirm functionalisation of MSN surfaces with NIPAM. As 
previously stated, Section 4.3.1, FTIR could not determine the surface modification 
steps of amination and bromination, due to the low grafting densities employed 
(Figure 4.5). 
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Figure 4.5. The infrared spectra of the three varying surface densities of pNIPAM, 0.2 
mol%, 1 mol% and 2.5 mol% amination with respect to TEOS, the parent MSNs and 
the Adsorption Control compared to pNIPAM polymerised using ATRP. Inset 
highlights the infrared spectra between 1300 cm-1 and 1700 cm-1.  
The stretches observed representing the MSNs are between 1015-1190 cm-1 
representing Si-O-Si stretching and bending vibrations,64-66 stretches around 800 cm-
1, indicative of Si-O-Si stretches,67 and those centred at ~550 and ~450 cm-1 
representing tri and tetracyclosiloxane rings of siloxanes.68 These are coupled with the 
stretches representing NIPAM, C-H bending (~1400 cm-1), C-N bending (~1450 cm-
1), N-H amide bending (~1500 cm-1) and C=O stretching (~1600 cm-1) appearing for 
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the 0.2 mol%, 1 mol%, 2.5 mol% and Adsorption Control.69  The IR spectra obtained 
are identical to the FTIR spectra obtained by Yang et al. for their pNIPAM 
functionalised MSNs.33 This shows that NIPAM is present on the MSNs obtained after 
the polymerisation. The presence of these stretches in the Adsorption Control strongly 
suggest that some NIPAM physisorption has occurred. The O-H stretch (~3300 cm-1) 
appearing in the Adsorption Control and the 1 mol% samples appearing due to all the 
samples being dried from a water suspension of the MSNs. 
4.3.4 Dynamic Light Scattering 
Measurement of the hydrodynamic diameter was performed using dynamic 
light scattering in aqueous suspensions on the polymer grafted samples to observe if 
the surface density variation from 0.2 mol%, 1 mol% and 2.5 mol% had any effect on 
their colloidal behaviour (Table 4.2). 
Table 4.2. The hydrodynamic diameters and PDIs obtained from DLS of the pNIPAM 
functionalised Gd3+-DOTA MSNs with theoretical surface densities of 0.2 mol%, 1 
mol% and 2.5 mol% compared to the parent MSNs and the Adsorption Control. 
Theoretical pNIPAM grafting 
density on surface of Gd3+-DOTA 
MSNs / mol%* 
Hydrodynamic diameter / 
nm 
PDI 
0.2 726.3 ± 72.1 0.43 ± 0.02 
1.0 576.4 ± 94.2 0.41 ± 0.03 
2.5 362.1 ± 19.3 0.28 ± 0.02 
Adsorption Control 3170 ± 30.0 0.21 ± 0.14 
Parent MSNs 221.7 ± 53.8  0.26 ± 0.05 
 *mol% of APTES relative to TEOS. 
This analysis showed that that all MSNs that were reacted with NIPAM had a 
significantly larger hydrodynamic diameter than the parent MSNs (221.7 ± 53.8 nm). 
This suggests that NIPAM has been bound to the surface of the MSNs. There was 
decreased hydrodynamic diameter on increase in percentage surface functionalisation 
of NIPAM from 726.3 ± 72.1 nm for 0.2 mol% to 576.4 ± 94.2 for 1 mol% and finally 
362.1 ± 19.3 nm for 2.5 mol%. This suggested that the polymer chain length was 
increasing with decreased surface grafting density, increasing the volume of water 
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molecules able to interact with the extended (below LCST) hydrophilic polymer 
chains. This is due to the consistent amount of NIPAM monomer added to the ATRP 
reaction. That is 6.63 x10-3 mol NIPAM was added to each reaction containing 0.2 
mol%, 1 mol% or 2.5 mol% surface grafted BIBB initiator; this resulted in longer 
polymer chains with lower grafting density of surface initiator, as the polymerisation 
process proceeds from less initiator groups. Conversely, shorter polymer chain lengths 
are formed when higher grafting densities of surface initiator was used, as the NIPAM 
monomer grows from each initiator group, leading to overall shorter chains (Figure 
4.6). The large hydrodynamic diameter obtained by the Adsorption Control (3170 ± 
30.0 nm) shows that the physisorbed NIPAM monomer observed has destabilised the 
MSNs in aqueous solution. The polydispersity indexes, PDIs, for pNIPAM 
functionalised MSNs for 0.2 mol% was 0.43 ± 0.02, 1 mol% was 0.43 ± 0.03, 2.5 
mol% was 0.28 ± 0.03 and Adsorption Control was 0.21 ± 0.14. The PDIs for 0.2 
mol% and 1 mol% were significantly higher than the PDI obtained for the similarly 
prepared MSNs without surface grafted polymer chains, as described in Section 3.4.4, 
Chapter 3 (0.26 ± 0.05). This was expected as the addition of pNIPAM to the surface 
of the MSNs would have increased the polydispersity of MSNs in aqueous suspension 
due to greater variation in the diameter of the composite provided by the hydrophilic 
polymer chain on the MSN surface.  
   
Figure 4.6. Schematic representation of different surface grafting densities of 
pNIPAM (blue curves) grafted from parent Gd3+-DOTA-MSNs (grey spheres, a): b) 
0.2 mol%; c) 1 mol%; d) 2.5 mol%, e) Adsorption Control MSNs. Mol% as determined 
by the grafting density of the initiator, described in Figure 4.3.  
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4.3.5 Gel Permeation Chromatography 
Gel permeation chromatography, GPC, was used to investigate differences 
between polymer length chains. As GPC is not able to analyse polymers grafted onto 
nanostructure surfaces, the polymers had to be synthesised in the absence of MSNs. 
Therefore, three separate ATRP reactions were performed in the absence of MSNs, 
with the equivalent concentration of BIBB initiator added to the polymerisation 
mixture assuming 100 % conversion of surface amine groups to amide bound BIBB 
for each surface density investigated (Table 4.3 and Figure 4.7). The theoretical Mw 
was calculated using Equation 4.1 and Mn calculated by Equation 4.2 where Ni is the 
number of moles of each polymer species and Mi is the molar mass of that species. 
Theoretical Mw =  
Moles of monomer
Moles of initiator
x Mwmonomer (Equation 4.1) 
Mn =  
∑ NiMi
∑ Ni
 (Equation 4.2)  
Table 4.3. A table providing the calculated theoretical molecular weight, Mw, and the 
number averaged molar mass, Mn, with the polydispersity obtained by GPC of the 
calculated 0.2 mol%, 1 mol% and 2.5 mol% equivalent concentrations of BIBB. 
Sample Theoretical Mw / g 
mol-1 
Mn obtained by 
GPC / g mol-1 
Polydispersity by 
GPC 
0.2 mol% 54,800 41,900 1.62 
1 mol% 11,000 12,400 1.29 
2.5 mol% 4400 900 1.07 
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Figure 4.7. The plot of log of the molecular weight, logM, against normalised 
dwdlogM for the ATRP reactions involving the theoretical BIBB concentrations 
calculated for the 0.2 mol%, 1 mol% and 2.5 mol% surface functionalised MSNs. 
The GPC analysis showed that for 0.2 mol% the Mn of the pNIPAM was 41,900 g/mol, 
1 mol% was 12,400 g/mol and 2.5 % was 900 g/mol. This supports the DLS analysis 
that 0.2 mol% surface functionalised MSNs have longer pNIPAM chains on the 
surface compared to 1 mol% which in turn has longer pNIPAM chains than 2.5 mol%. 
The theoretical Mw calculated for 1 mol% was comparable to the Mn obtained by GPC 
(Theoretical Mw = 11,000 g mol
-1, Mn = 12400 g mol
-1). The Mn obtained by GPC 
varied from the theoretical Mw for 0.2 mol% (Theoretical = 54800 g mol-1, Mn = 
41,900 g mol-1) and 2.5 % (Theoretical = 4400 g mol-1, Mn = 900 g mol
-1). These 
smaller than calculated Mn values have been obtained because the polymerisation has 
likely not reached completion. Therefore, every monomer has not been incorporated 
into the polymer.  
4.3.6 Thermogravimetric Analysis 
 Thermogravimetric analysis, TGA, was performed to obtain the mass 
percentage of pNIPAM on the functionalised MSNs.  The samples analysed by TGA 
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were the three polymer grafted MSNs, 0.2 mol%, 1 mol% and 2.5 mol%, the parent 
Gd3+-DOTA functionalised MSNs, pNIPAM and the Adsorption Control (Figure 4.8).  
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Figure 4.8. The percentage mass loss obtained by TGA of the three grafting densities, 
0.2 mol%, 1 mol% and 2.5 mol%, Adsorption Control, the parent MSNs and pNIPAM 
versus temperature. Percentages represent the total percentage mass remaining at the 
end of the analysis. 
The parent MSNs exhibit the same thermal stability in the 30 OC to 600 OC 
temperature range observed in Chapter 3 Section 3.3.3. The pNIPAM compared to the 
parent MSNs was used to identify the temperature at which the mass loss due to 
pNIPAM would be observed. The pNIPAM has a significant mass loss (4.74 wt%) 
between 100 OC and 135 OC which represents water in the sample. The largest mass 
loss for pNIPAM occurs between 325 OC and 425 OC (62.4 wt%), which represents 
the degradation of the polymer. For the parent MSNs, like in section 3.4.3 Chapter 3, 
the loss of Gd3+-DOTA is not observed in the TGA analysis due to the percentage 
functionalisation being too low. There is mass loss for the parent MSNs between 325 
OC and 425 OC (1.9 wt%), however it is negligible in comparison to the mass loss in 
the pNIPAM sample. Therefore, the mass lost between 325 OC and 425 OC in the 
pNIPAM surface functionalised MSNs would predominantly be due to the loss of 
pNIPAM. So, the difference in mass at 325 OC and 425 OC relative to the starting mass 
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was used to analyse the percentage by mass of pNIPAM of the three different surface 
density functionalised Gd3+-DOTA MSNs (Table 4.4).  
Table 4.4. The percentage by overall mass of PNIPAM on the 0.2 mol%, 1 mol%, 2.5 
mol% pNIPAM surface density functionalised MSNs and Adsorption Control. 
Sample Percentage by overall mass of 
pNIPAM /wt% 
0.2 % 63.9  
1 %  29.7 
2.5 % 18.6 
Adsorption Control 6.1 
 
The percentage by overall mass of pNIPAM on the MSNs decreases with increased 
surface functionalisation from 63.9 % for 0.2 mol%, 29.7 % for 1 mol% and finally 
18.6 % for 2.5 mol% surface density, corresponding to the shortened polymer length 
chains being formed on the nanoparticle surfaces. This mass percent loss in the 
Adsorption Control (6.1 %) being higher than the Gd3+-DOTA MSNs (1.9 %) between 
325 OC and 425 OC confirmed a small amount of physisorption was occurring. 
4.3.7 Spectroscopic Analysis of Thermoresponsive Behaviour 
The most common measured macroscopic property analysed to prove 
thermoresponsive behaviour is the onset of aggregation via turbidimetry.36 this 
monitors the decrease in transmitted light once the polymer has been heated above its 
cloud point. The cloud point is the temperature at which phase separation between the 
polymer and the water solvent starts, causing the solution to turn opaque. This method 
of analysis measures the outcome of the transition not the transition itself.70 UV/vis 
spectroscopy at 700 nm between 25 OC and 50 OC was utilised to observe the cloud 
point of the MSNs of the varying surface density pNIPAM functionalisation, 0.2 
mol%, 1 mol% and 2.5 mol% compared to the Adsorption Control and Gd3+-DOTA 
MSNs (Figure 4.9). The cloud point quoted was calculated as the temperature when 
the background normalised 1/transmittance is half the maximum 1/transmittance 
obtained for the sample.  
 123 
 
 
Figure 4.9. The background normalised 1/ transmittance at 700 nm between 25 OC 
and 50 OC of 0.2 mol%, 1 mol% and 2.5 mol% MSN surface coverage of pNIPAM, the 
Adsorption Control and the parent MSNs. The cloud point quoted calculated as the 
temperature which the background normalised 1/transmittance is half the maximum 
1/transmittance obtained for the sample. The schematics represent the transition of 
pNIPAM from its extended formation below its LCST to the contracted formation 
above its LCST facilitating aggregation. 
The parent MSNs have no increase in 1/transmittance with increased 
temperature, which would show the presence of a cloud point. This shows that the 
colloidal stability of the parent MSNs in aqueous suspension is independent of 
temperature. There is a significant increase in 1/transmittance for each of the three 
pNIPAM surface functionalised samples, indicating the transition through the cloud 
point. The cloud point varies depending on the surface density of pNIPAM on the 
MSNs from 36.4 OC for 0.2 mol%, 37.4 OC for 1 mol% and finally 42.3 OC for 2.5 
mol%. This variation in observed cloud points between varying the surface density of 
pNIPAM from 0.2 mol% to 1 mol% and 2.5 mol% could be due to the lower surface 
densities not having enough surface coverage to ensure polymer-solvent interactions 
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exclusively, allowing solvent-substrate interactions to be present.71 This results in the 
responsive behaviour of the polymer and resulting cloud point being significantly 
different as the contribution of the underlying substrate will vary.72 T 
his variation in cloud point could also be due to the larger pNIPAM surface 
density of 2.5 mol% inhibiting complete conversion of polymer-water interactions to 
polymer-polymer interactions because of steric hindrance of nearby pNIPAM chains. 
Thus providing colloidal stability to the MSNs up to higher temperatures.  These 
results show that the LCST of the surface pNIPAM can be tuned and optimised to a 
desirable LCST which can also be observed visibly (Figure 4.10). There is no cloud 
point for the Adsorption Control. Thus, proving that the minimal physisorption of 
monomer observed by TGA and FTIR is not providing the MSNs with any 
thermoresponsive properties. 
A)  
B)  
Figure 4.10. Photographs of 2.5 mol%, 1 mol%, 0.2 mol% pNIPAM surface 
functionalise Gd3+-DOTA MSNs with the mol% representing the mol% of amine 
functionalisation relative to TEOS, water and parent MSNs at A) 35 OC and B) 40 OC. 
All MSNs analysed at 10 mg/mL. 
At 35 OC all the pNIPAM surface functionalised MSNs, 0.2 mol%, 1 mol% and 2.5 
mol% are observed to be in suspension in the aqueous solution, as evidenced by the 
opaque appearance of the suspensions. However, after increasing the temperature to 
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MSNSWater 
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40 OC both the 0.2 mol% and 1 mol% pNIPAM surface functionalised MSNs have 
clearly aggregated out of suspension. The parent Gd3+-DOTA MSNs show no 
precipitation upon increasing temperature, demonstrating that the behaviour is because 
of the presence of the grafted thermoresponsive polymers. The 2.5 mol% MSNs, on 
the other hand, have remained suspended in the water solution, as their cloud point 
(42.3 OC according to Figure 4.9) has not yet been achieved.  
Yang et al. was also able to acquire thermoresponsive MSNs using CTAB as a soft 
template and TEOS as a silica source, however used sodium hydroxide instead of TEA 
which was used in this investigation.33 This reaction obtained MSNs of 200 nm (parent 
MSN = 47.4  ± 4.5 nm).The pNIPAM functionalised MSNs obtained had a cloud point 
in the range 30 – 34 OC, which is lower than the cloud points observed for 0.2 mol%, 
1 mol% and 2.5 mol%. However, this discrepancy is due to the large variation in 
surface density of functionalisation between MSNs. Yang et al. surface functionalised 
the MSNs with 0.28 mL APTES to 1.265 mL TEOS to obtain a surface density of 21.4 
% compared to 40 µL APTES to 1.454 mL TEOS for the highest surface density of 
2.5 mol% in this research. The ratios of NIPAM monomer used in the ATRP reaction 
were also considerably higher (0.228 g or 0.906 g NIPAM to ~5 mg MSNs) than those 
used in this investigation (0.75g NIPAM to ~100 mg MSNs). Yang et al. performed 
no analysis on the grafted polymer to ascertain the Mn, however this large variation 
between investigations would suggest that there is a large discrepancy between 
polymer chain lengths obtained by Yang et al. and this investigation.  It was also noted 
by TEM in the research by Yang et al. that the polymer chain length was effect by the 
monomer to initiator ratio but was not investigated further to observe its effect on 
thermoresponsivity. 
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4.4 Investigation into the pNIPAM Surface Functionalised 
Gd3+-DOTA MSNs’ application as an MRI Contrast Agent 
4.4.1 Relaxometry analysis 
The pNIPAM functionalised MSNs were analysed at 13.1 MHz at room temperature 
(~20 OC) to obtain their relaxivity and therefore the MSNs effectiveness as MRI 
contrast agent. This was calculated exactly as previously described in Equation 3.1 
and 3.2, Section 3.5.1 Chapter 3 (Figure 4.11).  
 
Figure 4.11. The plots of Gd3+ concentration versus water normalised R1 for A) 0.2 
mol%, B) 1 mol% and C) 2.5 mol% pNIPAM modified MSMs. The mol% is amine 
group functionalisation with respect to TEOS. Each sample has three repeats which 
correspond to three separate aliquots of the same batch of MSNs and R1 analysis was 
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performed at room temperature. slope is relaxivity according to Equations 3.1 and 3.2 
Section 3.5.1 Chapter 3. 
As in Chapter 3 the slope of the linear plot provides the relaxivity in mM-1 s-1. The R2 
values here are lower (0.2 mol% = 0.93 ± 0.02, 1 mol% = 0.99 ± 0.01 and 2.5 mol% 
= 0.92 ± 0.01) than the >0.99 values previously obtained for Gd3+-DOTA MSNs 
prepared in Figure 3.16, 3.17 and 3.18, Appendix, Chapter 3. These slightly lower 
values are, however, reproducible and are therefore likely due to the Brownian motion 
of the thermoresponsive pNIPAM attached to the MSNs. This size fluctuation due to 
Brownian motion is observed in the larger PDIs obtained for the surface pNIPAM 
Gd3+-DOTA MSNs (0.2 mol% = 0.43 ± 0.02, 1 mol% = 0.41 ± 0.03 and 2.5 mol% = 
0.28 ± 0.02 mol%) compared to parent MSNs (0.26 ± 0.05). This polymer motion 
resulting in steric interactions that cause deviations in water accessibility to the 
internally Gd3+-DOTA bound MSNs to such an extent that variations in the 
interactions occur between the thermoresponsive MSNs and the surrounding water 
molecules. This minor fluctuation between the amount of water molecules that can 
interact with the Gd3+-DOTA complexes inside the pores results in differences 
between repeated T1 analysis of the same MSN batch and concentration. These results 
were used in calculating the mean and standard deviation of the relaxivity of the 
samples (Figure 4.12). 
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Figure 4.12. A bar chart showing the comparison in relaxivity between Gd3+-DOTA 
MSNs (CTAB Internal MSNs, Figure 3.11, Section 3.5.1 Chapter 3), 0.2 mol%, 1 mol% 
and 2.5 mol% of amine functionalisation of MSNs with respect to TEOS. at room 
temperature. The mean and standard deviation calculated by measurements obtained 
from three separate samples of the same batch of MSNs. 
The relaxivities obtained, 0.2 mol% = 38.8 ± 2.8 mM-1 s-1, 1 mol% = 43.1 ± 1.9 mM-
1 s-1 and 2.5 mol% 33.4 ± 1.9 mM-1 s-1 are higher than the relaxivity of the Gd3+-DOTA 
MSNs = 31.39 ± 4.17 mM-1 s-1. This shows there is no reduction in relaxivity due to 
the pNIPAM chains on the surface of the MSNs hindering water access to the 
internalised Gd3+-chelate species. This is an essential first consideration for these 
nanocomposites to be explored as diagnostic MRI contrast agents. The slightly 
heightened relaxivity values observed may be due to the pNIPAM chains slowing the 
tumbling of the MSNs. Slowing down the tumbling rate of the Gd3+-chelate is known 
to increase contrast and is represented in Solomon-Bloembergen-Morgan (SBM) 
Theory, specifically in Equations 1.5 and 1.6 in Section 1.3.3, Chapter 1.73-75  
 As copper was used in the ATRP reaction as a catalyst and is paramagnetic 
and therefore could affect the relaxivity of the pNIPAM functionalised Gd3+-DOTA 
MSNs, ICP-MS was performed to observe the amount of copper contamination (Table 
4.5). 
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Table 4.5. The ICP-MS analysis of copper and gadolinium in the samples 0.2 mol%, 
1 mol% and 2.5 mol% pNIPAM surface functionalised MSNs, mol% of amine 
functionalisation with respect to TEOS. 
Sample Gd / ppb Cu / ppb 
0.2 mol% 25.22 35.63 
1 mol% 23.11 63.21 
2.5 mol% 27.22 42.31 
 
The ICP-MS analysis showed that Cu impurities were present in the samples 
and that the concentration of Cu was consistently higher than the concentration of Gd. 
To investigate this further a second control, Cu Control, was made with all the 
synthetic steps of the 0.2 mol% pNIPAM surface coverage protocol except the Gd3+-
DOTA functionalisation step (Figure 4.3, A), to investigate how much the copper 
impurity was affecting the relaxivity of the samples (Figure 4.13).  
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Figure 4.13. The plots of Cu concentration versus water normalised R1 for the Cu 
Control. The three repeats correspond to three separate aliquots of the same batch of 
MSNs and R1 analysis was performed at room temperature. slope is relaxivity 
according to Equations 3.1 and 3.2 Section 3.5.1 Chapter 3. 
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The Cu concentration obtained by ICP-MS for the Cu Control was 53.00 ppb 
which is equivalent to the concentrations of Cu obtained by the 0.2 mol% (35.63 ppb), 
1 mol% (63.21 ppb) and 2.5 mol% (42.31 ppb) samples. The relaxivity obtained by 
the Cu Control was very low at 3.61 ± 0.27 mM-1 s-1 compared to the relaxivities 
observed for all the variations of PNIPAM surface functionalised Gd3+-DOTA MSNs 
(0.2 mol% = 38.8 ± 2.8 mM-1 s-1, 1 mol% = 43.1 ± 1.9 mM-1 s-1 and 2.5 mol% 33.4 ± 
1.9 mM-1 s-1). This shows that the relaxivity is predominantly sourced from the water 
interacting with the Gd3+. 
4.4.2 MR Imaging Analysis at Clinical Field Strengths 
The limitation of the relaxivity analysis in the 13.1 MHz Xigo machine is that it is 
unable to analyse precipitated MSNs effectively due to averaging the relaxation 
obtained across a defined area. Therefore, to analyse the MSNs after aggregation, a 3 
Tesla Clinical MRI Scanner was used to collect phantom images of behaviour both 
below and above the cloud points of the composites (Figure 4.13). 
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Figure 4.14. Phantom T1 weighted images obtained by a 3 Tesla MRI scanner of the 
pNIPAM surface density functionalised MSNs, 2.5 mol%, 1 mol% and 0.2 mol% 
amination with respect to TEOS compared to water and Gd3+-DOTA MSNs at A) 35 
OC and B) 40 OC. 
The Parent MSNs and the water sample were analysed as a positive and negative 
control respectively. As can be observed at 35 OC all the samples, 0.2 mol%, 1 mol% 
and 2.5 mol% plus the Parent MSNs are all significantly brighter than the water 
proving that MSNs are an applicable construct for the application as a positive MRI 
contrast agent. At 40 OC the parent MSNs remain in suspension showing that there is 
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no inherent precipitation at increased temperature. The pNIPAM functionalised MSNs 
however are in various degrees of precipitation due to transitioning through their cloud 
points. This shows that the contrast ability of the MSNs does not disappear on 
precipitation, but rather that aggregation results in a ‘concentration’ of positive signal 
in the region of MSN aggregation. The sample with the lowest grafting density of 
polymer (0.2 mol%) and lowest overall cloud point of 36.4 OC (as previously described 
in Section 4.4.7) has precipitated to the bottom of the tube and resulted in a 
‘concentration’ of the positive MRI signal in this area. The sample with the higher 
grafting density of 1 mol% shows some level of precipitation and aggregation of 
signal, as the nanocomposite has transitioned through its cloud point of 37.4 OC, but 
it still undergoing aggregation at the bottom of the tube. The highest grafting density 
on the other hand, 2.5 mol%, appears to remain in suspension and demonstrates no 
aggregation of particles and hence positive signal. This is due to the sample not yet 
having reached its transition temperature of 42.3 OC, and therefore remaining well 
dispersed in suspension. 
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4.5 Conclusions 
In this chapter the aim was to develop a synthetic strategy to produce temperature 
responsive MSNs and observe their applicability to overcome traditional challenges 
in clinical diagnostic medicine by exploiting MRI. The synthetic protocol was 
achieved by the internal functionalisation of MSNs with Gd3+-DOTA. Then post graft 
functionalising the surface of these Gd3+-DOTA MSNs with amine groups provided 
by APTES. Finally, by binding BIBB initiator to the amine groups and performing an 
ATRP reaction with NIPAM monomer. The protocol steps involved were followed by 
Zeta potential and the retention of the MSN structure after the binding of pNIPAM 
proven by TEM.  The successful pNIPAM surface functionalisation of the MSNs 
proved by IR, TGA and DLS. However, low levels of adsorption of pNIPAM was 
observed.  
Three sets of MSNs with varying surface density of amine groups with respect to 
TEOS, 0.2 mol%, 1 mol% and 2.5 mol% were synthesised and was found to change 
the cloud point of the MSNs (0.2 % = 36.4 OC, 1 % = 37.4 OC and 2.5 mol% = 42.3 
OC), with no observable cloud point found for the Adsorption Control. The relaxivity 
was analysed at 13.1 MHz to observe how the pNIPAM affected the Gd3+-DOTA 
MSNs ability to be used as an MRI contrast agent. The relaxivities obtained (0.2 % = 
38.8 ± 2.8 mM-1 s-1, 1 mol% = 43.1 ± 1.9 mM-1 s-1 and 2.5 mol% 33.4 ± 1.9 mM-1 s-1) 
were all above the relaxivity obtained by plain Gd3+-DOTA MSNs (31.39 ± 4.17 mM-
1 s-1) which proved that there was no negative effect of binding pNIPAM to the surface 
of Gd3+-DOTA MSNs on their ability to be used as MRI contrast agents. Low 
concentrations of Cu contamination were observed, however, this contamination had 
only a small effect on the relaxivity observed (3.61 ± 0.27 mM-1 s-1). Finally, the ability 
of all the samples (0.2 mol%, 1 mol% and 2.5 mol%) were investigated in a clinically 
used 3 Tesla MRI machine to observe their possible use as a thermoresponsive MRI 
contrast agent. This analysis obtained clear positive results that showed that the 
MSNs’ aggregation with increased temperature could be observed by MRI.  
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4.6 Future Work 
 This work has the potential to be used for specific disease diagnosis, such as 
cancerous tumours which are well known to have slightly higher temps than healthy 
tissues due to the faster metabolism of cancer cells. For this application the precision 
and range of this temperature interaction tuneability should be investigated further by 
varying the surface density of pNIPAM on the MSNs and the pNIPAM polymer chain 
length. The Gd3+-DOTA functionalisation and the Cu contaminant removal system is 
another avenue of optimisation. There was significantly less Gd found in the samples 
(3.37 ± 0.83 ng of Gd per mg MSN) by ICP-MS than were found in the Gd3+-DOTA 
MSNs (~100 ng/mg). This is due to the acid method applied for the removal of Cu, 
protonating the DOTA chelate therefore causing dissociation of Gd3+ from the DOTA 
chelate. Other methods were investigated before the acid method was used, such as 
Cuprisorb and ethylenediaminetetraacetic acid, EDTA, however none were more 
effective than brief stirring in acidified solution to remove the Cu from the MSNs. 
Another possible solution to the Gd3+ loss would be to place the MSNs in the GdCl3 
solution after pNIPAM surface functionalisation and the subsequent acid conditions 
required to remove the Cu catalyst. This route however could result in an 
uncontrollable amount of Gd3+ physisorption to the pNIPAM which would require 
investigation. 
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Chapter 5 
5. Designing MSNs for Targeting of 
Colorectal Cancer 
 
5.1 Chapter Summary 
The ability to specifically highlight tumour tissue to allow for facile diagnosis is a 
highly desirable functionality. Imaging of tumour cells in a targeted manner can be 
facilitated by imaging active nanoparticles with a targeting moiety on their surfaces. 
A major challenge with the use of nanomaterials for targeting is non-specific binding, 
leading to the imaging species being adsorbed or taken up indiscriminately by cells 
within the body, which does not provide significant value clinically. Past research has 
discussed how the addition of a N-methyl-N-vinylacetamide (NVA) and methacrylic 
acid (MAA) copolymer can be utilised to minimise interactions between nanoparticles 
and cells by sterically blocking the nanoparticle binding with the cell whilst itself 
being inert. Furthermore, that the amide binding of Arachis hypogaea lectin (peanut 
agglutinin, PNA) with the MAA of the copolymer allowed for specific binding to 
colorectal cancer cells to be observed. Herein, we sought to investigate this; two 
different polymerisation approaches were employed to surface modify fluorescent 
MSNs at different surface grafting densities. Free radical, though successful in 
grafting polymer onto surfaces and in lowering non-specific binding events between 
the polymer-grafted nanocomposites, additionally led to a significant level of surface 
adsorbed monomer.  Atom transfer radical polymerisation, ATRP, on the other hand, 
enables minimisation of surface physisorption, whilst also providing a route to 
controlling polymer chain length on nanoparticle surfaces. The NVA/MAA copolymer 
surface functionalised MSNs obtained using ATRP were found to have the same low 
non-specific binding with colorectal cancer cells, SW480, that was observed with the 
free radical polymerised NVA/MAA copolymer. Therefore, the ATRP NVA/MAA 
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fluorescent mesoporous silica nanoparticles, MSNs, were functionalised with PNA, 
PNA MSNs, in a bid to now introduce specific targeting capability.  The PNA MSNs 
were incubated with colorectal cancer cells and found to have a high affinity to the 
colorectal cancer cells, SW480, suggesting that a more specific binding interaction 
was being observed. Finally, a toxicity test was performed to confirm the 
biocompatibility of the PNA MSNs, which proved the non-toxicity of the PNA MSNs 
up to 1.25 mg/mL.   
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5.2 Introduction 
Colorectal cancer, CRC, is the third most commonly diagnosed cancer among both 
men and women in the United States.1 In 2017 it is projected that 135,430 individuals 
will be diagnosed with CRC with 50,260 deaths from the disease in the U.S.A.2 39 % 
of patients diagnosed with CRC are in the localised stage, defined as when the cancer 
is limited to its origin with no sign of spread,  where the 5 year survival rate is 90 %. 
However the 5 year survival rate drops to 71 % if diagnosed in the regional stage, 
defined as when the cancer has spread to nearby lymph nodes, tissues or organs, and 
14 % in the distant stage of the disease, defined as when the cancer has spread to 
organs far from the origin.3 the deterioration in survival rate highlights the essential 
need to diagnose and treat CRC at the initial localised stage. 
 If CRC is diagnosed at an early stage local treatments such as polypectomy,4 
local resection5 and total mesorectal excision6 are able to be performed. All these 
surgical operations involve removal of the cancerous tissue and some of the local 
tissue.7, 8 For all these operations the elucidation of cancerous tissue is essential to 
minimise cancerous tissue left in the patient. Colonoscopy is the principal method of 
CRC tissue observation.9 The major limitation of standard white-light colonoscopy is 
that tumour tissues are only able to be detected with a diameter ~1 cm. Tumours of 
this size are likely of metastasis.8, 9 This limitation has been partially overcome by 
magnifying endoscopy.10, 11 However, there is still a high demand for novel imaging 
strategies.10-14 
 Another method of improving the detection of CRC tissue is by the 
administration of an imaging agent.15 Endoscopic imaging agents need to have four 
key properties. Firstly, the imaging agent needs to be non-toxic. Secondly, the agent 
needs to provide a distinctive signal using an imaging technique. For endoscopy this 
generally involves some form of fluorescence.15-20 Thirdly the imaging agent requires 
a low affinity to healthy cells to minimise background noise. A method to minimise 
this non-specific binding to healthy tissue is by the functionalisation with an inert 
polymer, in particular polyethylene glycol, PEG.21 PEG functionalisation, 
PEGylation, was introduced by A. Abuchowski et al. in 1977, who noted the superior 
immunogenic properties obtained by PEGylation as well as enhanced circulation 
lifetimes and reduced immunogenicity.22, 23 PEGylation induces these properties by 
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providing a steric barrier against the attachment of plasma proteins such as opsonins 
and recognition by the cells of the mononuclear phagocyte system, resulting in a 
decreased rate of clearance from blood circulation.24  These advantages in addition to 
PEG’s low toxicity has led to a wide variety of small molecules and nanoparticles, 
including MSNs, being PEGylated, in a bid to confer these properties on the 
nanoparticles.25-32 However it has been observed a repeat dose of pegylated liposomes 
after several days results in the loss of the long-circulating properties and 
accumulation extensively in the liver due to the accelerated blood clearance 
phenomenon.33-36  
The final required property in the design of enhanced imaging agents for 
cancer detection is a high affinity to cancerous cells. This is usually acquired from a 
specific interaction being exploited between cancerous tissue and an external molecule 
which can be utilised to bind the imaging agent specifically to the CRC cells of 
interest. Numerous molecules have been investigated that have an observed affinity to 
CRC cells above healthy cells such as antibodies16, 17, 37, 38 and lectins, for example 
helix pomatia agglutinin,39, 40 soybean agglutinin,41 wheat germ agglutinin,18, 42, 43 
galectin 344-46 and peanut (Arachis hypogea) agglutinin, PNA.19, 20, 47-50 PNA binds to 
the Thomsen-Friedenreich, TF, antigen through the recognition of its terminal sugar, 
β-D-galactosyl-(1-3)-N-acetyl-D-galactosamine, Gal-β(1-3)GalNac (Figure 5.1).51-58  
 
Figure 5.1 The chemical structure of the Gal-β(1-3)GalNac terminal sugar on the TF 
antigen. 
The TF antigen is specifically expressed on the mucosal side of CRC cells in the early 
stages as well as breast and prostate carcinomas.51, 56, 59 The role of the TF antigen is 
to facilitate a docking system for the cancerous cells onto endothelium by specifically 
interacting with the endothelium-expressed β-galactoside binding protein, galectin-
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3.60, 61  Also, the TF antigen- bearing glycoproteins are capable of mobilization of 
galectin-3 to the surface of endothelial cells, thus priming them for harbouring 
metastatic cancer cells.62 TF antigen is masked by an oligosaccharide side chain 
extension or sialylation in healthy cells, making it an ideal selection for targetting.63 
 S. Sakuma et al. have performed a lot of research into endoscopy imaging 
agents.19, 47, 48, 64-69 These imaging agents are based on polystyrene bound copolymers 
of N-vinylacetamide and methacrylic acid.70 The polystyrene forming the hydrophobic 
core of the nanoparticles and the N-vinylacetamide and methacrylic acid copolymer 
forming the hydrophilic surface. Both the copolymer and polystyrene polymerisations 
were performed using free radical polymerisation with azobisisobutyronitrile, AIBN, 
as the initiator (Figure 5.2). 
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Figure 5.2. The reaction mechanism for free radical polymerisation of styrene using 
AIBN as initiator. Highlighting the three stages of free radical polymerisation, 
initiation, propagation and termination, where n and m represent the number of 
monomer repeat units.  
S. Sakuma et al. performed many investigations on these polystyrene nanoparticles 
such as observing the non-specific binding between the nanoparticles and CRC cells64 
and their low toxicity both in-vitro and in-vivo.20, 69 PNA was chemically bound to the 
MAA/ N-vinylacetamide copolymer and it was proven that specific binding was 
acquired with the nanoparticles and CRC cells both in vitro and in vivo.19, 47, 48, 65-68, 71 
Initiation
Propagation
Termination
Combination
Disproportionation
Chain Transfer
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This was performed using the free amine groups in PNA and the carboxylic acid 
functional groups in MAA utilising the coupling agents N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride, EDC-HCl. This method can be optimised by the 
addition of N-hydroxysuccinimide, NHS, which is preferable as it increases the 
stability of the activated ester  (Figure 5.3).72 
 
 
Figure 5.3. The general reaction mechanism for amide bond formation using EDC-
HCl and NHS coupling agents. 
5.2.1 Aims 
The aim of this work was to synthesise fluorescent MSNs that specifically bind to 
colorectal cancer cells whilst avoiding non-specific binding that plagues traditional 
non-modified nanoparticles, such that they could be used in location resection or 
colectomy surgeries. It further aimed to develop a reliable and reproducible 
nanoparticle functionalisation route which is transferrable to several oxide-type 
nanoparticles, including MRI and imaging agents, towards highly specific targeting 
and evading non-specific uptake of new imaging tools 
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5.3 Free Radical Polymerisation Approach 
Internally amine functionalised MSNs (0.15 mol% with respect to TEOS) were 
synthesised using the same protocol as Chapter 3, Figure 3.5. Internal 
functionalisation was chosen to exploit all surfaces available and prevent potential 
unwanted interactions with polymer reagents. Therefore, locating the fluorescein, 
FITC, in the pores of the MSNs would provide a physical barrier between the 
fluorescein and the polymer on the surface. The amine groups were then reacted with 
a N-hydroxysuccinimide, NHS, activated fluorescein ester to form fluorescent 
nanoparticles (Figure 5.4). External surface amination was carried out on the 
fluorescein functionalised MSNs at surface loadings of 0.2 mol% and 1 mol% with 
respect to tetraethyl silicate, TEOS. Surface density was varied to facilitate ease of 
varying polymer surface loading, allowing determination of the impact polymer 
grafting density has on controlling non-specific binding of nanoparticles to human cell 
lines. 4,4′-Azobis (4-cyanovaleric acid), ACVA, was used as it is a common initiator 
used for free radical polymerisation with two free carboxyl groups which would be 
available to form an amide bond with the surface amine groups on the MSNs.73 
ACVA, was covalently bound to the external amine groups using NHS and N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, EDC-HCl, coupling to 
form an amide bond. Finally, a free radical polymerisation was performed using NVA 
and MAA as the monomers and ACVA as the initiator. Free radical polymerisation 
was used as this method is the most common polymerisation protocol utilised for 
MAA polymers (Figure 5.4).19, 20, 47, 48, 64-71, 74, 75 
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Figure 5.4. A Schematic of the functionalisation method to obtain fluorescent MSNs 
with NVA/MAA copolymer surface functionalisation using free radical 
polymerisation. A) FITC functionalisation inside the pores of the MSNs, FITC MSNs, 
B) external surface amine functionalisation of FITC MSNs, C) 4,4′-Azobis (4-
cyanovaleric acid), ACVA, initiator surface functionalisation and D) N-methyl-N-
vinylacetamide (NVA) and methacrylic acid (MAA) copolymer surface functionalised 
fluorescent MSNs obtained using free radical polymerisation, where n and m 
represent the number of monomer repeat units. 
5.3.1 Dynamic Light Scattering and Zeta Potential Analysis of 
Nanocomposites 
Dynamic light scattering, DLS, and zeta potential, Table 5.1, were used to monitor the 
stepwise surface modification as shown in Figure 5.4. 
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Table 5.1 The Hydrodynamic diameter, polydispersity index, PDI, and zeta potential 
obtained after the key steps in the synthesis of NVA/MAA copolymer surface 
functionalised MSNs.  
Synthetic 
step 
Sample 
0.2 mol%* 1 mol%* 
Hydrodynamic 
diameter / nm 
PDI Zeta 
potential 
/ mV 
Hydrodynamic 
diameter / nm 
PDI Zeta 
potential 
/ mV 
Parent 
MSNs 
266.9 ± 36.6 0.29 
± 
0.02 
-23.4 ± 
0.6 
304.7 ± 50.2 0.34 
± 
0.02 
-27.6 ± 
2.3 
Fluorescein 
modified 
MSNs 
274.9 ± 19.8 0.23 
± 
0.09 
-18.4 ± 
2.7 
354.7 ± 27.3 0.28 
± 
0.03 
-29.6 ± 
1.2 
Externally 
aminated 
MSNs 
1042.0 ± 144.6 0.45 
± 
0.04 
10.7 ± 
0.8 
612.3 ± 98.7 0.28 
± 
0.10 
20.8 ± 
1.03 
Final 
composite 
after free 
radical 
NVA/MAA 
copolymer 
modification 
584.3 ± 125.2 0.36 
± 
0.02 
-11.0 ± 
0.5 
667.1 ± 132.8 0.31 
± 
0.06 
-18.2 ± 
1.3 
*mole percent (mol%) with respect to tetraethyl orthosilicate, TEOS for external 
amine modification. 
MSNs prepared with internal amination at 0.15 mol%, used to prepare original parent 
MSNs, had sizes within error of one another (0.2 mol% 266.9 ± 36.6 nm and 1 mol% 
= 304.7 ± 50.2 nm).  The zeta potentials for the MSN batches are both in the expected 
range for MSNs prepared with 0.15 mol% internal amination (-23.4 ± 0.6 mV and -
27.6 ± 2.3 mV respectively).76 Theses are negative due to the abundant surface silanol 
groups of the MSNs.  The hydrodynamic diameters obtained for each fluorescein 
functionalisation (0.2 mol% = 274.9 ± 19.8 nm and 1 mol% = 354.7 ± 27.3 nm) were 
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within error of the hydrodynamic diameters obtained after the respective MSN 
synthesis (0.2 mol% = 266.9 ± 36.6 nm and 1 mol% = 304.7 ± 50.2 nm). The 
fluorescein functionalisation also does not have a large effect on the zeta potential (0.2 
mol% = -18.4 ± 2.7 mV and 1 mol% = -29.6 ± 1.2 mV).  Due to the low concentration 
(0.15 mol%) of fluorescein being bound to the MSNs this fluorescein functionalisation 
was expected to have little effect on hydrodynamic diameter and zeta potential. The 
external amination caused a significant change in the hydrodynamic diameter of the 
MSNs (0.2 mol% = 1042.0 ± 144.6 nm and 1 mol% = 612.3 ± 98.7 nm). This is 
because the surface charge has been affected by the predominantly negatively charged 
surface of the MSNs, due to Si-OH groups, becoming more positive due to the amine 
groups provided by (3-aminopropyl) triethyoxysilane, APTES. This results in strong 
electrostatic interactions between the different surfaces charges on neighbouring 
particles, causing increased interactions between numerous particles, which are then 
observed by the machine as a larger particle. The explanation for the dramatic increase 
in hydrodynamic diameter obtained by 0.2 mol% compared to 1 mol% is that the 1 
mol% surface amine functionalised MSNs will be more uniformly positively charged 
compared to 0.2 mol%.  This greater variation in surface charge (between 
neighbouring positive and negative surfaces) for 0.2 mol% creates greater electrostatic 
interactions between MSNs causing more aggregation and therefore resulting in a 
larger observed hydrodynamic diameter. This also correlates with the increased PDI 
values (0.2mol% = 0.45 ± 0.04, 1 mol% = 0.28 ± 0.10) and zeta potentials observed 
(0.2 mol% = 10.7 ± 0.8 mV and 1 mol% = 20.8 ± 1.03 mV), with a higher positive 
zeta potential for the more heavily loaded MSNs.  Upon polymerisation the 
hydrodynamic diameters (0.2 mol% = 584.3 ± 125.2 nm and 1 mol% = 667.1 ± 132.8 
nm) are larger than the parent MSNs, due to the polymer chains present on the surfaces 
increasing the hydrodynamic sizes of the particles because of increased van der Waals 
interactions and interchain interactions. The large sterically-induced size obtained by 
0.2 mol% external amination is no longer observed as the external surface amino 
groups have been used during subsequent surface modification, and polymer 
stabilisation aids in preventing such steric interaction. This is clearly demonstrated by 
the PDI of the NVA/MAA surface functionalised MSNs (0.2 mol% = 0.36 ± 0.02, 1 
mol% = 0.31 ± 0.06) returning to similar values to those of the parent MSNs (0.2 
mol% = 0.29 ± 0.02, 1 mol% = 0.34 ± 0.02). The NVA/MAA external 
functionalisation of the MSNs returned the zeta potential to negative (0.2 mol% = -
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11.0 ± 0.5 mV and 1 % = -18.2 ± 1.3 mV) due to the methacrylic acid in the copolymer. 
The change in zeta potential from surface amination to the NVA/MAA copolymer 
functionalisation of 0.2 mol% and 1 mol% varies considerably (Δ0.2 mol% = - 21.7 
mV, Δ1 mol% = - 39 mV).  This large change in zeta potential for 1 mol% compared 
to 0.2 mol% coupled with the similar hydrodynamic diameter obtained suggests that 
increasing the surface density has increased the number of polymer chains without 
affecting the polymer chain length (Figure 5.5). 
 
Figure 5.5. The proposed schematic for the variation in zeta potential whilst still 
having equivalent hydrodynamic diameters obtained by DLS. A) 0.2 mol% surface 
functionalised NVA/MAA copolymer, B) 1 mol% surface functionalised NVA/MAA 
copolymer. Where n and m represent the number of monomer repeat units for MAA 
and NVA respectively. 
5.3.2 Transmission Electron Microscopy Analysis of Nanocomposites 
Transmission electron microscopy, TEM, was utilised to observe the structural 
integrity and porosity of the MSNs after the NVA/MAA copolymer surface 
functionalisation using free radical polymerisation (Figure 5.6). 
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Figure 5.6. The TEM images obtained for A) CTAB Internal MSNs (Chapter 3, Section 
3.3.1), B) 0.2 mol% and C) 1 mol% NVA/MAA copolymer surface functionalised 
MSNS. The diameters of the MSNs were calculated by the mean and standard 
deviation of 100 MSN diameters. 
As can be observed in the images the porosity remains intact and the mean 
diameter (0.2 mol% = 49.2 ± 3.7 nm and 1 mol% = 46.8 ± 5.6 nm) is within error of 
the parent MSNs (46.7   6.2 nm). The NVA/MAA copolymer can’t be observed 
because no negative staining was performed due to the analysis of the MSN structure 
and size being the principal objective of this procedure. 
5.3.3 Gel Permeation Chromatography Analysis of 0.2 mol% and 1 
mol% NVA/ MAA Copolymer 
In order to provide an estimate of the polymer chain length which has been grafted 
onto the MSNs surfaces, and as this technique cannot be carried out on polymer-
nanoparticle composites, NVA/MAA copolymer was synthesised using the theoretical 
ACVA initiator concentrations for 0.2 mol% and 1 mol% surface grafting density. 
Here two separate free radical polymerisation reactions were performed in the absence 
of MSNs, with the equivalent concentration of ACVA initiator added to the 
polymerisation mixture assuming 100 % conversion of surface amine groups to amide 
bound ACVA for each surface density investigated. These copolymers were analysed 
by gel permeation chromatography, GPC (Table 5.2). Mn calculated by Equation 4.2 
where Ni is the number of moles of each polymer species and Mi is the molar mass of 
that species. 
Mn =  
∑ NiMi
∑ Ni
 (Equation 4.2) 
Particle diameter = 49.2  3.7 nm Particle diameter = 46.8  5.6 nm
100 nm 100 nm100 nm
Particle diameter = 46.7  6.2 nm
A) B) C)
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Table 5.2. The number average molecular weight, Mn, obtained by GPC with the 
polydispersity of the calculated 0.2 % and 1 % concentrations of ACVA. 
Sample Mn / g mol-1 PDI 
0.2 mol% NVA/MAA 6100 1.28 
1 mol% NVA/MAA 7000 1.20 
 
The Mn values obtained for the polymer obtained with 0.2 mol% and 1 mol% 
were similar with 0.2 mol% = 6100 g mol-1 and 1 % = 7000 g mol-1. The PDIs are also 
very similar with 0.2 mol% = 1.28 and 1 mol% = 1.20. These results in addition to the 
similar plots obtained for dwdlogM against logM strongly suggest that the copolymers 
obtained by the 0.2 mol% and 1 mol% surface densities using free radical 
polymerisation were very similar (Figure 5.7).  
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Figure 5.7. The plot of logM against normalised dwdlogM for the free radical 
polymerisation reactions involving the theoretical ACVA concentrations calculated 
for the 0.2 mol% and 1 mol% surface functionalised MSNs. 
The asymmetry of 0.2 mol% NVA/MAA and 1 mol% NVA/MAA is due to the amount 
of uncontrolled termination occurring using free radical polymerisation. The small 
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variation between 0.2 ml% NVA/MAA and 1 mol% NVA/MAA is due to the larger 
number of uncontrolled termination reactions occurring, shown by the increased PDI 
(0.2 mol% NVA/MAA = 1.28, 1 mol% NVA/MAA = 1.20). This supports the theory 
represented in Figure 5.5 that the only significant difference between the copolymer 
bound MSNs obtained using the 0.2 mol% and 1 mol% free radical protocols is the 
surface density, not also the chain length, which was the behaviour previously 
observed when atom transfer radical polymerisation, ATRP, was employed in Chapter 
4.  
5.3.4 Infrared Spectroscopy 
To confirm that there was no chemical difference between the NVA/MAA copolymers 
obtained by using the 0.2 mol% and 1 mol% ACVA concentrations, IR spectroscopy 
was performed on the samples (Figure 5.8). 
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Figure 5.8. The IR Spectra of the NVA/MAA copolymers obtained using 0.2 mol% and 
1 mol% concentrations of ACVA initiator. 
The IR spectra obtained for the free radical polymerisation of NVA and MAA using 
0.2 mol% and 1 mol% ACVA relative to TEOS gave the same principal transmittance 
peaks. The appearance of both the carboxyl stretches (1165 cm-1 = C-O stretch, 1676 
cm-1 = C=O stretch, 2578 cm-1 = O-H stretch) and the amide stretches (1583 cm-1 = 
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C=O stretch) shows that both NVA and MAA are present making the polymer a 
copolymer of these monomers.77 
After this the IR spectra of the respective copolymers were compared with the 0.2 
mol% and 1 mol% surface functionalised MSNs (Figure 5.9). 
 
Figure 5.9. The comparison between the IR spectra obtained for A) 0.2 mol% and B) 
1 mol% NVA/MAA copolymer surface functionalised MSN to their respective 
copolymers and parent MSNs. 
As can be seen in both NVA/MAA surface functionalised MSNs the stretches 
observed are between 1015-1190 cm-1 representing Si-O-Si stretching and bending 
vibrations,78-80 stretches around 800 cm-1, indicative of Si-O-Si stretches,81 and those 
centred at ~550 and ~450 cm-1 representing tri and tetracyclosiloxane rings of 
siloxanes.82 However, there are minor peaks at 1672 cm-1 and 2920 cm-1 which are 
found in the copolymer (representing C=O (carboxyl) stretch and C-H stretch 
respectively) in the MSN spectra. The presence of these suggest that NVA/MAA 
copolymer surface functionalisation has occurred. 
5.3.5 Thermogravimetric Analysis 
To observe the temperature that the copolymer is thermally removed, 
thermogravimetric analysis, TGA, was performed on the 0.2 mol% and 1 mol% 
copolymers obtained in the absence of MSNs using the theoretical amount of ACVA 
bound to the MSNs. These were compared with the parent MSNs to confirm the 
variation between their degradations (Figure 5.10). 
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Figure 5.10. The percentage mass loss against temperature for the NVA/MAA 
copolymers obtained using 0.2 mol% and 1 mol% theoretical concentrations of ACVA 
compared to the Parent MSNs between 30 OC and 600 OC. 
The small mass loss of 11.4 wt% of original mass for the parent MSNs shows the 
stability of the fluorescein functionalised MSNs between 30 OC and 600 OC, this loss 
representing the loss of adsorbed solvent and surface silanol groups. In the NVA/MAA 
copolymers using 0.2 mol% and 1 mol% ACVA, there is significant mass loss between 
310 OC and 460 OC which represents the degradation of the copolymer (mass loss for 
0.2 mol% = 53.0 wt% and 1 mol% = 70.6 wt%). Another increase in mass loss appears 
at 160 OC to 260 OC in both 0.2 mol% (26.0 wt%) and 1 mol% (15.1 wt%). This 
represents impurities in the sample, most likely MAA (boiling point = 161 OC) as all 
the other starting reagents have boiling points not comparable to the degradation 
temperatures observed (ACVA melting point = 118 – 125 OC, NVA boiling point = 
70 OC and ethyl acetate = 77.1 OC, water = 100 OC). There is also significant mass loss 
in the 0.2 mol% NVA/MAA copolymer between 70 – 190 OC of 17.8 wt% which is 
most likely a mixture of NVA, ethyl acetate and water impurities evaporating off the 
sample. Both the NVA/MAA copolymers have almost completely degraded at 600 OC, 
due to the organic nature of the polymers. 
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With the temperature identified as between 310 OC and 460 OC for the NVA/MAA 
copolymer degradation obtained using free radical polymerisation, both the 0.2 mol% 
and 1 mol% NVA/MAA surface functionalised MSNs were analysed (Figure 5.11). 
 
Figure 5.11. The percentage mass loss versus temperature of A) 0.2 mol% NVA/MAA 
MSNs and B) 1 mol% NVA/MAA MSNs compared to their respective copolymers 
synthesised in the absence of MSNs and the Parent MSNs. 
There are significant mass losses in both samples between 70 OC and 250 OC which 
represents the starting reagents and water (0.2 mol% = 37.4 wt% and 1 mol% = 44.4 
wt%). As it was found that the mass loss that represents NVA/MAA copolymer 
appeared between 310 OC and 460 OC the mass loss between these two temperatures 
relative to the starting mass was used as the percentage by mass of NVA/MAA 
copolymer in the sample. It was calculated that for 0.2 mol% NVA/MAA surface 
functionalised MSN the percentage by mass of copolymer was 25.9 wt% whereas for 
1 mol% it was 12.5 wt%. The percentage by mass of copolymer was contrary to the 
proposed scheme where both 0.2 mol% and 1 mol% had same NVA/MAA copolymer 
chain lengths, but 1 % had more of NVA/MAA chains attached than 0.2 mol% (Figure 
5.5). However, both 25.9 wt% and 12.5 wt% calculated for the percentage by mass 
lost between 310 OC and 460 OC were significantly higher than the mass lost between 
these two temperatures for the parent MSNs (1.9 wt%). This proves that copolymer is 
present on the surface of the MSNs for 0.2 mol% and 1 mol% NVA/MAA MSN 
samples. As such, these 2 nanocomposites were still appropriate for assessing for 
efficacy of NVA/MAA copolymer MSN surface functionalisation on cellular uptake 
and binding. 
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5.4 Investigation into the Non-Specific Binding of the Surface 
Functionalised NVA/MAA copolymer MSNs using Free 
Radical Polymerisation with the Colorectal Cancer Cells 
5.4.1 Colorectal Cancer Cell Binding Assay 
To assess binding between nanoparticles and cells, we chose to work with 
SW480 human caucasian colorectal adenocarcinoma cells line. Initially, non-polymer 
grafted fluorescent MSNs were incubated at a range of different concentrations 
(ranging 1.22 µg/mL– 1250 µg/mL) with the cells for 24 hrs in standard cell conditions 
(See Chapter 2 Experimental for details, Section 2.2.3.7). After this time, cells were 
thoroughly washed, and their fluorescence signal was analysed. Remaining 
fluorescence was indicative of nanoparticles which had a strong binding interaction 
with the cells. This was confirmed through carrying out control experiments in the 
absence of nanoparticles and cells respectively. This procedure was then repeated with 
the 0.2 mol% and 1 mol% NVA/MAA MSNs (Figure 5.12). 
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Figure 5.12. The background normalised fluorescence obtained at 528 nm after 
excitation at 485 nm from serial dilutions from 1250 µg/mL to 1.22 µg/mL after 
incubation with SW480 cells for 24 hrs and subsequent washes. The results shown are 
of the Parent Fluorescent MSNs, 0.2 mol% NVA/MAA MSNs and 1 mol% NVA/MAA 
MSNs. 
The parent MSNs exhibit strong fluorescent emission, which increases linearly 
with increasing incubation concentrations, as would be expected due to strong 
interactions with the cells. Both 0.2 mol% and 1 mol% NVA/ MAA MSNs 
demonstrate a similar trend to each other.  Once again, increasing the number of 
nanoparticles applied to cells during incubation increases the fluorescent emission 
observed. The large fluorescence observed for 1250 µg/mL compared to 625 µg/mL 
is due to in situ precipitation occurring in the large dosage of 1250 µg/mL and so 
uptake would be higher regardless of the particle type. However, a significant decrease 
in interactions between the polymer grafted MSNs occurred between 1250 µg/mL and 
625 µg/mL (0.2% NVA/MAA Δ% fluorescence = 89.4 %, 1 % NVA/MAA MSNs = 
85.6 %). This indicates that the polymer modified nanoparticles have a weaker binding 
interaction with the cells. Therefore, the presence of the polymer reduces the effect of 
non-specific binding. The percentage fluorescence for 0.2 % NVA/MAA MSNs and 
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1 % NVA/MAA MSNs were within error of each other at all incubation concentrations 
suggesting binding was independent of polymer grafting density.  
However, there was speculation over whether the NVA/MAA copolymer was 
the primary factor in causing the lowering in non-specific binding due to the TGA 
showing a high concentration of impurities in the samples. Therefore, atom transfer 
polymerisation, ATRP, was utilised due to the successful application of ATRP in 
Chapter 4 with low monomer impurities observed in the TGA analysis. Also, because 
the control of chain length by variation in the BIBB initiator concentration would 
allow for future investigation into how polymer chain lengths affect colorectal cancer 
cell binding. 
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5.5 Preparation and Characterisation of Fluorescent MSNs 
with Surface Functionalised NVA/MAA Copolymer 
Synthesised using Atom Transfer Radical Polymerisation 
and PNA Binding 
Internally aminated MSNs were functionalised as previously stated with fluorescein 
NHS ester. The fluorescein MSNs were externally aminated using the same protocol 
as before. Only 0.2 % surface amine functionalisation was performed as this method 
provided equivalent binding to the 1 %, but with less contaminants (0.2 mol% = 37.4 
wt% and 1 mol% = 44.4 wt%). Then α-Bromoisobutyryl bromide, BIBB, initiator was 
covalently bound to the amine groups via an amide bond. ATRP reaction was 
performed using the surface bound BIBB and a Cu ion catalyst ligated by 
N,N,N′,N′′,N′′-Pentamethyldiethylenetriamine, PMDETA, in the same conditions as 
used in Chapter 4 except with NVA and MAA monomers instead of NIPAM. Finally, 
the PNA was bound to the carboxyl group using EDC-HCL and NHS coupling using 
the same conditions used to bind the ACVA initiator to the amine groups for the free 
radical NVA/MAA copolymer surface functionalised MSNs (Figure 5.13). 
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Figure 5.13. A schematic of the synthetic steps performed to obtain fluorescent MSNs 
with NVA/MAA copolymer surface functionalisation using ATRP. A) Internal 
fluorescein functionalisation of MSNs, FITC MSNs, B) external amine 
functionalisation of FITC MSNs, C) Surface BIBB binding via an amide bond, D) 
NVA/MAA copolymer surface functionalised fluorescent MSNs obtained using ATRP, 
E) Binding PNA to the carboxyl group of the MAA using EDC-HCl and NHS coupling. 
5.5.1 Dynamic Light Scattering and Zeta Potential 
The synthetic steps were monitored using hydrodynamic diameter and zeta potential 
to confirm successful functionalisation (Table 5.3). 
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Table 5.3. The hydrodynamic diameters and PDIs obtained by DLS with the zeta 
potentials of MSNs prepare at each of the key steps required to synthesise NVA/MAA 
copolymer surface functionalised MSNs using ATRP with PNA amide bound to the 
methacrylic acid carboxyl functional group. 
Synthetic step Hydrodynamic 
diameter / nm 
PDI Zeta 
potential / 
mV 
1. Parent MSNs 311.7 ± 37.8 0.21 ± 0.03 -28.5 ± 0.6 
2. Fluorescein modified 
MSNs 
265.4 ± 29.4 0.31 ± 0.04 -23.8 ± 4.5 
3. Externally aminated 
MSNs 
1461.0 ± 348.1 0.36 ± 0.14 5.6 ± 2.1 
4. ATRP NVA/MAA 
copolymer 
modification 
1025.0 ± 62.3 0.58 ± 0.09 -22.5 ± 0.6 
5. Final composite after 
PNA functionalisation 
409.0 ± 75.2 0.44 ± 0.05 -26.6 ± 0.6 
 
The hydrodynamic diameter obtained for the parent nanoparticle (311.7 ± 37.8 nm) is 
within error of the two hydrodynamic diameters observed for MSN synthesis for the 
free radical copolymerisation (0.2 mol% = 266.9 ± 36.6 nm and 1 mol% = 304.7 ± 
50.2 nm, Table 5.1). The zeta potential observed (-28.5 ± 0.6 mV) was similar to the 
zeta potential observed in Section 5.4.1 for the MSN synthesis for the 1 mol% free 
radical NVA/MAA MSNs (-27.6 ± 2.3 mV), expected due to the predominantly 
negative silanol surfaces. The hydrodynamic diameter of fluorescein functionalisation 
(265.4 ± 29.4 nm) is equivalent to the diameter obtained in Section 5.4.1 for 0.2 mol% 
free radical fluorescein functionalisation of MSNs (274.9 ± 19.8 nm). This is also 
expected as there is no deviation between the two protocols up to this point and the 
low concentration (0.15 mol%) of fluorescein functionalisation was expected to have 
little effect on hydrodynamic diameter and zeta potential. The zeta potential (-23.8 ± 
4.5 mV) is also within error of the 0.2 mol% (-18.4 ± 2.7 mV). Finally, the 0.2 mol% 
surface amine functionalisation for the ATRP MSNs gave a hydrodynamic diameter 
of 1461.0 ± 348.1 nm compared to the 0.2 mol% surface aminated free radical MSNs 
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1042.0 ± 144.6 nm, which are within error of each other. The dramatic increase in 
hydrodynamic diameter obtained by external amine functionalisation compared to the 
fluorescein functionalisation is due to the amine groups providing areas of positive 
charge on the MSNs creating greater electrostatic interactions between MSNs causing 
more aggregation and therefore resulting in a larger observed hydrodynamic diameter.  
The zeta potential obtained for 0.2 mol% amination for the ATRP MSNs is slightly 
lower than the zeta potential of the 0.2 % free radical MSNs (5.6 ± 2.1 mV compared 
to 10.7 ± 0.8 mV respectively). However, the change from a negative zeta potential to 
a positive zeta potential strongly suggests successful surface amine functionalisation 
and this small discrepancy may be due to a slightly different concentration of particles 
being measured. The PDIs up to Step 3 (1. MSN synthesis = 0.21 ± 0.03, 2. Fluorescein 
binding = 0.31 ± 0.04 and 3. 0.2 % surface amination = 0.36 ± 0.14) are all below 
0.40, suggesting good aqueous stability.  
Upon modification of the nanoparticles with polymer using the ATRP method, ATRP 
NVA/MAA MSNs, the PDI increased dramatically to 0.58 ± 0.09. This is indictive of 
unstable MSNs aggregating and the presence of polydisperse materials within the 
sample. This is due to the copolymers on MSNs becoming intertwined with 
copolymers bound on adjacent MSNs. This also explains the large hydrodynamic 
diameter obtained (1025.0 ± 62.3 nm). The zeta potential also changed from positive 
to negative (5.6 ± 2.1 mV to -22.5 ± 0.6 mV) due to the addition of methacrylic acid 
to the MSNs, as expected. The differences between the hydrodynamic diameter, PDI 
and zeta potential obtained for the ATRP of NVA/MAA compared to the free radical 
polymerisation of NVA/MAA (hydrodynamic diameter = 584.3 ± 125.2 nm, PDI = 
0.36 ± 0.02 and zeta potential = -11.0 ± 0.5 respectively) suggests a difference in chain 
length of the copolymer obtained using the two different polymerisation protocols. 
The larger hydrodynamic diameter, PDI and more negative zeta potential obtained for 
the ATRP NVA/MAA copolymer suggests that the polymer chain length obtained is 
significantly larger than NVA/MAA copolymer obtained by free radical. The variation 
between hydrodynamic diameter, PDI and zeta potential obtained before and after 
ATRP proved that the MSNs had been chemically changed and that methacrylic acid 
was present so the PNA addition step was performed. The hydrodynamic diameter 
after PNA addition changed dramatically to 409.0 ± 75.2 nm and the PDI lowered to 
0.44 ± 0.05 showing an increase in stable MSN suspension in water. The 
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hydrodynamic diameter decreasing shows that the bound PNA minimises the 
interaction and subsequent entanglement of NVA/MAA copolymers on adjacent 
MSNs possibly via steric hindrance. The zeta potential has not changed significantly 
from the attachment of NVA/MAA copolymer surface functionalisation and PNA 
binding (-22.5 ± 0.6 mV to -26.6 ± 0.6 mV), showing that the binding of PNA to the 
ATRP MSNs has little effect on the surface charge of the MSNs. These changes in 
hydrodynamic diameter, PDI and zeta potential from the starting MSNs suggested 
successful PNA binding to the MSNs. 
5.5.2 Transmission Electron Microscopy 
TEM images of the parent MSNs, the MSNs after NVA/MAA copolymer surface 
functionalisation using ATRP and the MSNs after PNA binding were obtained to 
allow for comparison (Figure 5.14).  
 
Figure 5.14. The TEM images of The Parent MSNs compared to the ATRP MSNs and 
the PNA MSNs. The diameter calculated as the mean and standard deviation of 100 
MSNs. 
As can be seen by the MSN particle diameters obtained for each set of TEM images 
(ATRP MSNs = 48.6 ± 4.6 nm and PNA MSNs = 49.6 ± 4.9 nm), there is no significant 
change to the particle diameter after ATRP and PNA binding. The porosity of the 
MSNs does not appear to have been affected by the subsequent synthetic steps either. 
The NVA/MAA copolymer or PNA can’t be observed because no negative staining 
was performed due to the analysis of the MSN structure and size being the principal 
objective of this procedure. 
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5.5.3 Infrared Spectroscopy  
NVA/MAA copolymer synthesised by ATRP using 0.2 mol% BIBB in the absence of 
MSNs was analysed by IR spectroscopy to confirm that the copolymer obtained had 
the same structure as the copolymer obtain using free radical polymerisation (Figure 
5.15). As before in Chapter 4 and for the NVA/MAA copolymer obtained using free 
radical polymerisations, the BIBB bound MSNs were replaced by the theoretical 
concentration of BIBB on the MSNs for 0.2 mol% surface functionalisation. 
5001000150020002500300035004000
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
T
ra
n
s
m
it
ta
n
c
e
Wavenumber (cm
-1
)
 0.2 mol% Free radical NVA/MAA copolymer
 0.2 mol% ATRP NVA/MAA copolymer
 
Figure 5.15. the IR spectra of the NVA/MAA copolymer using 0.2 mol% concentration 
of initiator by free radical polymerisation and ATRP. 
As can be observed in the IR spectra all the same prominent absorption peaks (1165 
cm-1 = C-O (carboxyl, stretch), 1583 cm-1 = C=O (amide, stretch), 1676 cm-1 = C=O 
(carboxyl) stretch, 2578 cm-1 = O-H (carboxyl) stretch and 2919 cm-1 = C-H stretch 
are observed corresponding to the functional groups as expected from a NVA/MAA 
copolymer.77  
With the NVA/MAA copolymer obtained by ATRP confirmed as having a similar 
composition to the free radical, the NVA/MAA MSNs and the PNA MSNs were 
analysed by IR to observe copolymer and PNA functionalisation (Figure 5.16). 
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Figure 5.16. The IR spectra of NVA/MAA copolymer using 0.2 mol% equivalent BIBB 
in the absence of MSNs, 0.2 mol% ATRP NVA/MAA surface functionalised MSNs and 
PNA bound 0.2 mol% NVA/MAA surface functionalised MSNs compared to Parent 
MSNs. 
The shifts representing the silica nanoparticle in ATRP NVA/MAA MSN samples are 
present at 1015-1190 cm-1 representing Si-O-Si stretching and bending vibrations,78-
80 stretches around 800 cm-1, indicative of Si-O-Si stretches,81 and those centred at 
~550 and ~450 cm-1 representing tri and tetracyclosiloxane rings of siloxanes.82 There 
are also organic shifts such as the C=O stretches present at 1612 cm-1 (amide), 
representing the NVA amide, and 1689 cm-1 (carboxyl), representing the carboxyl 
group in MAA. There is a stretch at 3346 cm-1 which represents O-H stretch from 
water impurity. There is a shoulder on this broad O-H stretch at 2952 cm-1 which 
represents C-H stretches of the copolymer. These organic stretches observed 
confirmed the presence of NVA/MAA copolymer.77  
The IR spectra for the PNA MSNs had no significant variation from the ATRP 
NVA/MAA MSNs with stretches present for C=O (amide) at 1538 cm-1, C=O 
(carboxyl) at 1635 cm-1 and a stretch at 2942 cm-1 representing C-H stretches. The 
stretch representing O-H stretching at 3325 cm-1 was significantly broader than for 
ATRP NVA/MAA MSNs, however this is more likely due to increased water 
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impurities than proof of PNA binding. A large variation in the IR spectra was not 
expected however for the binding of PNA as it is a protein that consists mainly of 
amide, carboxyl and C-H groups, like the NVA/MAA copolymer, but could also show 
a low loading density of PNA on the final composites. 
5.5.4 Thermogravimetric analysis 
The NVA/MAA copolymer obtained using ATRP was analysed by TGA to observe if 
changing from free radical polymerisation to ATRP had minimised monomer 
impurities (Figure 5.17). 
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Figure 5.17. The percentage mass loss versus temperature for the 0.2 mol% NVA/MAA 
copolymer obtained using ATRP in the absence of MSNs compared to the 0.2 mol% 
and 1 mol% NVA/MAA copolymer obtained by free radical polymerisation. 
For the 0.2 mol% NVA/MAA ATRP copolymer sample a consistent degradation is 
observed from 30 OC to 310 OC (23.10 wt%). This represents unreacted reagent species 
such as the significant acceleration in mass loss between 200 OC and 245 OC of 8.96 
wt% which represents as N, N, N′, N′′, N′′-Pentamethyldiethylenetriamine (PMDETA, 
boiling point = 198 OC). Like the 0.2 mol% and 1 mol% NVA/MAA free radical 
copolymers the largest mass loss for 0.2 mol% NVA/MAA ATRP copolymer is 
between 310 OC and 460 OC which represents the degradation of the copolymer (mass 
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loss for 0.2 mol% NVA/MAA free radical = 53.0 wt%, 1 mol% NVA/MAA free 
radical = 70.6 wt% and 0.2 mol% NVA/MAA ATRP = 63.1 wt%). 
The NVA/MAA copolymer surface functionalised MSNs obtained using ATRP were 
analysed in three iterations (Figure 5.18). The ATRP NVA/MAA MSNs (Figure 5.13, 
D) were analysed and compared to the ATRP NVA/MAA MSNs NHS/EDC-HCl 
coupled with PNA, PNA MSNs (Figure 5.13, E). Finally, the PNA MSNs were 
compared with ATRP NVA/MAA MSNs that were incubated with PNA without 
NHS/EDC-HCl, PNA Adsorption Control. This control was to confirm whether the 
PNA was chemically binding to the NVA/MAA copolymer and to define which peak 
represented PNA attached to the NVA/MAA copolymer. 
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Figure 5.18. The percentage mass loss versus temperature for PNA MSNs compared 
to pNVA/MAA MSNs, pNVA/MAA synthesised in the absence of MSNs and the PNA 
Adsorption Control. 
In the NVA/MAA functionalised MSNs using ATRP the large mass loss 
between 70 OC and 250 OC found in the free radical NVA/MAA MSNs (ATRP 
NVA/MAA MSNs = 6.3 wt%, 0.2 mol% NVA/MAA free radical MSNs = 37.4 wt% 
and 1 mol% NVA/MAA free radical MSNs = 44.4 wt%), representing monomer and 
solvent impurities in the sample has been removed.  The only significant mass loss 
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observed is the loss representing the hydrocarbon and other functional groups of 
NVA/MAA copolymer between 310 OC and 460 OC. The percentage by mass of 
copolymer was calculated to be 13.8 %. This is significantly lower than the percentage 
by mass of copolymer found using the same 0.2 % of initiator for free radical 
polymerisation (25.9 %). This could be due to less successful attachment of the BIBB 
initiator to the MSNs used in the ATRP reaction compared to the ACVA initiator 
bound MSNs for the free radical polymerisation. The small amount of mass loss 
observed in all MSN samples before 310 OC (ATRP NVA/MAA MSNs = 9.0 wt%, 
PNA Adsorption Control = 9.3 wt% and PNA MSNs = 7.9 wt%) represent physisorbed 
water and surface silanol groups. 
A comparison of the PNA Adsorption Control and the ATRP NVA/MAA MSNs 
shows conclusively that no PNA is being adsorbed onto the MSNs due to the lack of 
variation in mass loss with increasing temperature. This is highlighted by the same 
percentage mass loss being obtained at the end of the analysis (ATRP NVA/MAA 
MSNs = 68.6 % and PNA Adsorption Control = 68.4 %). The PNA MSNs however 
have a significant mass loss between 470 OC and 560 OC of 28.6 % which represents 
the loss of bound PNA. The presence of this significant mass loss which is solely 
observed in the PNA MSNs confirms that the PNA is bound to the MSNs via the 
methacrylic acid and therefore the PNA MSNs were progressed to colorectal cancer 
cell binding analysis.  
5.5.5 Gel Permeation Chromatography 
The copolymer of NVA/MAA synthesised using ATRP copolymer in the absences of 
MSNs, but with the equivalent theoretical moles of BIBB initiator assuming 100 % 
conversion of the surface amine groups on the MSNs, was analysed by GPC (Figure 
5.19) to obtain the Mn and PDI obtained using the conditions used for the BIBB bound 
MSNs.  
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Figure 5.19. The plot of logM against normalised dwdlogM for the ATRP reactions 
involving the theoretical BIBB concentration calculated for the 0.2 mol% amine 
surface functionalised MSNs. 
The Mn = 19,000 g mol
-1 was significantly higher than the Mn obtained using 0.2 % 
and 1 % ACVA initiator free radical polymerisation (0.2 % = 6100 g mol-1 and 1 % = 
7000 g mol-1). This is due to ATRP being a living polymerisation method, thus making 
the rate of growth linear and dependent on initiator and monomer concentrations.83, 84 
Whereas free radical polymerisation is not living and therefore the growth follows a 
logarithmic trend.84, 85 This results in the monomer and initiator concentrations having 
an independent relationship with polymer chain length. The PDI obtained for the 0.2 
mol% ATRP NVA/MAA copolymer was 1.81 compared to 1.28 and 1.20 for the 0.2 
mol% and 1 mol% free radical NVA/MAA copolymers respectively. This is very high 
showing that little control of chain length is being claimed by the addition of the Cu-
PMDETA chelate used in this ATRP reaction. The asymmetry of the plot for the 0.2 
mol% ATRP NVA/MAA copolymer is due to uncontrolled termination occurring 
highlighted by the high PDI. 
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5.6 Investigation into the Specific Binding of the PNA 
Functionalised MSNs with the Colorectal Cancer Cells 
5.6.1 Colorectal Cancer Cell Binding Assay 
This was performed using the same procedure performed to investigate the non-
specific binding of the MSNs with the colorectal cancer cells in Section 5.5.1 of this 
chapter (Figure 5.20).  ATRP NVA/MAA grafted fluorescent MSNs were incubated 
at a range of different concentrations (ranging 1.22 µg/mL– 1250 µg/mL) with the 
cells for 24 hrs in standard cell conditions (See Chapter 2 Experimental for details, 
Section 2.2.3.7). After this time, cells were thoroughly washed, and their fluorescence 
signal was analysed. As before, increased fluorescence indicates increased binding 
between nanoparticles and cells due to electrostatic interactions. It should be noted 
that control experiments carried out in the absence of nanoparticles and the absence of 
cells respectively showed negiligible fluorescence signal, indicating that the observed 
fluorescent signal originates from an interaction between the particles and the cells.  
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Figure 5.20. The background normalised fluorescence obtained at 528 nm after 
excitation at 485 nm from serial dilutions from 1250 µg/mL to 1.22 µg/mL after 
incubation with SW480 cells for 24 hrs and subsequent washes. The results shown are 
of ATRP NVA/MAA MSNs, free radical 0.2 mol% NVA/MAA surface functionalised 
MSNs (Section 5.4.1 Figure 5.12) and PNA bound ATRP NVA/MAA surface 
functionalised MSNs, PNA MSNs, compared to the Parent MSNs. 
There is a large variation in the amount of fluorescence at 625 µg/ml-1 between the 
ATRP 0.2 mol% NVA/MAA MSNs (36.73 ± 3.63 %) and the free radical 0.2 mol% 
NVA/MAA MSNs (10.65 ± 3.31 %). This shows that there is a larger amount of non-
specific binding in the ATRP NVA/MAA MSNs than the free radical NVA/MAA 
MSNs at this concentration. The ATRP NVA/MAA MSNs are within error of the 
parent MSNs (51.00 ± 21.80 %).  This is due to the lower amount of polymer chains 
bound to the MSNs after ATRP (13.8 wt%) than free radical (25.9 wt%) and the lower 
amount of physisorbed starting reagents according to TGA. This has allowed for 
stronger interaction between the cells and the MSN surface due to the absence of 
polymer and physisorbed reagents preventing recognition of the nanoparticles by the 
cells. However, at 0.31 mg/mL there is a clear deviation between the fluorescence for 
ATRP NVA/MAA MSNs (9.96 ± 0.56 %) and the parent MSNs (26.67 ± 12.92 %). 
This shows that the NVA/MAA copolymer synthesised using ATRP is minimising 
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non-specific binding between cells and the MSNs. There is more binding for the ATRP 
NVA/MAA MSNs than for free radical MSNs (5.53 ± 0.91 %), however this 
difference was attributed again to the greater polymer loading and physisorbed starting 
reagents inhibiting MSN to cell interactions. 
  The chemical binding of PNA to the ATRP NVA/MAA MSNs, PNA MSNs, 
had a dramatic effect on cell binding. At 0.625 mg/mL the fluorescence is within error 
of the parent MSNs (PNA MSNs = 68.96 ± 20.00 % compared to Parent MSNs = 
51.00 ± 21.80 %). However, whereas the parent MSNs and both the NVA/MAA MSNs 
fluorescence drop at 0.31 mg/mL the PNA MSNs fluorescence remains (85.47 ± 14.05 
%) and is within error of the fluorescence obtained at 0.625 mg/mL down to a 
concentration of 1.22 µg/mL (55.17 ± 14.97 %). This clearly shows that specific strong 
interactions are occurring between the PNA and the SW480 cells. Sakuma et al. 
performed a very similar experiment with polystyrene nanoparticles surface 
functionalised with PNA bound N-vinyl acetamide/MAA copolymer.65 4 mg/mL of 
the functionalised nanoparticles were administered to SW480 at left to incubate for 30 
mins, compared to the 24 hrs in this project. The cells were then centrifuged out to 
remove excess nanoparticles and analysed by fluorescence. In this research it was 
found that there was binding of the nanoparticles to the SW480 cells, but not as 
significant an amount as was found with other human carcinoma cells that were also 
analysed. This was explained to be due to a possible lowering in expression of the TF 
antigen compared to the other cells. 
5.6.2 Cell Viability Test 
A resazurin viability assay was carried out on a range of phosphate buffered saline, 
PBS, -suspended PNA-MSN samples (1.2 µg/mL to 1250 µg/mL).  Viable cells were 
identified through a change in absorbance of the assay due to metabolic conversion of 
resazurin to resofurin. (Figure 5.21).86  
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Figure 5.21. The cell viability of SW480 colorectal cancer cells incubated for 24 hrs 
with serial dilutions from 1250 µg/mL to 1.22 µg/mL PNA MSNs normalised to the 
cell viability of the control cells with no addition of PNA MSNs. 
There is no decrease in cell viability compared to the control (100.0 ± 2.0 %) even up 
to the highest concentration of 1250 µg/mL (101.9 ± 4.3 %). This exemplifies the low 
toxicity of the MSNs. This result also confirms the relevance of the concentration 
range used in the binding assays as all concentrations analysed were non-toxic. The 
absence of any toxicity characteristics displayed by the SW480 up to 1250 µg/mL 
agrees with the research Yu et al. performed on non-small-cell lung cancer cells 
incubated with MSNs of particle diameter 120 ± 25 nm.87 In this research numerous 
toxicity assays were performed and it was found that MSNs did not affect the cell 
viability of A549 cells up to 500 µg/mL. Cancer epithelial cells were resistant to 
proliferation inhibition due to MSN treatment up 1000 µg/ mL post 72 hrs exposure. 
The plasma membrane integrity of the A549 cells was unaffected by MSNs after 24 
hrs incubation with 250 µg/mL of MSNs. Also, that no haemolytic toxicity was 
observed for incubation with 100 µg/mL of MSNs. Sakuma et al. have rigorously 
tested the toxicity of grafted N-vinyl acetamide/MAA copolymer in vivo.69 in this 
research N-vinyl acetamide/MAA copolymers surface grafted onto polystyrene beads 
with coumarin encapsulated were administered to rats using both oral and intrarectal 
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administration  at 50 mg/mL, administering 20 mL per kg of body weight. The rats 
were observed for 7 days and no change in body weight, food consumption or water 
consumption was observed compared to the controls. Also, no significant difference 
was observed in haematological and blood biochemical parameters was observed. 
Necropsy revealed that there was no macroscopic nanoparticle-induced change in the 
rat organs. Finally, that after histopathological examination, there was no induced 
toxicity to the digestive organs, liver, kidneys or mesenteric, the membrane that 
attaches the intestine to the abdominal wall, lymph nodes.  
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5.7 Conclusions 
The aim of this project was to produce fluorescent MSNs with the capability to 
differentiate between colorectal cancer cells and healthy cells such that they can be 
distinguished to facilitate earlier diagnosis and treatment. Initial investigations 
involved fluorescent MSNs synthesis and incubation with SW480 colorectal cancer 
cells. There was found to be non-specific binding present between the MSNs and the 
SW480 cells. So, the fluorescent MSNs were surface functionalised with NVA/MAA 
copolymer, synthesised using free radical polymerisation and functionalisation 
confirmed by TGA, DLS and IR, which had previously in literature been utilised to 
minimise non-specific binding with polymeric nanoparticles. Then it was investigated 
whether this copolymer could perform the same function on MSNs. Two surface 
densities were investigated 0.2 mol% and 1 mol%, to observe if this would affect non-
specific binding. It was found that both 0.2 mol% (10.6 ± 3.3 % fluorescence at 0.625 
mg/mL compared to 1.25 mg/mL) and 1 mol% (14.4 ± 1.8 %) had low binding with 
SW480 cells, however the large amount of starting reagents impurity in the MSNs (0.2 
% = 37.4 wt% and 1 % = 44.4 wt%), made the efficacy of the NVA/MAA copolymer 
ambiguous. Therefore, ATRP was utilised to minimise starting reagent contamination 
and allow for polymer chain length control. ATRP was found to greatly minimise 
starting reagent impurity. However, the control of polymer chain length usually 
acquired using ATRP was not obtained (PDI = 1.81). The ATRP MSNs then had PNA 
bound to them via an amide bond to the MAA in the copolymer. The PNA MSNs were 
incubated with SW480 colorectal cancer cells and found to strongly specifically bind. 
It was found that even down to concentrations as low as 1.22 x10-3 mg/mL there was 
significant fluorescence compared to unfunctionalized NVA/MAA MSNs (55.2 ± 15.0 
% of 1.25 mg/mL fluorescence obtained at 1.22 x10-3 mg/mL compared to 1.8 ± 0.9 
% obtained for unfunctionalized NVA/MAA MSNs). Finally, the toxicity of these 
PNA MSNs was analysed by assessing cell viability. It was concluded from this that 
even with 24 hrs incubation with 1.25 mg/mL of PNA MSNs there was no effect on 
the metabolism of the colorectal cancer cells compared to the control cells incubated 
with no PNA MSNs (Cell viability for control SW480 cells = 100.0 ± 2.0 %, cell 
viability of SW480 incubated with 1.25 mg/mL of PNA MSNs for 24 hrs = 101.9 ± 
4.3 %). 
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5.8 Future Work 
An area of further investigation is to analyse how the PNA bound NVA/MAA 
copolymer surface functionalised MSNs interact with healthy colorectal cells to 
ascertain whether the binding is specific to cancerous colorectal cancer cells. Also, all 
the investigations were in vitro so in vivo studies would need to be performed to 
observe whether other interactions occur in a more complex system. On the synthetic 
side the ATRP reaction optimisation requires investigation. The PDI obtained of 1.81 
is high for a controlled polymerisation. Therefore, investigating the chelate used to 
bind to the Cu and monomer concentrations are required. The benefit of this 
optimisation would be that the copolymer chain length and its relative composition 
could be investigated to observe their effect on binding, like in Chapter 4. Finally, 
synthetically, the binding of the PNA needs to be optimised. Despite the protocol’s 
success at binding PNA, this came with a detriment to the overall fluorescence of the 
MSNs. This is due to the EDC-HCl or NHS compounds quenching the fluorescein.  
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Chapter 6 
6. Conclusions 
 
 Mesoporous silica nanoparticles, MSNs, are a highly desirable nanostructure 
for potential medical applications due to their high surface area, ease of 
functionalisation and biocompatibility. In biomedicine, a vast amount of research has 
been dedicated to exploiting MSNs for therapeutic delivery applications. Their high 
internal volumes provide large payload capacity, in addition to the possibility of 
stimuli-responsive capping and surface targeting, makes them an ideal structure for 
drug encapsulation. MSNs have additionally found use as hosts for active agents, for 
example, in the development of imaging agents with enhanced properties. MSNs have 
previously highlighted their efficacy as a diagnostic agent for magnetic resonance 
imaging, MRI. This is due to the considerable contrast enhancement obtained by the 
binding of gadolinium ion-based contrast agents, GBCAs, to the MSN surfaces, 
producing enhancements resulting from favourable interactions with water, as 
governed by Solomon- Bloembergen-Morgan (SBM) theory. This enhancement has 
several highly desirable outcomes for potential biomedical applications. Increased 
signal enhancement can effectively lower doses required, an important consideration 
in patient safety. This is particularly pertinent given recent evidence of the deposition 
of Gd in patient tissue. Additionally, the biocompatibility and ability for surface 
modification of these species provides the opportunity to further develop their 
properties to provide precise diagnostics through, for example, targeting species, or 
the ability to ‘switch’ their contrast signal ‘on/off’ in the presence of disease. In this 
work, a series of MSN systems have been designed in a bid to further develop this 
exciting field and produce highly tuned, targeting and diagnostic MRI agents. 
 The investigation into the sensitivity and optimisation of MSNs’ previously 
successful application as an MRI contrast agent was probed further. The importance 
of water access to Gd3+-chelates on the mesoporous structure of MSNs was 
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investigated, specifically examining how even small changes in pore size can impact 
the resulting MRI behaviour (Chapter 3). This research confirmed that even with a 
very low concentration of GBCA bound to the surface of MSNs, a six-fold 
enhancement in contrast can be obtained compared to the GBCA alone. Also, that this 
exceptional relaxation enhancement is maintained independent of the location of the 
GBCA binding onto the MSNs of pore diameter ~3.5 nm. However, with a pore 
diameter of ~2.6 nm there is a reduction in the relaxation enhancement found when 
binding the Gd3+-chelate inside the pores due to restriction of water access to the Gd3+-
chelate. The change in relaxation observed shows the importance in ensuring 
appropriate construct design. In addition, when using larger pore size materials, the 
absence of change in relaxation behaviour allows a range of functionalities to be 
incorporated onto nanoparticle structures for future multi-functional applications. 
These additional desirable functionalities were pursued by the surface 
functionalisation of MSNs with bound GBCAs with a thermoresponsive polymer, in 
a bid to design contrast agents with switchable signal capable of disease diagnostics 
(Chapter 4). This would allow for the control of the contrast, by either intrinsic 
pathological temperature variation such as between tumour and healthy tissue or the 
application of a temperature gradient via an external source (e.g. hyperthermia 
ablation), allowing for further minimisation of the dosages required for facile 
successful diagnosis. This research utilised atom transfer radical polymerisation, 
ATRP, of a well-known thermoresponsive polymer in a ‘grafting from’ synthetic 
approach onto MRI-active MSNs. This resulted in the successful synthesis of a GBCA 
that was able to aggregate, resulting in an area of localised signal. This could 
potentially provide opportunities in disease diagnosis as MSNs would aggregate at the 
site of interest. Importantly the aggregation stimulus response was performed at 
physiological temperatures with the ability for further tuning of the response 
depending on polymer chain length and polymer surface functionalisation density. 
This allows the GBCA response to be tailored to its target’s thermal fingerprint. 
Another desirable result of this investigation is that it obtained a robust method of 
polymer surface functionalisation with polymer chain length control that is not 
restricted to MSNs but able to be transferred to several oxide-type nanoparticles. This 
allows for a diverse variety of surface polymer functionalisation to be achieved able 
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to respond to different stimuli, like pH, and various other functions through 
modification of the functional groups present on the polymer. 
In order to further develop our systems for precise biological function, such as 
biological targeting, we investigated the uptake behaviour of MSNs. Non-specific 
binding is a common problem, so the MSNs were polymer surface functionalised to 
perform the function of masking the MSNs from cells (Chapter 5). Firstly, the type 
of polymerisation was varied from ATRP to free radical to allow direct comparison to 
previous literature. As well as successfully functionalising the MSNs, the copolymer 
was able to efficiently minimise the interactions between MSNs and colorectal cancer 
cells. This was developed further by reverting to ATRP, regaining the polymer chain 
length control. In order to then bestow targeting capabilities onto the MSNs, a 
colorectal cancer binding lectin (peanut agglutinin) was covalently bound to the 
polymer/MSN nanocomposite and it was observed that this successfully facilitated 
MSN binding interactions with colorectal cancer cells. Essentially it was also 
confirmed that the lectin/polymer surface functionalisation of the MSNs had no effect 
on the low cytotoxicity usually observed by MSNs. Finally, the MSNs throughout this 
investigation were fluorescent, acquiring this property using the same chemistry 
applied to GBCA binding to MSNs. This allows for the truly unique possibility in 
diagnostic agents to provide enhancement contrast properties to complimentary 
imaging techniques.  
This research could be developed further by developing an MSN system tuned 
to a specific disease by for instance responding to unique stimuli the specific cell type 
provides or having a response due to binding to the cell. This would be beneficial as 
it would remove ‘false positives’ and improve diagnostics. In the future the addition 
of drug encapsulation into the pores of the MSNs could be incorporated. The obtained 
drug delivery system plus the functionalities that were probed in this thesis could 
achieve an all-in-one drug administration system that is capable of disease diagnosis 
and drug release with specific targeting.  
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3.7 Appendix Chapter 3: Investigating the Impact of 
Nanoparticle Design on MRI Contrast Agent Behaviour 
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Figure 3.13. The IR spectra of the three synthetic repeats of A) CTAB Internal, B) 
CTAB Edge, C) CTAB External, D) MYRI Internal, E) MYRI Edge and F) MYRI 
External against their respective surfactant, CTAB or MYRI. 
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Figure 3.14. The TGA analysis of the three repeats for the synthetic protocols between 
30 – 600 OC A) CTAB Internal, B) CTAB Edge, C) CTAB External, D) MYRI Internal, 
E) MYRI Edge and F) MYRI External compared to their respective surfactants CTAB 
and MYRI.  
 
 190 
 
 
A)
I)
II)
 191 
 
 
B)
I)
II)
 192 
 
 
C)
I)
II)
 193 
 
 
D)
I)
II)
 194 
 
 
E)
I)
II)
 195 
 
 
F)
I)
II)
 196 
 
 
G)
I)
II)
 197 
 
 
H)
I)
II)
 198 
 
 
I)
I)
II)
 199 
 
 
J)
I)
II)
 200 
 
 
K)
I)
II)
 201 
 
 
L)
I)
II)
 202 
 
 
M)
I)
II)
 203 
 
 
N)
I)
II)
 204 
 
 
O)
I)
II)
 205 
 
 
P)
I)
II)
 206 
 
 
Figure 3.15. All the rest of the the data acquired by SAXs for A) CTAB Internal MSNs 
Repeat 2, B) CTAB Internal MSNs Repeat 3, C) CTAB Edge MSNs Repeat 1, D) CTAB 
Edge MSNs Repeat 2, E) CTAB Edge MSNs Repeat 3, F) CTAB External MSNs Repeat 
1, G) CTAB External MSNs Repeat 2, H) CTAB External MSNs Repeat 3, I) MYRI 
Internal MSNs Repeat 1, J) MYRI Internal MSNs Repeat 2, K) MYRI Internal MSNs 
Repeat 3, L) MYRI Edge MSNs Repeat 1, M) MYRI Edge MSNs Repeat 2, N) MYRI 
Edge MSNs Repeat 3, O) MYRI External MSNs Repeat 1, P) MYRI External MSNs 
Repeat 2, Q) MYRI External MSNs Repeat 3,  with the area representing I) the particle 
diameter and II) the pore diameter of the MSNs being analysed using the EasySAXS 
modelling software.28 
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EasySAXS general protocol 
The area of the q versus intensity is highlighted that represents the property that is 
being analysed (Low q = particle diameter, high q = pore diameter). Then an estimated 
size is given to the model to make a hypothetical equation, which is plotted against the 
analysed area. This is repeated until a fit is obtained between the hypothetical plot and 
the data obtained by the sample. With this optimised plot a Fourier transform is 
performed. Finally, the ranges of diameters observed is calculated (Equation 3.3) 
where Δq is the distance between peak oscillations.28 
𝐷𝑖𝑎𝑚𝑒𝑡𝑒𝑟 =  
2𝜋
∆𝑞
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Figure 3.16. The plot of R1 against Gd concentration for the molecular Gd
3+-DOTA 
control with three repeats.  
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Figure 3.17. The graphs of R1, observed – R1, solvent against Gd concentration for all the 
CTAB MSNs functionalised with Gd3+-DOTA bound either in the Internal, Edge and 
External positions. 
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Figure 3.18. The graphs of R1, observed – R1, solvent against Gd concentration for all the 
MYRI MSNs functionalised with Gd3+-DOTA bound either in the Internal, Edge and 
External positions. 
 
 
 
 
 
